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Chapter 1 Introduction 
 
 
1.1 General introduction 
 
Cancer is the second leading cause of death globally, and is responsible for an estimated 
9.6 million deaths in 2018 [1]. After decades of research in cancer cell biology, many 
distinct molecular pathways involved have been discovered. This broad disease profile 
has prompted the tailoring of individualized cancer therapy. The novel personalized 
therapy has shown immense success in many cancer types for patients with access to 
those possibilities. According to the World Health Organization (WHO), many of these 
malignant tumors could be prevented with earlier diagnosis using more precise 
visualization tools, which could lead to a more effective and personalized therapy. 
Various modern imaging technologies have been widely used to monitor structural, 
functional, and molecular changes in cancer tissues and diagnose the tumor at an early 
stage [2-5]. 
In recent years, molecular imaging has emerged as an important medicine discipline and 
has had a great impact on clinics for generating non-invasive high-resolution images of 
the human body in real time [6-9]. These include optical imaging (bioluminescence or 
fluorescence), X-ray imaging (X-Ray), computed tomography (CT), magnetic resonance 
imaging (MRI), positron emission tomography (PET), single-photon emission computed 
tomography (SPECT), and ultrasound tomography (US) [9-11]. Each imaging modality 
has its own unique strength and intrinsic limitations, such as spatial/depth resolution and 
sensitivity, making the achievement of precise and reliable information at the disease 
site difficult. In order to circumvent the limitations of a single imaging technique and 
exploit their advantages synergistically, multimodal molecular imaging has been 
considered. The combined systems like PET-CT, PET-MRI and PET-OI have been 
developed to gather a more comprehensive information about the disease [12-15]. 
 
PET is an established clinical tool for whole-body imaging [13]. This imaging technology 
utilizes radiopharmaceuticals containing positron-emitting radionuclide. The positron as 
a source of annihilation results into two γ-rays emitted at an angle of ~180O. This allows 
the reconstruction of the images to generate an imaging contrast. The most frequently 
used radioactive agents include 18F, 68Ga and 11C but for scientific purposes also other 
positron emitting radionuclides such as 13N, 15O, 44Sc, 62Cu, 64Cu, 72As, 74As, 76Br, 82Rb, 
86Y, 89Zr, and 124I are utilized [16]. 
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Additionally to the broad range of radiotracers, nanoparticles (NPs) have emerged as a 
new approach for PET and other imaging techniques due to their tunable biodistribution 
and target site accumulation of imaging contrast agents [17]. Ultrasmall nanoparticles 
(USNPs), with sizes in the 1−3 nm range, exhibit unique properties distinct from those of 
free molecules and larger sized nanoparticles. These properties are greatly sensitive to 
both the composition and size of the particles. When applied in medical science, they 
give rise to the term of “nanomedicine” which has found more applications in preclinical, 
translational, and clinical research. 
The research in the area of nanomedicine spans multidirectional applications varying 
from diagnosis, drug delivery, gene delivery, targeted therapy, biomarker mapping, to 
the area of our interest: molecular imaging [7, 18]. Many of these developments are 
starting to be translated into viable clinical products [19, 20]. The distinct intrinsic 
properties and facile tailorability of the NPs makes them potential targeted theranostics 
agents [21]. 
 
Some cancer nanomedicines have already been approved by either the Food and Drug 
Administration (FDA) or European Medicines Agency (EMA) and are used in the clinic to 
diagnose and cure the disease for over 20 years, while several systems are currently 
under clinical trials [19, 20, 22]. Doxil, a polyethylene glycol (PEG) functionalized 
liposomal doxorubicin, was the first approved (FDA 1995) cancer nanomedicine, 
followed by Abraxane, an albumin-bound paclitaxel NP. More recently approved 
products such as Marqibo, MEPACT, Feraheme, AuroLase and Cornell Dots (C-Dots) 
exhibit the strong presence of inorganic NPs in clinical trials [20, 23]. Inorganic NPs have 
been studied extensively for past decades and have paved a way in this direction [24]. 
Their unique material- and size-dependent physicochemical properties, the ability to 
modulate pharmacokinetics through surface chemistry, application of targeting 
mechanisms to advance the biodistribution and enhancement of contrast signals by 
incorporating multiple imaging moieties in a single scaffold make them attractive 
alternatives for imaging and ablation of malignant tissue [25-37]. 
 
Cornell Dots (C-Dots), for example, are derivatized silica NPs that are used for 
enhancing standard PET-optical dual-modality imaging is the nanoconstruct of our 
interest [23, 38]. The NP particle size of ~7 nm facilitates renal excretion, a near-infrared 
(NIR) cyanine 5 fluorophore to optimize fluorescence imaging, a PEG coating to avoid 
opsonization and subsequent internalization by macrophages in the liver. A 124I-
radiolabeled cRGDY peptide which functions as both, a radiolabeled molecule that 
facilitates PET imaging and as a targeting peptide to improve targeting and accumulation 
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in ανβ3 integrin expressing tumors. The first-in-man clinical trial of C-Dots for imaging of 
cancer in patients with metastatic melanoma were shown to be: (i) well tolerated with no 
reported toxic or adverse events, (ii) stable in vivo, (iii) provide consistent 
pharmacokinetic patterns, and (iv) capable of imaging lesions, including metastatic 
lesions, in distinct areas of the body. Effective doses of C-Dots for the clinical trials were 
comparable to the commonly used diagnostic radiotracers. 
 
The ultimate biocompatibility and extraordinary pharmacokinetics revealed from these 
studies led to the exploitation of silicon nanoparticles (Si NPs) in the field of bioimaging 
and biosensing [39-41]. Si NPs featuring benign biocompatibility and unique optical 
properties (i.e., strong fluorescence coupled with ultrahigh photostability) are emerging 
as novel high-quality fluorescent nanoprobes for biological imaging analysis, particularly 
for tracking dynamic biological procedures in long-term and real-time manners [41-43]. 
 
The hydrothermal synthesis of the Si NPs has been optimized by several research 
groups to achieve large-scale synthesis of ultrasmall, hydrophilic, surface functionalized 
Si NPs [44]. The large surface area of the synthesized Si NPs also provides an extensive 
platform for combining multiple imaging modalities. These Si NPs are exploited as a core 
for attachment of labeling and targeting moieties to develop a multi-labeled targeted 
contrast agent [40, 45-56]. The high surface area and surface-functionalization of the Si 
NPs can accommodate a variety of substituents including drugs for therapeutic 
purposes, biological vectors for targeted theranostics, radionuclides for PET/SPECT 
imaging, fluorophores for optical imaging (OI), and linkers and spacers for antifouling 
properties (Figure 1.1) [26, 38, 41, 43, 57]. 
 
The focus of this graduation project is the development of customizable Si NPs based 
mono-labeled PET or OI and dual-labeled PET-OI imaging probes and examination of 
their in vitro and in vivo behavior. 
 
For OI, NIR fluorophores like cyanines have been employed extensively due to their high-
resolution visualization in tissue. Several studies show their optical characteristics in cells 
studies, biodistribution experiments and imaging applications like the tumor-targeted 
detection and image-guided surgery [58-61]. As a part of this thesis, we have tested the 
sulfo-cyanine 5 (sulfo-Cy5) and the IRDye 800 CW-Si NP conjugates for in vitro and in 
vivo studies. 
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Figure 1.1.1: Representation of an idealized multimodal nanoparticle for cancer diagnostic and 
therapeutic applications. 
A multifunctional nanoparticle (size < 10 nm) coupled to modular ligand systems for PET and OI and targeted 
vectors via linkers for cancer diagnostics. Therapeutic agents can also be conjugated for theranostics 
applications. Adapted from [17] 
 
For PET and SPECT imaging techniques, specific radionuclides are reported for 
diagnostic and imaging purposes with favorable half-lives and decay properties. Copper-
64 (64Cu: t1/2 = 12.8 h; β+, 19%; β−, 40%; and electron capture 40%) is a distinct 
radionuclide that is exploited for its diagnostic potential [62, 63]. It is a cyclotron-produced 
radionuclide, produced by 64Ni(p,n)64Cu reaction and separated from the Ni-target 
material with a high molar activity [64]. Generator-based Gallium-68 (t1/2 = 68 minutes, 
β+ = 89 %, Emax, β+ = 1.92 MeV) on the other hand, is also a common radionuclide used 
for assessment of shorter biochemical processes due to its short half-life [16, 65]. The 
aforementioned properties permit binding of the radiometal to a targeting moiety, tissue 
accumulation, and clinical administration in vivo in a manageable time frame. 
The radionuclide is complexed by a specific bifunctional chelating agent (BFCA), which 
can be coupled to the NPs for PET imaging of the biological system. The required 
properties of an ideal BFCA are its ability to rapidly form a thermodynamically stable and 
kinetically inert complex with the radionuclide at ambient temperature under 
physiological conditions [66-70]. At the same time, it should allow easy linking with vector 
molecules. A series of BFCAs compatible to the 64Cu radionuclide are available 
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portraying excellent chelation properties [71]. Multidentate azamacrocyclic chelators 
such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-
triazacyclononane (TACN), and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) are 
well-known promising chelators for PET applications [15, 72, 73]. 
 
Hexadentate 3,7-diazabicyclo[3.3.1]nonane derivatives, commonly known as bispidines, 
have been chosen as the main chelator system for this project [74, 75]. The ability to 
form different functional derivatives and kinetically inert Copper(II) complexes, bispidines 
behave as an optimal PET imaging agent; therefore, they were studied as potential 
BFCAs for targeted molecular imaging [76-78]. A series of bispidines were synthesized 
with varying functional moieties compatible to sensitive fluorophores and appropriate 
biomolecules to prepare targeted multimodal imaging modalities. Therefore, an 
isothiocyanate-terminated bispidine derivative was coupled to amine-terminated TATE 
(Tyr3-Octreotate) peptide specific to somatostatin receptor (SSTR-2) and a 
dibenzocyclooctyne (DBCO)-terminated bispidine to the tailor-made single-domain 
antibody (sdAb) to target the epidermal growth factor receptor (EGFR). These receptors 
are overexpressed in specific cancer malignancies and can be detected by the targeted 
PET imaging agents. The bispidine derivatives were examined for their effectiveness as 
potential targeting agents for cancer diagnosis. 
1,4,7-triazacyclononane-triacetic acid (NOTA) is another suitable chelator for both 64Cu 
and 68Ga radiometals that has been used for the development of Si NP based unimodal 
and bimodal imaging agents [72, 79]. The biocompatibility, fast and efficient 
radiochelation properties and commercial availability of this chelator has led to its 
exploitation for PET-based analysis. 
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1.2 Aims and objectives of the thesis 
 
The aim of this dissertation is the optimization and development of PET and OI agents 
for cancer diagnosis with high efficiency and non-invasive procedures. The major 
challenge is to develop a system highly biocompatible and with low side effects to 
translate into the clinics. Si NPs are suitable candidates due to their extraordinary 
intrinsic and surface properties. The ultimate goal is the development of ultrasmall multi-
functionalizable Si NPs that can be modified by appropriate labels for uni and bimodal 
imaging. These particles are to be modified in such a way that additional functionalities 
such as molecules for targeting can be easily added. 
The first aim focuses to determine the in vitro and in vivo behavior of the functionalized 
Si NPs and render them suitable for diagnostics. Bispidines were modified as a primary 
PET ligand and modified with diverse functionalities to permit an easy linkage to the NPs 
and biomolecules. For OI, commercially available fluorophore, IR 800 dye was 
employed. In parallel, tailor-made bifunctional bispidines were developed as targeted 
PET imaging agents. TATE peptide (SSTR-2) and sdAb (EGFR) were employed as 
biological vectors to achieve cancer targeting. 
The second aim was the functionalization of Si NP core by PET/OI ligands and their in-
depth characterization and evaluation of surface properties. The ultrasmall size and 
tunable surface properties of the Si NPs (< 5 nm) make them renally clearable, which is 
an advantage over large sized particles that tend to accumulate in non-targeted tissue 
of the in vivo system. Furthermore, Si NPs are biodegradable in nature, causing no harm 
over long-term cancer treatments. Several surface coating strategies have already been 
optimized to be upscaled by efficient and cost-effective techniques in shorter time 
durations (0.5 − 3 hours).  
The third aim was to study the in vitro and in vivo behavior for the different labeled Si 
NPs. This includes the cytotoxicity evaluation in cells and absorption, distribution, 
metabolism and excretion (ADME) studies in small animals. 
Altogether, this thesis aims to compile the in vitro and in vivo information gained by the 
synthesized mono- and dual-labeled Si NP-based (PET/OI) imaging agents and the 
novel bispidine-based PET imaging agents, and thus, mark its contribution towards 
cancer diagnostics. 
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Chapter 2 Literature review and theoretical part1 
 
 
2.1 Molecular imaging of cancer 
 
Molecular imaging is the “visualization, characterization, and quantification of biological 
processes at the molecular and cellular levels in humans and other organisms”, as 
defined by the Society of Nuclear Medicine [80]. 
Currently, there are six major imaging modalities available to assist clinicians in 
diagnosing and curing human cancer: X-ray (plain film and computed tomography (CT), 
ultrasound (US), magnetic resonance imaging (MRI), single-photon emission computed 
tomography (SPECT), positron emission tomography (PET), and optical imaging (OI). 
These modalities cover the electromagnetic spectrum ranging from radio waves (MRI) 
via near-infrared (NIR) down to gamma radiation (PET/SPECT) (Figure 2.1.1) [4, 6, 28, 
81-85]. These non-invasive techniques illustrate, characterize and measure 
physiological and pathophysiological processes on a molecular level in cells, tissues and 
living systems. Of these, only CT, MRI, SPECT, and PET are capable of three-
dimensional (3D) imaging. Each technique has its own unique strength and intrinsic 
limitations, such as spatial depth, resolution and sensitivity, making the achievement of 
precise and reliable information at the disease site difficult. In order to compensate the 
weak aspects, multimodal molecular imaging has been considered in recent years. This 
technique involves the combined usage of the modalities that synergistically exploits the 
advantages of each individual technique combating its drawbacks. 
 
The central theme of this thesis is to develop ultrasmall (< 5 nm) probes capable of 
imaging cancer by a combination of PET and OI. This thesis will also discuss the 
research efforts made towards evaluating the suitability of developed probes for 
application in cancer diagnosis [86, 87]. 
 
                                                          
1 Few sections of this chapter are an excerpt of the published reviews: 
Singh, G.; Gott, M.D.; Pietzsch, H.-J.; Stephan, H. Nuclear and optical dual-labeled imaging agents 
DOI: 10.1055/s-0037-1616472. 
Joshi, T.; Kubeil, M.; Nsubuga, A.; Singh, G.; Gasser, G., Stephan; H. Harnessing the Coordination 
Chemistry of 1,4,7- Triazacyclononane for Biomimicry and Radiopharmaceutical Applications  
DOI : 10.1002/cplu.201800103. 
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Figure 2.1.1: Electromagnetic spectrum and operating ranges of the different imaging modalities: 
from radiowaves (MRI) via near-infrared (NIR) to gamma radiation (PET/SPECT). 
 
2.1.1 Positron Emission Tomography 
 
PET is a valuable functional imaging techniques mainly used to detect the dynamic 
changes in the metabolic function of substances in the human body. PET imaging has 
an advantage of excellent tissue penetration, high detection efficiency, and superb 
quantitative efficiency. It is used to provide real-time, non-invasive, and quantitative 
monitoring of the biodistribution, pharmacokinetics and tumor-targeting efficacy in tumor 
diagnosis. The shortcomings of PET are low spacial resolution, limited acquisition time 
owing to radionuclides with short half-lives, and radiation exposure [88, 89]. 
PET is based on the principle of detecting of gamma (γ) rays from the body (Figure 
2.1.2). A radiolabeled biomolecule is injected into the body, where the radionuclide emits 
a positron (β+) and undergoes annihilation process interacting with an electron (e−). The 
annihilation leads to a pair of 511 keV γ-rays moving in approximate opposite directions. 
These γ-rays may be detected by a set of scintillation crystals that converts it into 
photons. These photons are then detected by photomultiplier or silicon avalanche 
photodiodes. The detection of coincident pairs of these photons is finally recorded and 
transformed to a 3D PET image by a reconstruction software. 
PET requires the use of a cyclotron to generate short-lived radionuclides such as 18F (t1/2 
= 109.8 min), 64Cu (t1/2 = 12.7 h), and 76Br (t1/2 = 16.2 h), or ultra short-lived radionuclides 
such as 11C (t1/2 = 20.3 min), 13N (t1/2 = 10 min), and 15O (t1/2 = 2.04 min) depending upon 
the application and requirements. Of these, 64Cu has garnered specific interest due to its 
favorable decay characteristics. The production method and decay characteristics of  
radionuclides 64Cu, 67Cu and 68Ga are shown in Table 2.1.1. 
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Figure 2.1.2: Illustration of the mechanism and utility of PET imaging.  
 
Table 2.1.1: Production and properties of PET radionuclides (EC = electron capture) [72, 90, 91] 
Radionuclide t1/2 Decay mode γ MeV (%) Production  
  β- MeV (%) β+ MeV (%) EC (%)   
64Cu 12.7 h 0.573 (38.4) 0.655 (17.8) 43.8 
(43.8) 
0.511 (35.6) 
1.35 (0.6) 
Cyclotron, 
64Ni(p,n)64Cu 
68Ga 68 min - 1.9 (87.7%) 11 
(12.3) 
 68Ge/68Ga 
 69Ga(p,2n)68Ge 
 
2.1.1.1 Ligands for radiometals for PET imaging and therapy 
 
Metal-based radiopharmaceutical applications require chemically robust and 
radiolytically stable ligands, which can form radiometal complexes of high 
thermodynamic stability and kinetic inertness. A range of well-established ligands that 
follow the prerequisite of forming inert radionuclide complexes under physiological 
conditions, even at their nanomolar concentrations, have been reported [92-95]. 
Examples of commercially available radiometal chelators that have been derived from 
two well-known azamacrocycles cyclam (1,4,8,11-tetraazacyclotetradecane) and TACN 
(1,4,7-triazacyclononane), include TETA and NOTA. 
The stability constants and coordination geometries of the Cu(II) complexes formed by 
these, and other widely used macrocyclic chelators, are reported in Table 2.1.2. The 
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crystal structures of the two frequently employed chelators Cu(II)-DMPTACN and Cu(II)-
NOTA are shown in Figure 2.1.3. These ligands specifically are known to form 
mononuclear complexes with 1:1 metal-ligand stoichiometry. 
 
Rapid radiolabeling at room temperature becomes essential when working with chelators 
conjugated to antibodies, which are usually temperature sensitive, or when using 
radionuclides with short half-life such as 68Ga. Highly preorganized scaffolds like 
substituted cross-bridged macrocycles and their derivatives and 3,7-
diazabicyclo[3.3.1]nonane (bispidines) which show optimal chelation properties are 
excellent examples of such biologically suited chelators. The facile synthesis of these 
chelators makes them one of the most exploited ligand systems for biomedical 
applications. 
 
 
Figure 2.1.3: The crystal structures and coordination sphere geometry of Cu(II)-NOTA, Cu(II)-TACN 
and Cu(II)-DMPTACN. 
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Table 2.1.2: Macrocyclic ligands with their structure, thermodynamic stability constants (log KCu(II)-L) 
and coordination geometry (Copper(II)-Ligand stoichiometry 1:1). 
Ligand Structure log KCu(II)-L 
(Coordination geometry) 
Ref 
NOTA 
(1,4,7-triazacyclononane- 
1,4,7-triacetic acid) 
 
21.6 
(Distorted trigonal prism) 
[96] 
DMPTACN 
bis(2-pyridylmethyl)-1,4,7-
triazacyclononane 
 
> 25 
(Distorted square 
pyramidal) 
[97] 
NODAGA 
1,4,7-triazacyclononane,1-
glutaric acid-4,7-acetic acid 
 
20 
(Distorted trigonal prism) 
[72] 
DOTA 
(1,4,7,10-
tetraazacyclododecane-
1,4,7,10-tetraacetic acid) 
 
22.7 
(Distorted octahedron) 
[98] 
 
Cyclam 
(1,4,8,11-
tetraazacyclotetradecane) 
 
27.2 
(Square planar) 
 
[99] 
TETA 
(1,4,8,11-
tetraazacyclotetradecane- 
1,4,8,11-tetraacetic acid) 
 
21.9 
(Distorted octahedron) 
[100] 
 
As a part of this thesis, we will discuss the radiolabeling and biodistribution studies of 
bispidine and NOTA based 64Cu-labeled PET and PET/OI dual-labeled imaging agents.  
 
2.1.1.1.1 NOTA as a radioligand for 64Cu and 68Ga 
 
Owing to the favorable binding affinity of NOTA for 64Cu and 68Ga radionuclides, in vivo 
studies have mostly been performed with 64Cu(II) complexes of NOTA-attached 
biomolecules and, derivatives thereof [97]. For example, 64Cu–NOTA was coupled to a 
bombesin (BBN) tetradecapeptide derivative via a linker to target the gastrin-releasing 
peptide receptor (GRPR). Similarly, 64Cu–NOTA-ML (multi-leucine peptide) was 
developed for PACE4-targeted prostate cancer detection, 64Cu–NOTA-KCCYSL 
(bacteriophage selected peptide) for recognizing epidermal growth factor receptor 
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(EGFR)-rich breast carcinoma, 64Cu–NOTA-a-MSH (alpha-melanocyte stimulating 
hormone) for melanoma imaging and 64Cu–NOTA-HsTX1 for targeting potassium 
channels for autoimmune diseases. Moreover, with the aim of dual targeting, 64Cu–
NOTA derivatives coupled to peptides that target prostate- specific membrane antigen 
(PSMA)-rich and GRPR-rich tumors have also been developed. NOTA has also been 
used for 64Cu radiolabeling of A33 antibodies to evaluate a pre-targeting approach. 
Derivatives of NOTA with different functionalities like amines, isothiocyanates, 
maleimides and active NHS ester have been reported and utilized in various coupling 
reactions (Figure 2.1.4). 
 
 
Figure 2.1.4: Derivatives of NOTA (1,4,7- triazacyclononane-1,4,7-triacetic acid) chelator with amine, 
isothiocyanate, maleimide and active succinimide ester functionalities. 
 
2.1.1.1.2 Bispidines as 64Cu based PET imaging agents 
 
Bispidine is a bicyclic compound formed by two piperidine molecules over three carbon 
atoms. The highly preorganized and exceedingly rigid bidentate structure of bispidines 
makes them exceptional candidates to study transition metal coordination chemistry 
[101]. Because it resembles naturally occurring alkaloid sparteine (Figure 2.1.5), it is an 
accessible scaffold for interacting with ion channels, G-protein coupled enzymes and 
receptors, and the development of new radiotracers [74, 75, 102-106].  
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Figure 2.1.5: Structure of the natural product sparteine and its resemblance to Bispidine. 
 
The detailed literature available on the configuration, confirmation and the radio-
complexation of bispidines opens up new ventures to explore its possibilities in the field 
of radiopharmaceuticals for the development of potential PET imaging agents [21, 77, 
103, 107-109]. A summary of established hexadentate and octadentate ligands along 
with the substituents is reported in Table 2.1.3. The tetra, penta and hexadentate ligands 
have been optimized for 64Cu mononuclear radiometal complexes for PET imaging to 
study their in vivo targeting capability and stability, whereas the octadentate complexes 
which do not optimally complex 64Cu but form heavy metal complexes (177Lu, 111In and 
225Ac) are currently under investigation [76, 110-113]. 
 
 
Table 2.1.3: Hexadentate (1−8) and octadentate (9) bispidine ligands (L) with their substituents [102]  
L R1 
(C2/4) 
R2 
(N3) 
R3 
(N7) 
R4 
(C1/5) 
X 
(C9) 
 Y 
(C9) 
1 
  
 
 
 
 
 
2 
    
 
 
 
3 
    
 
 
 
4 
    
 
 
 
5 
    
 
 
 
6 
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9 
    
 
 
 
 
Stereochemistry of bispidine 
 
Bispidines are usually synthesized by a multi-component double Mannich condensation 
reaction. An elaborate synthesis of the bispidine core and its derivatives is reported in 
Chapter 3.1. Bispidines usually exist in three conformations, chair-chair (cc), chair-boat 
(cb), and boat-boat (bb) (Figure 2.1.6). The studies suggest that the chair-chair (cc) 
conformer is the most stable one; however, the introduction of substituents can cause 
conformational changes. 
 
 
Figure 2.1.6: Three possible conformations of bispidines (chair-chair, chair-boat and boat-boat). 
 
The diazabicyclononanes derivatives are schematically represented in their usual 
numbering, as shown in Figure 2.1.7. The modified skeleton of the bispidines, in general, 
includes a ketone (or a hydroxyl group) at the C9 carbon atom with two electron 
withdrawing ester groups flanking on the C1/5 positions (R4). The C2/4 positions (R1) 
usually incorporate electron donating aromatic groups, such as the pyridyl moieties and 
show strong metal ligation tendency. 
 
 
Figure 2.1.7: Bispidines in their usual numbering system. 
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Upon modification, the bispidine skeleton can adopt one of the following three 
conformations: chair−chair (cc), chair−boat (cb), or boat−chair (bc). The boat−boat (bb) 
conformation has been found to be energetically unfavorable. Moreover, the substituents 
at positions C2 and C4 can independently exist in either axial or equatorial position, as 
endo-endo (equatorial-equatorial), endo-exo (equatorial-axial) and exo-exo (axial-axial) 
(Figure 2.1.8). This leads to three possible diastereoisomers per conformation. 
However, the configuration required for highly stable metal complexation is the endo-
endo configuration (cis-isomer) because it constitutes the thermodynamically favored 
isomer. 
 
 
Figure 2.1.8: Conformations adapted by C2/4 substituted bicyclic bispidines. 
(The wiggly bonds represent the possible equatorial/axial orientation of the substituents).
 
Cu(II)-Bispidine complexes 
 
2,4-pyridyl-substituted bispidine ligands form Cu(II) complexes with high kinetic inertness 
and thermodynamic stability, and show fast kinetics as well as particularly good 
selectivity for Cu(II) complexation. A comparison of stability constants for tetra, penta 
and hexadentate bispidines is summarized in Table 2.1.4 for different metal ions. 
Molecular modeling calculations of pyridine-substituted hexadentate bispidines confirms 
Cu(II) metal ions to be the most suitable ones with ideal size and shape for complexation, 
in contrast to Ni(II) and Zn(II). Jahn-Teller distortions are frequently observed for Cu(II) 
d9 electronic configuration, which leads to an axial elongation or tetragonal compression 
of the complexes forming distorted geometrical structures [102]. 
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Table 2.1.4: Stability constants of 1:1 Ni(II), Cu(II) and Zn(II) complexes of tetra, penta and 
hexadentate bispidines.[76, 102] 
 
 
Structure 
 
 
 
 
 
 
Denticity Tetradentate Pentadentate Pentadentate Hexadentate 
 Stability constants (log KMetal-Ligand) 
Ni(II) n.d. 6.10 9.54 5.02 
Cu(II) 16.56 18.31 15.66 16.28 
Zn(II) 11.37 8.28 13.57 9.18 
 
 
Another interesting study of the tetrapyridyl-substituted hexadentate bispidines-Cu(II) 
complex reported by Comba et al. confirms a repulsion between the α-hydrogen atoms 
of the two in-plane pyridine donors in a cis configuration (Figure 2.1.9) [114]. This 
interaction generates significant strain in the complex and therefore leads to a loss in 
complex stability. Substituting one pyridine moiety in the system with a pyridazine 
relieves this stress but the lower basicity of pyridazine (pKa = 2.33 vs. 5.23 for pyridine) 
counteracts the steric effect. Structural studies in the solid state and in solution confirmed 
the relief of steric distortion, but potentiometric titration as well as competition 
experiments and the redox potentials revealed similar stabilities for both the Cu(II) 
complexes. The pyridine substituents at the N3/5 and C2/4 positions of bispidines 
provide much-needed sites to form highly stable metal-ion coordination bonds. 
Therefore, an additional functional group is needed on this system if further coupling to 
biological vectors is desired for any potential biomedical applications. 
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Figure 2.1.9: Chemical and Cu(II)-complexed X-ray structures of N7 pyridine (1) and N7 pyridazine 
substituted (2) bispidines.  
[Cu(II)-1]2+ (left) and [Cu(II)-2]2+ (right) with α-hydrogen atoms represented as red balls. (ester moieties and 
the C9 keto group are omitted for clarity) Reprinted and modified from [114] 
 
Ideally, this functionality should be remote to the donor groups involved in complexation 
in order to avoid any kind of interference in chelation. The bispidines skeleton presents 
three potential sites for (two esters C1/5 and a ketone C9) that can be directly exploited 
for incorporating a bioconjugatable functionality [78]. 
 
Biodistribution studies of 64Cu(II)-Bispidine bioconjugates 
 
A reported in vivo biodistribution study of 64Cu(II) labeled bispidine-bombesin derivative 
conjugate shows very fast clearance of the imaging agent through kidneys and urine, 
with very little activity remaining after 1 hour and more in organs other than the kidney 
[76]. The fast-renal elimination and target tissue accumulation of the biomarker is 
expected due to the considerable hydrophilicity and the in vivo stability of the bispidine 
complex. 
 
2.1.1.2 Bifunctional chelating agents (BFCAs) 
 
BFCAs are organic chelators with terminal reactive groups line amines, thiols and 
carboxylic acids which have been used for indirect radiolabeling of biomolecules, 
rendering them suitable for imaging and therapy. It serves the dual purpose of binding to 
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the radionuclide efficiently and forming a highly stable complex, as well as of providing 
a functionality and/or site for attaching targeting vectors, fluorophores (for dual imaging: 
combined PET (or SPECT) and optical imaging) and NPs as a core to provide a platform 
for multifunctionality [63, 66-71, 73, 115-117]. Common bioconjugation strategies utilize 
functional groups such as carboxylic acids or activated esters (e.g. N-
hydroxysuccinimide (NHS)-ester, tetrafluorophenyl (TFP)-ester for coupling amino 
groups to generate amides and to isothiocyanates to form thiourea bonds. The thiol 
functional groups couple to maleimide moieties to form succinimide acid amides. 
 
Copper-free click chemistry is gaining popularity in bioconjugate chemistry with reactions 
like strain-promoted azide–alkyne cycloadditions (SPAAC) [118] (e.g. 
dibenzocyclooctyne/azide reaction) and Diels–Alder click reactions (e.g. 
transcyclooctene/1,2,4,5-tetrazine) (Figure 2.1.10). The azide–alkyne Huisgen 1,3-
dipolar cycloaddition ‘‘click’’ reaction cannot be used for 64Cu-based PET studies for it 
requires copper(I) metal ion as a catalyst, which also has a tendency to complex with the 
ligand itself, thus, hampering its efficiency as a PET ligand. 
 
The chelation of the radionuclides to the BFCAs can be performed by two different 
strategies (Figure 2.1.10): 
1. Pre-labeling strategy: labeling of BFCAs with radionuclides followed by their 
attachment to the conjugates like biomolecules or fluorophores. 
2. Post-labeling strategy: where the BFCAs are first decorated by the sensitive 
conjugates (biological vectors or fluorophores) followed by their radiolabeling. 
 
The structure and physical properties of the radiometal-chelator complex have a large 
impact on the overall pharmacokinetic properties of the radiopharmaceutical construct, 
with many radiometal complexes being very hydrophilic and subsequently leading to 
rapid renal excretion when attached to small vectors like peptides and monoclonal 
antibodies. Linkers are often utilized to connect the biomolecule to the BFCA backbone, 
which helps to further tune the overall lipophilicity, charge and aqueous solubility of the 
radiolabeled conjugate, and thus the inclusive biodistribution and pharmacokinetic 
properties. 
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Figure 2.1.10: Radiolabeling and bioconjugation strategies for the preparation of radiolabeled BFCA–
biomolecule conjugates along with the choice of radionuclides for diagnostic and therapeutic 
applications. 
 
2.1.2 Optical imaging 
 
Optical imaging is a method of obtaining biological information by signals emitted from 
cells, tissues and organisms using optical detection techniques combined with optical 
detection molecules like inorganic nanomaterials or organic fluorophores. The 
fluorescent report groups use excitation light to reach a higher excitation level and then 
emit a longer wavelength visible light to form a biological light source in vitro or in vivo 
for detection. 
An impressive example of multimodal fluorescent probe, demonstrating the potential of 
nanoscale systems, has been reported by Kobayashi et al. A generation 6 PAMAM 
dendrimer was simultaneously equipped with 120 DTPA (diethylenetriaminepentaacetic 
acid) molecules for SPECT imaging (111In) and five NIR dyes (Cy5, Alexa 660, 680, 700, 
780) four molecules each. These dual-labeled probes allow the simultaneous 
visualization of five distinct lymphatic drainages (Figure 2.1.11). 
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Figure 2.1.11: In vivo dual-modal, five-color lymphatic drainage imaging with the ability to visualize 
five distinct lymphatic drainages. 
(a) In vivo multiexcitation spectral fluorescence (right) and post mortem in situ radionuclide (left) images of 
a mouse injected with five distinct G6-(Bz-DTPA)119-(NIR)4-(Bz-DTPA-111In)1 nanoprobes 
intracutaneously into the middle digits of the bilateral upper extremities, the bilateral ears, and at the median 
chin, as shown in the schema (mouse 7 in Table 1). Five primary draining lymph nodes were simultaneously 
visualized with different colors through the skin in the in vivo spectral fluorescence image and are more 
quantitatively seen in the radionuclide image. (b) Ex vivo spectral fluorescence and radionuclide images of 
resected eight draining lymph nodes correlate well to the in vivo imaging. (c,d) The imaging results were 
consistent for all mice examined. Reprinted from [119]  
 
In recent years, fluorescence techniques have been extensively used for studying 
molecular biology as well as the metabolism of small molecules in small animal in vivo 
and ex vivo studies [120]. The resolution of fluorescent probes is high for in vitro systems. 
The near-infrared fluorophores (NIRF) emitting at wavelengths 600 − 900 nm provide a 
better resolution inhibiting the autofluorescence originating from the tissues. Two 
fluorescent dyes, ICG Indocyanine Green (ICG) and methylene blue have thus, been 
approved by the FDA and EMA and have been widely used for animals and also started 
to be used for human applications for optical imaging of tumors (Figure 2.1.12). 
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Figure 2.1.12: FDA and EMA-approved fluorescent dyes for in vitro and in vivo imaging. 
 
The NIRF employed in this thesis are sulfo-Cyanine 5 and IRDye CW 800 that provide 
the necessary penetration depth for in vivo studies in mice, and their emission 
wavelengths also does not overlap with the auto-fluorescence of the tissues (Figure 
2.1.13) [121, 122]. 
 
 
Figure 2.1.13: NIRF dye derivatives (IRDye 800CW was used for this research work). 
 
2.2 Multimodal molecular imaging 
 
Multimodal imaging is a technique that combines two or more non-invasive molecular 
imaging technologies which provides a more efficient and convenient system for 
obtaining further information in disease diagnosis, treatment and monitoring compared 
to unimodal molecular imaging [123, 124]. With its rapid technological advances, pre-
symptomatic detection, targeted therapy, and personalized medicine may be possible in 
the near future using multimodal molecular imaging [12, 125-132]. The development of 
multimodal imaging can be directed in two ways; either by developing exogenous 
techniques, which is the combination of several imaging technologies as a single identity 
or by developing endogenous probes which brings several imaging agents under one 
platform (Figure 2.2.1) [133]. 
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Figure 2.2.1: Representation of the development of medical imaging technique towards multimodal 
imaging. 
Structural imaging: X-ray, CT, MRI, US; Functional imaging: SPECT, PET, OI, MRI 
 
The synergistic combination of PET and OI systems by combining radionuclide and 
fluorescent labeling to a NP platform can be utilized for pre-clinical trials to detect cancer 
tumors. The combination of the direct visualization of OI with the tomographic 3D 
properties, quantification and whole body penetration of PET can be further employed 
for fluorescence-guided surgeries and personalized cancer treatment. An interesting 
example of cancer tumor diagnosis by dual-labeled SPECT/CT and OI modalities is 
represented in Figure 2.2.2. 
Functional NPs, in this regard have gained considerable attention for their ability to graft 
a multitude of functionalities, such as targeting units, solubility enhancers, fluorescent 
tags and chelating agents, onto their surface. Hence, higher sensitivity may be achieved 
compared to small molecules, and there is an almost infinite variability regarding the 
surface functionalization. Their diagnostic, sensor, imaging, vaccine and drug delivery 
applications provide an effective bridge to connect NPs to biological systems [85, 134-
138]. Si NPs, in this regard, with their tunable size and surface properties, extreme 
hydrophilicity and less cytotoxicity make potential candidates for multimodal imaging. 
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Figure 2.2.2: SPECT/CT and NIR imaging for cancer tumor diagnosis. 
Mice bearing human breast cancer xenograft (MDA-MB-231) were injected with 2 nmol of the conjugate 
DLIA-IL-11RR i.v. Representative images show results 24 h after injection. Tumors (arrows) show more 
conjugate uptake than muscle in both SPECT/CT and NIR images. High signal intensity in kidneys showed 
the excretion route of this agent even at very low injection dose. Reprinted and modified from [139] 
 
2.2.1 Silicon nanoparticles as multimodal imaging agents2 
 
Silicon-based NPs hold great promise for wide-ranging optoelectronic and 
biotechnological applications because of their several unique merits including excellent 
optical/mechanical/electronic properties, facile surface modification, and compatibility 
with imaging technologies [42, 140]. As far as biomedical applications are concerned, to 
date, the Si NPs have been applied in bioimaging [141-143] and in real-time 
immunofluorescence imaging [44, 57, 144-147]. For instance, to target cells in a specific 
way, Si NPs have been successfully coupled with single-stranded DNA [148-150], folic 
acid [151], sugars [152, 153], peptides [145] and antibodies [146, 147], and several in 
vitro studies have been performed on their cellular uptake [154-156] and cytotoxicity 
[157-159]. 
The biodistribution and PET imaging of Si NP-based imaging agents was performed for 
the first time by Kauzlarich et al. in C57BL/6 mice. The dextran-coated, manganese-
doped, Si NPs were surface functionalized with a 1,4,7,10-tetraazacyclododecane-1,4,7-
                                                          
2 The terminologies used in the dissertation are according to the ISO/TS 80004-2:2015 (https://www.iso.org)  
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triacetic acid (DO3A) derivative for labeling with 64Cu, enabling PET studies (Figure 
2.2.3). Owing to their relatively large hydrodynamic diameter (HD) (15.1 ± 7.6 nm), the 
particles were rapidly cleared from the bloodstream but with considerable liver uptake. 
To date, only a few biodistribution studies of renal clearable NPs incorporating 
radiolabels high potential for in vivo imaging have been reported [23, 82, 160-164]. 
 
 
Figure 2.2.3: Representation of 64Cu-functionalized dextran-coated silicon quantum dots 
administered intravenously to the in vivo system and a PET image 5 min p.i. showing renal clearance 
and liver accumulation. Reprinted from [40] 
 
Erogbogbo et al. [151, 165] encapsulated Si NPs encapsulated in phospholipidic 
micelles and functionalized them with specific peptides for targeted in vivo cancer 
imaging and sentinel lymph node mapping. Examples of Si NP-based bimodal probes 
have been described by Kauzlarich et al. [45, 166], where iron or manganese doping 
enabled simultaneous MRI and OI. Blue- and red-emitting Si NPs, prepared via 
biomimetic synthesis from diatoms, were very recently reported for dual-color 
immunofluorescent cellular imaging as well as in vivo imaging in C. elegans worms [167]. 
Notably, Sailor et al. reported that porous Si NPs (∼100 nm) could be biodegradable in 
vivo in a relatively short period of time (∼8 h) and the biodegraded product, orthosilicic 
acid, is biocompatible to numerous tissues and is readily cleared via renal clearance [41, 
42]. In a recent study of the biodistribution of Si NPs in a healthy mouse, Prasad et al. 
found that Si NPs of size < 15 nm (micellar and porous) are prone to degrade in the liver 
and spleen within two months [168]. 
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To summarize, the most interesting features borne by the ultrasmall Si NPs to behave 
as promising imaging agent are: 
1. Tunable intrinsic photoluminescence - depends on the morphology and surface 
composition [169]; 
2. Chemical stability - delivered by the covalent Si-C bond;  
3. Functionalizable surface groups; 
4. Biocompatibility, biodegradability and nontoxicity for in vitro and in vivo systems 
[41, 42, 170, 171]. 
 
2.2.1.1 Synthesis of ultrasmall Si NPs 
 
Various high efficacy and workable synthesis strategies have been introduced recently 
for the bulk synthesis of highly fluorescent, chemically robust and photostable Si NPs. 
The particles can be produced either by the electrochemical (top-down) approach or the 
wet- chemical (bottom-up) approach [26, 172-176]. Usually, the top-down methods 
produce samples of higher purity but, with the bottom-up techniques the control on the 
size and surface termination of the NPs is much higher. In recent years, the bottom-up 
strategy for developing Si NPs has been widely pursued. An example for each kind of 
bottom-up synthesis is shown in Figure 2.2.4. The major modes of synthesis are the 
reduction of the silicon precursor, oxidation method, microwave assisted oxidation and 
reduction reactions and the thermal reduction of silsesquioxanes [177-193]. All these 
reactions involve the reduction or oxidation of a silicon precursor in the presence or the 
absence of a surfactant, under inert conditions, to produce hydrogen or halogen-
terminated Si NPs. 
In most cases, the obtained NPs are further functionalized through a hydrosilylation step, 
catalyzed by a platinum catalyst, UV irradiation, or through a reaction with alkyllithium 
reagents. The type of surfactant as well as the reducing agent used for the synthesis can 
dramatically influence the final size of the produced NPs. 
In conclusion, bottom-up techniques provide the opportunity to functionalize the surface 
of the particles with different functional groups ranging from alkyl or alkenyl chains to 
amine, epoxy-, alkoxy-, and azide-groups. Usually the size of particles obtained with 
these methods is very small (< 10 nm), and the emission properties can be tuned from 
blue to red according to the synthetic method used. 
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Figure 2.2.4: Synthesis strategies of ultrasmall Si NPs. 
Reduction of a silicon source (X = OMe, Cl, Br; reducing agent = LiAlH4, NaBH4, LiBH4 or superhydride; 
Surfactant = Tetraoctyl ammonium bromide (TOAB), Pentaethylene glycol monododecyl ether (C12E5), 
Tetrabutyl ammonium bromide (TBAB), Cetyltrimethyl ammonium bromide (CTAB), Didodecyldimethyl 
ammonium bromide (DDAB), Dodecyltrimethyl ammonium bromide (DTAB) or Tetradodecyl ammonium 
bromide (TDAB); R = amine, alkyl chain, epoxy group, alkenyl chain); Oxidation of a silicon source (R = alkyl 
chain, alkenyl chain); Microwave-assisted synthesis; Thermal decomposition of hydrogen silsesquioxanes 
(R = amine, alkyl chain, epoxy group, alkenyl chain). Adapted from [26] 
 
This also suggests that the best methods for synthesis of Si NPs applicable for 
bioimaging purposes would be the ones that can produce ultrasmall, highly hydrophilic 
NPs with small size distribution and bioconjugatable surface groups. As a part of this 
thesis, the microwave assisted hydrothermal synthesis was modified to produce 
ultrasmall, amine-terminated Si NPs with surface properties desirable for the 
development of mono-labeled and dual-labeled imaging agents. 
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2.2.2 Factors affecting the biodistribution and pharmacokinetics of NPs 
 
2.2.2.1 General remarks 
 
The development of NPs is a well-researched area for the last twenty years, although 
we still have very limited knowledge of the in vitro and in vivo behavior of this system. 
For the NPs to behave as perfect imaging agents, its morphology and physicochemical 
properties play a significant role. The in vivo biodistribution pattern dramatically changes 
upon the variation in structure, size, shape, surface charge and functionalities, and the 
density of the construct. These differences are also reflected in the pharmacokinetics 
(e.g. its circulation time, clearance, intracellular fate, and its organ accumulation), the 
toxicity, targetability and clearance mechanism of the NPs. The challenge lies in difficult 
characterization methods, synthetic reproducibility and the multiple combinations of 
factors such as the size and charge and surface groups on the NPs influencing the nano-
bio situations [26, 194-198]. 
 
Size 
 
The NPs of size between < 6 nm efficiently pass through the glomerulus in the kidneys 
and thus are cleared from the system by renal filtration while the particles with larger 
HDs tend to clear via mononuclear phagocytic cells (MPS). MPS include monocytes, 
which circulate in the blood, dendritic cells and macrophages, like Kupffer cells, which 
are present in tissues like liver, spleen, lungs, and bone marrow. These cells rapidly 
sequester particulate matter with HDs larger than approximately 100 nm. A large fraction 
of these NPs also ends up being recognized and engulfed by macrophages as a result 
of “opsonization”. This involves the nonspecific adsorption of various serum proteins 
(immunoglobulins, apolipoproteins, clotting factors, and complement proteins) to the 
surface of the NPs, which eventually leads to the complete loss of targeting capabilities 
[199-201]. 
 
Surface charge 
 
Charged NPs are reported to induce cytotoxicity by causing a disruption in the cell 
membrane, thus, hampering the integrity of the cell. Such NPs also tend to interact with 
the serum proteins due to the electrostatic interactions. Modification strategies such as 
PEGylation, acetylation, succinylation or surface coating of NPs with amphiphilic 
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zwitterionic coatings have been applied to neutralize the surface charge, modulate the 
toxicity of the NPs and prevent its coating with proteins. 
 
Protein Corona  
 
NPs used as targeting agents, upon intravenous administration, come in contact with 
blood as a complex media made up of salts, sugars as well as serum proteins which 
mask the NPs and form a shell around it known as the ‘protein corona’. The formation of 
this adduct can cause an increase in the HD, leading to the reversible or irreversible 
effects on the protein conformation, or the NP surface, its targetability and can induce 
toxic effects on cells/organs or even apoptosis. Various studies are being conducted to 
identify the protein corona, specific proteins associated with NPs, to correlate various 
physicochemical properties to the binding and to understand the underlying mechanism 
(Figure 2.2.5) [197, 202-210]. 
 
 
Figure 2.2.5: Schematic drawing of the structure of nanoparticle-protein complexes in plasma.  
The “core” nanoparticle is surrounded by the protein corona composed of an outer weakly interacting layer 
of protein (left, full red arrows) rapidly exchanging with a collection of free proteins and a “hard” slowly 
exchanging corona of proteins (right). Reprinted from [211] 
 
2.2.2.2 Elimination of the NP-based imaging agents from the body 
 
Renal Clearance 
 
Rapidly eliminating diagnostic agents are preferred over the constructs that tend to 
reside in the body for longer period of time. The major and more preferred pathway for 
such artificial constructs is the renal elimination mechanism, which involves minimum 
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cellular interaction [26, 201, 212-216]. The critical size (HD) for a particle to be renally 
excretable is ≤ 6 nm. Particles larger than this size prefer the hepatic mode of elimination. 
Surface-related properties like overall charge and plasticity also play an important role in 
determination of the fate of the particles. Figure 2.2.6 demonstrates the mechanism of 
renal clearance of the intravenously administered NPs from the body [153, 201, 214, 
217, 218]. Renal clearance mechanism involves the glomerular filtration of the NPs, 
passing through the fenestra present on negatively charged glomerular basement 
membrane. The fenestrae are the nanosized pores which allow a definite sized molecule 
to pass through it. The glomerular basement membrane being negatively charged, 
facilitates a faster elimination of the neutral and positively charged molecules in general, 
and also positively charged NPs compared to its negatively charged equivalents. This is 
probably the primary reason for the kidney retention of the anionic conjugates. This was 
confirmed by a study reporting the renal threshold of anionic NPs to be ~3.7 nm when 
administered intravenously to the in vivo system. NPs larger than the threshold tend to 
stay in the kidneys for a long-term leading to nephrotoxicity and radiation exposure side 
effects in case of radiolabeled NPs [219-223]. 
 
 
Figure 2.2.6: Section of kidney cortex: Typical biodistribution behavior and renal clearance of 
ultrasmall NPs in kidney tissue. 
The NPs below the renal threshold in vivo hydrodynamic diameter of < 6nm are filtered through the 
glomerulus. Positively charged NPs with in vivo diameter of 6-8 nm are more readily filtered than their equally 
sized counterparts possessing anionic surfaces due to electrostatic repulsion by negative charges of the 
glomerular basement membrane. Based on the charge of the NPs, they can either be sustained in the kidney 
cortex or can be resorbed through the tubular fluid to the proximal tubule or filtered out to the collecting duct 
in the form of urine. 
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Hepatic Clearance 
 
Liver is the primary hepatic organ responsible for the catabolism and biliary excretion as 
well as the elimination of all foreign substances in the organism. The NPs larger than the 
threshold to eliminate via renal pathway are considered for hepatobiliary mode of 
excretion. After systemic administration, these nanomaterials are trapped in the 
reticuloendothelial system organs such as liver and spleen. The bigger NPs in circulation 
are directed towards the liver with a dual vascular supply with arterial (hepatic artery) 
and well as venous (portal vein) blood mixing in the fenestrated liver capillaries called as 
the sinusoids. The hepatocytes (endothelial cells) or Kupffer cells (macrophages) 
present here engulf the NPs leading to endocytosis. NPs endocytosed by the 
hepatocytes are potentially processed and passed into the bile, to the intestines, and 
excreted in the form of feces. Other NPs that do not get taken up by these cells rejoin 
the systemic circulation, redistribute, and may return to the MPS organs over the 
subsequent pass and therefore, cleared from the blood stream over time [26, 214, 224]. 
 
Even after severe research investigations, it is still a challenge to designate an ‘ideal NP 
size, geometry or surface functionality’ for biomedical applications. It is crucial to study 
each set of NPs for their specific in vivo behavior, pharmacokinetics and interactions 
within the system to gather more detailed information required for developing more 
effective imaging agents. 
 
2.2.3 Tumor targeting strategies for molecular imaging agents 
 
Considering the NP-based approaches to target cancerous tumors, a series of biological 
vectors have been reported to diagnose and bind specifically to the tumors. According 
to the reported investigations, it is clear that the accumulation of the targeting agents in 
the tumors could be either via passive or active targeting. 
 
2.2.3.1 Passive targeting (Passive accumulation) 
 
The ability of the NPs with sizes between 30–200 nm to target solid tumors is referred to 
as passive targeting [26, 199, 225]. This owes to the enhanced permeability and 
retention (EPR) effect that occurs due to the poorly organized vasculature of the solid 
tumors lacking in structured fenestrations due to the high proliferation of cancer cells. 
This “leaky” vasculature, combined with poor lymphatic drainage, promotes the passive 
accumulation of NPs into it, providing the opportunity to concentrate reasonably sized 
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NP-based therapeutics and diagnostics within cancerous tissue (Figure 2.2.7) [21, 199, 
226-229]. 
 
2.2.3.2 Active targeting 
 
The two main strategies for targeted cancer imaging can be illustrated as:  
 Tumor cell targeting 
 Tumor vasculature targeting 
 
Tumor cell targeting can be achieved by conjugation of specific biological vectors (e.g., 
antibodies, peptides, small molecules) to NPs. These conjugates undergo tumor 
recognition and selective binding to the receptors that are overexpressed on a certain 
tumor cell surface (e.g., epidermal growth factor receptor (EGFR), human epidermal 
growth factor receptor-2 (HER-2), somatostatin receptor-2 (SSTR-2) [122, 229]. 
The high surface area-to volume ratio of NPs allows a high local density of the modified 
NPs to enable better targeting efficiency. However, tumor cell targeting can only work if 
the functionalized NPs are able to effectively reach the tumor cell surfaces after 
extravasation across the vasculature endothelium. The general rules governing the 
extravasation of NPs still remain largely unknown, since NPs with near identical surface 
coating and charge could display surprisingly different extravasation behavior in vivo. 
Even if NPs with suitable shape, size and surface modification could efficiently 
extravasate, they still must overcome many biological barriers (e.g., high interstitial fluid 
pressure, dense collagen matrix) and must penetrate tens to hundreds of micrometers 
through the vasculature endothelium and cell layers before reaching the tumor cell 
surface and binding to the target of interest. All of these challenges explain why most 
tumor cell targeted NPs show highly targeting efficacy in vitro, but rarely exhibit 
significantly higher uptake in vivo in solid tumors when compared with the non-targeted 
counterparts (Figure 2.2.7) [21, 26, 225]. 
 
Tumor vasculature targeting 
 
Tumor vasculature targeting is an alternative strategy, which could be applied to a wide 
variety of well-functionalized NPs regardless of tumor types. This method has several 
benefits over directly targeting the tumor cell. Firstly, all solid tumors depend on 
angiogenesis to receive sufficient blood flow. Therefore, targeting the tumor vasculature 
(i.e., targeting receptors overexpressed on the tumor vascular endothelial cells) could be 
an effective strategy for most solid tumors in vivo. Secondly, while tumor cells maybe far 
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away from blood vessels, tumor endothelial cells are directly exposed to circulating 
blood, which can greatly facilitate the binding of functionalized NPs without the barrier of 
extravasation [230]. Vasculature targeting of tumor angiogenesis can be achieved using 
biomarkers on the surface of tumor endothelial cells. Vasculature targeting moieties, 
including vascular endothelial growth factor (VEGF) and RGD (Arg-Gly-Asp) peptides, 
have been conjugated to the surface of different NP such as quantum dots (QDs), single-
walled carbon nanotubes (SWNT), and graphene oxide (GO) for enhanced tumor 
targeted imaging and drug delivery [21, 26, 225]. 
 
 
Figure 2.2.7: Difference between the active and passive targeting of tumors. 
(Left) In normal healthy tissue, endothelium of the vessels is quite impermeable for nanomaterials. Leaky 
fenestrated endothelium in the tumor bed allows the particles to diffuse and accumulate primarily due to the 
enhanced permeability and retention effect. (Right) In active targeting, the extravasated particles due to the 
presence of targeting vectors facilitate the interaction with the overexpressed receptors on the tumor cells 
resulting in an enhance accumulation and preferential cellular uptake through a receptor-mediated process. 
 
As a conclusion, we can say that the contribution of NP-based passive targeting (EPR-
mediated) as well as active tumor targeting (via active receptor-ligand interaction) leads 
to an effectual diagnosis of the cancer tumors during pre-clinical and clinical trials but 
not much is known about the biological fate of the administered NPs. The extent of tumor 
targeting which is majorly determined by factors like size, shape and surface 
functionalization of the NPs is still an area of research. 
 
2.2.4 Targeted functionalization of NPs and BFCAs for imaging purposes 
 
Following the active tumor targeting strategy, selected tumor biomarkers are needed to 
facilitate effective localization of the multi-functionalized NPs in the tumor tissue and to 
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minimize unspecific uptake in non-targeted organs. A variety of targeting molecules 
including receptor-specific peptides, aptamers, carbohydrates as well as antibodies, their 
fragments and other proteins have been exploited for active tumor targeting of 
multimodal NPs. 
 
Camelid Single Domain Antibodies for EGFR Active Targeting 
 
The first choice for this purpose were nanobodies or single domain antibodies (sdAb) 
that are based on the single variable domain of heavy chain antibodies (HCAb − VHH) 
devoid of light chains [96, 121, 231, 232]. These are amongst the smallest known 
antibody-binding fragments (13-15 kDa) that can retain full functional advantages of the 
conventional antibodies (Figure 2.2.8). They are endowed with unique properties such 
as low immunogenicity, high solubility, tailored shelf-life and high specificity. With a 
diameter of only 2.4 nm and height of 4 mm, they are excellent choice as EGFR specific 
cancer biomarkers with their ability to recognize uncommon or hidden epitopes, high 
tumor binding avidity and penetration potential followed by fast circulation kinetics [233, 
234]. The sdAb are also reported to exhibit high stability in variable temperature and pH. 
Recently, an economic production of these nanobodies via microorganisms has also 
been reported by our laboratory [235]. 
 
 
Figure 2.2.8: Smallest known fully functional camelid antibody- fragment (Nanobody) derived from 
heavy chain only antibodies. 
(VHH- variable domain of the heavy chain of heavy-chain antibodies (HcAb)) 
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Somatostatin analogues (Octreotate, Octreotide) for Somatostatin receptor 
(SSTR) Active Targeting 
 
Somatostatin receptors (SSTR) are known to be expressed in a large number of human 
neuroendocrine tumors and represent the basis of in vivo targeting in humans. The 
crucial conditions for the targeting of tumor cells with a high density of SSTR shapes to 
a sufficiently long biological half-life, the possibility of labeling with various radionuclides 
and, in particular, the ability of SSTR-positive tumor cells to specifically bind and 
internalize radiolabeled SST analogues [236-242]. Several SST analogues labeled with 
γ-emitters such as 111In-labeled pentetreotide, 111In-labeled DTPA-octreotide 
(Octreoscan®) or 99mTc-labeled depreotide (NeoTect™) are commercially available and 
clinically successfully used for diagnosing different types of tumors and their metastases. 
The therapeutic application of SST analogues labeled with β-emitting particles (177Lu, 
90Y) is of major importance for such endocrine tumors. Alongwith its high therapeutic 
potential, it known to be accompanied by occurrence of delayed radiation-induced 
toxicity to kidney, bone marrow and liver [242-244]. 
 
The research idea was to improve the pharmacological behavior by preparing bispidine-
based TATE (Tyr3-Octreotate) conjugates that can behave as a targeted PET diagnostic 
agent. This may ensure a positive tumor detection as well as a rapid renal elimination 
from the in vivo system minimizing the chances of nephrotoxicity and low accumulation 
of the biomarker in the vital organs of the system. A TATE peptide modified with 
oxyethylene groups to increase hydrophilicity for tumor targeting is shown in Figure 
2.2.9. 
 
Figure 2.2.9: Structure of EG-TATE.3 
 
                                                          
3 EG in this context is an acronym for diethylene glycol. 
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Chapter 3 Results and Discussion 
 
 
The experimental work done for this dissertation can be conveniently divided into 
following sections: 
 
Chapter 3.1 
This section constitutes the design and synthesis of novel bispidine-based BFCAs. It 
involves the modification of the bispidine core at the C9-position, allowing the conjugation 
to a series of sensitive biomolecules and to the Si NPs. The optimized synthetic 
procedures, purification and characterization data of the novel derivatives has been 
reported in this section. The 64Cu complexation kinetics to determine the radiolabeling 
efficiency of the bispidines is also stated here. 
 
Chapter 3.2 
This section ascribes the bioconjugation of isothiocyanate-functionalized and 
dibenzocyclooctyne–functionalized bispidines with receptor-specific TATE peptide and 
sdAb 7C12 respectively, for active cancer tumor targeting via PET imaging. The synthetic 
protocols, purification strategies and characterization studies followed by preliminary 
radiolabeling and cytotoxicity studies of the bispidine bioconjugates has been 
encompassed in this section. 
 
Chapter 3.34 
This section is dedicated to the synthesis of multifunctional amine-terminated Si NPs. 
The hydrothermal synthesis of ultrasmall Si NPs along with the characterization data is 
descripted in this section. 
 
Chapter 3.4 
Towards the development to mono-labeled imaging agents, this section deals with the 
modification of the Si NP surface with PET or OI modular ligands. PET imaging agents 
were developed by coupling the Si NPs to the isothiocyanate-terminated bispidines and 
NOTA BFCAs respectively. OI agents, on the other hand, were produced by conjugating 
the fluorophores, taking advantage of the active NHS-ester chemistry. The synthesized 
                                                          
4 The synthesis and characterization of the Si NPs were performed in the group of Prof. Luisa De Cola 
(University of Strasbourg). 
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Si NP conjugates were characterized by unique methods and evaluated for their 
cytotoxic and biodistribution behavior.  
 
Chapter 3.5 
In this section, the amine-terminated Si NPs were modified to develop a distinct dual-
labeled imaging agent. Si NPs were conjugated to the IR 800 fluorophore and NOTA 
BFCA concurrently. The reaction synthesis was optimized by applying two different 
synthesis strategies: one pot method and stepwise synthesis. The Si NP-IR800-NOTA 
was meticulously characterized and further evaluated by cell and biodistribution studies. 
PET and OI molecular imaging techniques were used for the in vitro and in vivo 
examination. 
 
Chapter 3.6 
In this section, both, mono-labeled and dual-labeled fluorescent Si NPs were coupled to 
a chimeric anti-platelet factor 4, 5B9 peptide. The synthesis of the targeted Si NPs 
bioconjugates via a bifunctional linker (PEG) to produce Si NP-IR800-PEG-5B9 and Si 
NP-IR800-NOTA-PEG-5B9 is reported here. 
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Chapter 3 Results and Discussion 
 
 
3.1 Synthesis, characterization and radiolabeling studies of hexadentate 
bispidine-based bifunctional chelating agents 
 
Bispidine-based scaffolds have been extensively explored for radiopharmaceutical 
applications because they can form radiometal complexes with high kinetic inertness and 
thermodynamic stability [102, 113, 245]. In particular, there continues to be considerable 
interest in studying the coordination chemistry of bispidine-derived ligands with a view to 
developing them as suitable chelators in particular for radiocopper, as these can be used 
for both imaging (64Cu) and therapy (67Cu) [71, 77, 78, 102, 103, 113, 114, 208, 218, 
245, 246]. Recently, novel octadentate picolinic acid-based bispidine ligands have been 
also proposed for radiopharmaceutical applications using 111In, 177Lu and 225Ac [113]. 
The literature serves a good amount of data for such bispidine cores, confirming their 
facile synthesis, large synthetic variability, as well as the ease of derivatization with 
biological vectors [247-250]. Unless hindered by a bulky substituent, the bispidine core 
also adopts the most stable double chair configuration, with endo-endo being the favored 
orientation for the tethered substituent (Figure 3.1.1). 
 
 
Figure 3.1.1: The most stable double chair (cc) configuration of bispidine with endo-endo pyridyl-
substitution at C2/4. 
 
An interesting example delineating the impact of substituents on Cu(II)-binding efficiency 
of bispidines compares two isomeric pentadentate derivatives, with pyridyl groups 
positioned at the N3 and N7 positions respectively (Figure 3.1.2) [102]. The pyridyl-
substitution at N7 results in higher stability of the Cu(II) complex in comparison to the 
one featuring N3-positioned pyridyl arm (log K = 18.31 vs 15.66 for the N3 derivative). A 
probable reason for this chelation behavior is that the Cu(II) coordination sphere remains 
unaffected by the N3 substituent which contributes minimally for the radiometal chelation. 
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Although, the experimental and computational studies confirm that for biological 
applications, the hexadentate (N3 and N7 dipyridyl-substituted) ligands are a preferred 
choice due to better encapsulation of the metal ion in the coordination sphere under 
physiological conditions. 
 
 
Figure 3.1.2: The N3 and N7 substituted pentadentate bispidine isomers showing prominent 
differences in their stability constants for Cu(II) complexes. 
 
Interestingly, synthetic modification of the bispidine scaffold at the C9 position remains 
largely unexplored. This is despite the knowledge in hand that the C9-positioned 
substituents bear no direct influence on the Cu(II) coordinating environment. The X-ray 
crystal structure of tetrapyridy-bispidol (C2/4, N3/7 substituted) confirms that the C9 
position is remote to the coordination site of the metal atom and does not interfere with 
any electron-donating group participating in the chelating process (Figure 3.1.3) [218]. 
 
 
Figure 3.1.3: Coordination environment around the Cu(II) ion in Bispidol.  
Thermal ellipsoids drawn on a 30% probability level. Gray spheres denote carbon, red spheres oxygen, blue 
spheres nitrogen, and yellow spheres copper atoms. The overlay with the space-filled model shows the 
efficient encapsulation of the copper ions by the ligand. Reprinted from [76] 
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A discrete example for C9-modified bispidine involves the reduction of the keto group to 
form the corresponding bispidol, which was then linked to a boron-dipyrromethene 
(BODIPY) derivative, propargylamine or a bombesin (BBN) peptide sequence using a 4-
nitrophenyl bispidine carbonate derivative. Continued interest in bispidine-based 
bifunctional chelators prompted us to explore the possibility of developing hexadentate 
bispidines, modified at C9 position to provide a site for optional attachment of vector 
molecules and/or fluorescence tags. 
 
This chapter describes the synthesis and detailed spectroscopic characterization of a 
series of hexadentate bispidine derivatives and their bioconjugates, together with the 
assessment of their ability to form complexes with copper radionuclides for potential 
application in cancer diagnosis (PET imaging) and therapy (Chapter 3.1 and 3.2). 
 
3.1.1 Synthesis of hexadentate bispidine-based ligands 
 
3.1.1.1 Synthesis and characterization of Piperidone (B1’), Bispidone (B1) and 
Bispidol (B2) precursors5 
 
The synthesis of bispidine scaffold follows two consecutive Mannich reactions 
(Experimental section 5.4.1). A slightly modified synthetic route was applied for 
synthesizing hexadentate tetrapyridyl-bispidines (Scheme 3.1.1). In the first step, 2-
picolylamine (a) and 2-pyridinecarboxyaldehyde (b) react to generate an imine 
intermediate. The alpha-hydrogen of the dimethyl-1,3-acetonedicarboxylate (c) 
facilitates its keto-enol tautomerism, which reacts with the freshly formed imine. The 
reaction occurs twice for primary amines and furnishes the product Piperidone (B1’), 
which is a β-amino-carbonyl compound and also known as the Mannich base. The 
second reaction enables the formation of a rigid cyclonane ring when after Piperidone is 
attacked by the new imine formed by the reaction of formaldehyde (d) and 2-picolylamine 
(a). The product formed after the completion of two Mannich reactions is termed as 
Bispidone (B1) with a ketone at C9 position. The 13C NMR and FTIR spectra of B1 is 
reported as Figure 3.1.8 and Figure 3.1.9. 
                                                          
5 The ESI-MS and 1H NMR spectra of B1’, B1 and B2 are reported as supporting information Annex 
(Figure 7.1-7.4) 
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Scheme 3.1.1: The synthetic scheme of Bispidone (B1) via double Mannich reaction with Piperidone 
(B1’) as an intermediate. 
(a) 2-picoylamine, (b) 2-pyridinecarboxyaldehyde, (c) dimethyl-1,3 acetonedicarboxylate, (d) formaldehyde). 
 
The bispidone derivative once formed has a tendency to undergo a retro-Mannich 
reaction that leads to the formation of epimers by the ring cleavage and rotation of C-N3 
bond as represented in Scheme 3.1.2. 
 
Scheme 3.1.2: Retro-Mannich reaction caused by the carbonyl at C9 that might lead to the formation 
of epimers. 
 
To avoid this situation, the carbonyl group at the C9 was subjected to NaBH4-mediated 
reduction to form the corresponding bispidol (B2), prior to any further chemical 
modification. The reduction procedure was slightly modified from the literature data. 
Product B2 was purified by recrystallization as a white crystalline powder (Scheme 
3.1.3). 
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Scheme 3.1.3: Reduction of the C9 carbonyl of B1 to secondary hydroxyl group in B2. 
 
The reduction of keto group at C9 position was confirmed by appearance of a signal for 
the hydroxyl carbon at 72 ppm in the 13C NMR spectra, along with the disappearance of 
carbonyl resonance at 203 ppm (Figure 3.1.8). Moreover, a peak at m/z 596.2 
(calculated m/z 594.26) corresponding to [M+H]+ ion was the observed in the ESI-MS of 
B2 (Figure 3.1.4). As expected, the FTIR spectra showed a strong O-H stretch for the 
hydroxyl group of B2 at 3500 cm-1 in Figure 3.1.9. 
The literature corroborates B2 as a hexadentate ligand for 64Cu(II) radiotracers and its 
applicability for PET. The stability constant for the Cu(II)-B2 complex has been 
experimentally determined and reported to be log K 16.28 [102]. 
 
 
Figure 3.1.4: ESI-MS spectra of B2 showing the [M+H]+ ion peak at m/z 596.2. 
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3.1.1.2. Synthesis and characterization of C9-modified novel B2 derivatives B3−B5 
 
 Bispidine amine derivative B36 
 
B2  as a precursor was modified with a halo-alkyl amine linker at the C9 position to create 
an amine-functionalized bispidine-based bifunctional chelating agent, which can be 
conjugated to isothiocyanate or active NHS-ester terminated biological vector and can 
be utilized as targeted PET imaging agents. 
Propyl amine was the linker of choice to modify the hydroxyl group at C9 position of B2. 
The terminal amine of the bromo-propyl amine was protected by tert-butyloxycarbonyl 
(Boc) protecting group to develop L1 (Figure 3.1.4). A white crystalline product obtained 
in 70% yield after column chromatography was characterized by NMR. The 1H NMR 
spectra displayed a characteristic singlet at δ 1.3 ppm for the tert-butyl protons of L1 
(Figure 3.1.5). 
 
 
Scheme 3.1.4: The two-step synthesis scheme of the B3. 
(i) Reaction of B2 to L1 to form Boc-protected B3’, (ii) The deprotection reaction leading to the amine-
terminated B3. 
  
The reaction between B2 and L1 lead to the formation of a Boc-intermediate (B3’) as a 
result of nucleophilic substitution reaction. The hydroxyl group at C9 of B2, under basic 
conditions, attacks the brominated carbon, which is electrophilic in nature. Bromide ion, 
a good leaving group quickly cleaves off furnishing the B3’. The work-up of the crude 
product was performed to extract the product in chloroform by liquid-liquid extraction 
                                                          
6 The synthetic optimization of the precursor B3 was performed by Sebastian Hunoldt and Carmen Rühl at 
Helmholtz-Zentrum Dresden - Rossendorf. 
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against water. The organic layer was evaporated to extract a brown-oily product in 35% 
crude yield. The intermediate B’ was analyzed by NMR and mass spectroscopy. 
The 1H of crude B3’ depicted two peaks for the tert-butyl protons from L1 and B3’ 
between δ 1.4–1.3 ppm (Figure 3.1.5). ESI-MS confirmed the identity of B3’ with a 
[M+H]+ ion at m/z = 751.8 (calculated m/z 751.37)  (Annex Figure 7.6). 
 
 
Figure 3.1.5: Comparative 1H-NMR spectra (aliphatic region) of L1, (B3’+B3) and B3 with labeled 
characteristic signals. 
 
B3’ was deprotected under acidic conditions by trifluroacetic acid (TFA) to furnish B3. 
Mass spectrometry with a [M+H]+ ion at m/z = 651.4 (calculated m/z 651.32)  confirmed 
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the complete deprotection of the amine and the identity of product B3 (Annex Figure 
7.7). The product was purified by preparative reverse-phase HPLC (“Method B” Section 
5.2) (Rt = 11.5 min) (Figure 3.1.7) and characterized by 1H and 13C NMR and FTIR 
spectroscopy. 
A comparative NMR spectra of A, B3’ and B3 is displayed in Figure 3.1.5. 1H NMR 
spectra of B3 shows no peaks corresponding to tert-butyl protons from the Boc-group 
confirming a successful deprotection of B3’. An appearance of a singlet at δ 4.3 ppm for 
B3’ supports the functionalization via C9 hydroxyl moiety and its characteristic shift to δ 
4.75 ppm for B3 confirms the deprotection of the primary amine. The protons from the 
propyl chain on B3 appear in the range of δ 3.7–1.9 ppm (Figure 3.1.6). 
 
 
Figure 3.1.6: 1H-NMR spectrum of B3 (measured in CD3CN). 
 
The FTIR spectrum depicts a strong N-H stretch between 3500 to 2900 cm-1. The 
carbonyl vibration of esters (O=C-O) at C1 and C5 positions is recorded between 1800 
to 1750 cm-1. N-H bending peaks are observed from 1160 to 1130 cm-1 and the ether 
group (C-O stretch) is observed at 1200 cm-1 (Figure 3.1.9). This data thus confirms the 
successful synthesis of B3. 
The efficiency to encapsulate 64Cu and conjugate to biological vectors with compatible 
functionalities like active succinimide esters, isothiocyanates and the carboxylic acids 
makes B3 a potential BFCA for imaging and radiopharmaceutical applications. 
Therefore, after the successful synthesis and analysis of B3, it was used as a precursor 
for developing additional derivatives B4-B9, with varying functional moieties 
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complementary to the functionalities present usually on the delicate biomolecules like 
the antibodies and peptides (Scheme 3.1.5). 
 
 
Figure 3.1.7: Comparative RP-HPLC chromatograms for B1−B5 with their respective retention times 
(Rt). 
(RP-HPLC (Method B) Gradient 30% to 70% B in 30 min; Mobile phase: A = H2O + 0.1 Vol. % TFA, B = 
CH3CN + 0.1 Vol. % TFA; Flow rate = 1 mL/min, λ = 220 nm). 
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Figure 3.1.8: Comparative 13C-NMR spectra of ligands B1−B4 with labeled characteristic NMR 
signals. 
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Figure 3.1.9: Comparative FTIR spectra for B1−B5 with labeled characteristic vibrational frequencies. 
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Scheme 3.1.5: Modification and functionalization of B3 to develop bispidine-derivatives B4−B9 with 
different bioconjugatable functionalities. 
 
Bispidine isothiocyanate derivative B4 
 
 
Scheme 3.1.6: The synthesis of isothiocyanate-terminated B4 by reacting B3 with para-phenylene 
diisothiocyanate. 
 
B3 when reacted with para-phenylene diisothiocyanate under basic conditions, the 
nucleophilic amine attacks the electrophilic carbon of the isothiocyanate, resulting in a 
stable thiourea linkage (Scheme 3.1.6). No leaving group is involved in this reaction. 
Due to solubility differences, product B4 precipitates in diethyl ether and can 
conveniently be extracted. Although, B4 was also purified by RP-HPLC (“Method B” 
Section 5.2) with Rt = 26.1 minutes for a high purity content because of its subsequent 
applications in biological studies. 
The [M+H]+ ion peak at m/z 843.3 (calculated m/z 843.30) confirmed the identity of the 
isothiocyanate derivative B4 (Annex Figure 7.7). The 13C NMR of B4 showed an influx 
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of aromatic carbons in the range of 155–125 ppm and the characteristic resonance 
isothiocyanate carbon was observed at δ 182 ppm (Figure 3.1.8). The FTIR of the B4 
showed the characteristic N=C=S stretch at 2140 cm-1 (Figure 3.1.9). 
 
Bispidine dibenzocyclooctyne derivative B5 
 
 
Scheme 3.1.7: Modification of B3 to B5 by using NHS-DBCO reagent. 
 
Cyclooctynes are useful in strain-promoted copper-free click-chemistry based 
cycloaddition reactions as they can react with azide-functionalized biomolecules without 
the need for a Cu(I) catalyst to result in a stable triazole linkage. The absence of 
exogenous metal catalysts like Cu ions make the reactions suitable for the in vivo 
applications of bioorthogonal chemistry. For instance, Cu ions have a tendency to bind 
to bispidine that hampers its 64Cu(II) radiolabeling efficiency which is a crucial factor for 
PET-based imaging. 
Cyclooctyne-functionalized bispidine B5 was synthesized during overnight room 
temperature stirring of B3 with a commercially available active NHS-ester analogue of 
dibenzocyclooctyne (DBCO-NHS ester) (Scheme 3.1.7). The crude product B5 was 
purified by HPLC (“Method B” Section 5.2) with a retention time (Rt) of 26.1 minutes. 
The high retention time of B5 compared to the precursor B3 (Rt = 11.5 minutes) signifies 
an increase in the lipophilicity of B5 due to the addition of the aromatic DBCO moiety in 
the structure. 
The mass spectrometric characterization specifies the formation of B5 by [M+H]+ ion 
peak at m/z 939.1 (calculated m/z 938.41) (Figure 3.1.10). The 1H NMR of B5 shows a 
cluster of aromatic peaks between 7.6–7.2 ppm characteristic for protons of the dibenzyl 
group (Annex Figure 7.9). 
 
Results and Discussion 
 
50 
 
 
Figure 3.1.10: ESI-MS spectra of B5 showing the [M+H]+ ion peak at m/z 939.1. 
 
3.1.1.3. Synthesis and characterization of C9 modified novel derivatives 
B6−B9 
 
Thiolated bispidine derivatives B6 and B7 
 
Thiol-terminated BFCA are essential for bioapplications due to their compatibility with 
maleimide-terminated biological vectors. The coupling occurs via Michael type addition 
reaction. The synthetic scheme for two-sulfhydryl derivatives B6 and B7 is reported as 
Scheme 3.1.8.  
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Scheme 3.1.8: The synthesis of B6 (one step) and B7 (two steps) from the precursor B3. 
 
B6 was prepared in a single-step by reacting B3 with Traut’s reagent (2-iminothiolane) 
under basic conditions. The reaction proceeds with the 2-iminothiolane ring opening, 
leading to the formation of a terminal thiol group with an amidine bond. An interesting 
result was obtained by mass spectrometry analysis of B6. The mass spectrum depicts 
an intramolecular recyclization side reaction occurring within the molecule B6 (Scheme 
3.1.9). 
 
 
Scheme 3.1.9: Representation of intramolecular cyclization reaction of B6 and its determination by 
mass spectrometry. 
 
The ionization of B6 eventually leads to the loss of an immonium ion fragment (m/z 17) 
from the molecule as shown in the mass spectra (Figure 3.1.11). This hypothesis is 
supported by the literature and also confirms that this side reaction does not affect the 
coupling tendency of thiol-bearing B6 to maleimide-based compounds [251]. 
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Figure 3.1.11: ESI-MS spectra of B6 showing the [M+H-17]+ and [M-17+2H]++ ion peaks at m/z 736.2 
and 368.7. 
 
The second thiolated derivative B7 is synthesized by two consecutive coupling and 
deprotection reactions. B7’ intermediate was obtained by stirring B3 with N-succinimidyl-
S-acetylthioacetate (SATA) at room temperature for 2.5 hours leading to stable amide 
bond formation. SATA is a thiolating reagent ensuring the covalent modification of 
primary amines to protected yet exposable sulfhydryl groups. 
B7’ with a protected thiol can be stored safely for long period (upto 8 months) and can 
be treated with hydroxylamine to generate B7 with the labile sulfhydryl group when 
needed for further conjugation reactions. The deprotection reaction is performed under 
aqueous hydroxylamine/EDTA/sodium bicarbonate solution stirring for 3 hours. 
The product was purified by HPLC (“Method D” Section 5.2), followed by freeze drying 
of the pure fractions to obtained B7 as a colorless solid in 68% yield. The mass 
spectrometry of the [M+H]+ ion at m/z of 725.5 (calculated m/z 725.30) confirms the 
identity of B7 (Figure 3.1.12). 
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Figure 3.1.12: ESI-MS spectrum of B7 showing the [M+H]+ ion peak at m/z 725.5. 
 
Bispidine phenyl amine derivative B8 
 
The idea behind the development of an aromatic amine-derivative of the bispidine is to 
increase the blood retention times of its targeted bioconjugate (coupled to a peptide or 
monoclonal antibody) due to a lipophile attached to the amine-terminated bispidine. 
Shorter blood half-lives of the conjugates and rapid elimination is favored for diagnostic 
purposes but considering the therapeutic applications, slight body retention is a preferred 
choice [198, 252]. 
 
Scheme 3.1.10: The derivatization of B3 to B8 via a two-step synthesis. 
 
B8 derivative was produced by reacting precursor B3 to a freshly prepared linker L2, in 
small amount to test the feasibility of the two-step synthesis. The synthesis scheme of 
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L2 is shown in Figure 3.1.10. It was then purified by column chromatography and 
characterized by NMR spectroscopy. The 1H NMR of L2 (Figure 3.1.13) displayed a 
singlet at δ 1.5 ppm which corresponds to the 9 tert-butyl protons. The aromatic 
multiplets were observed between δ 7.5-7.3 ppm. 
 
 
 
Figure 3.1.13: 1H-NMR spectrum of L2. 
 
The coupling of the L2 to B3 was performed by a 24 hour stirring of the reaction at 85 
OC. The crude product was confirmed by mass spectrometry and the deprotection 
reaction was performed in situ. The intermediate B8’ and product B8 were identified by 
ESI-MS spectrometry as [M+H]+ ion at m/z 899.3 (calculated m/z 899.43) and 799.5 
(calculated m/z 799.38) respectively (Annex figure 7.13).  
 
Bispidine triglycine derivative B9 
 
The amine-terminated precursor B3 behaves as a potential BFCA to develop a proficient 
bioconjugate B9, for non-invasive, in vivo PET imaging and therapy. The aim was to 
perform sortase-A mediated site-specific labeling of single-domain antibody-fragments 
(sdAbs) by the triglycine-functionalized end of the conjugate B9 (mechanism explained 
in Chapter 3.2) [232]. Radiolabeling and cytotoxicity studies of this conjugate are not a 
part of this work. 
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Scheme 3.1.11: Synthesis of bioconjugate B9 via a two-step synthesis from B3. 
 
The bioconjugate B9 was prepared by a two-step synthesis strategy (Scheme 3.1.11). 
The first step involves the conjugation of B3 to a commercially available Fmoc-triglycine 
peptide by the formation of a stable amide bond. The intermediate B9’ was purified by 
RP-HPLC (“Method C” Section 5.2) and identified by mass spectrometry as [M+H]+ ion 
at m/z 1045.4 (calculated m/z 1045.4) (Annex Figure 7.14). 
In the second step, B9’ was deprotected under basic conditions using 20% piperidine in 
DMF to obtain the final bioconjugate B9. It was also purified by RP-HPLC (“Method C” 
Section 5.2). Mass spectrometry confirmed the identity of the B9 with the [M+H]+ ion 
peak at m/z 822.6 (calculated m/z 822.38) (Figure 3.1.14). 
 
 
Figure 3.1.14: ESI-MS spectrum of B9 showing the [M+H]+ ion peak at m/z 822.6. 
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3.1.1.4. Synthesis and characterization of C1/5 modified derivatives B10 and 
B11 
 
The bispidine-derivatives B10 and B11 showcase the modifications at C1/5 positions, 
contrary to the previous C9 modified derivatives (B3−B9). These modifications allows 
the study of the influence of different side chains on the physiological properties of the 
conjugates for in vivo experiments. 
 
Bispidine carboxylic acid derivative B10 
 
The C1/5 dicarboxylate derivative B10 was hydrolyzed by dissolving B3 in a cesium 
hydroxide-tetrahydrofuran solution and stirred for 24 hours at room temperature 
(Scheme 3.1.12). The white emulsion obtained was then acidified by 1M HCl and the 
solvent was evaporated. Crude B10 obtained was then purified by RP-HPLC (“Method 
D” Section 5.2) and characterized by NMR spectroscopy. 
 
 
Scheme 3.1.12: Hydrolysis of the C1/5 esters of B2 to yield dicarboxylic acid derivative B10. 
 
In 1H NMR, a loss of the characteristic 6 proton singlet of the methyl esters confirms the 
basic hydrolysis of B3 precursor (Annex Figure 7.17). The [M+H]+ ion peak at an m/z 
value of 566.8 (calculated m/z 566.23) confirms the identity of the product (Figure 
3.1.15). 
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Figure 3.1.15: ESI-MS spectrum of B10 showing the [M+H]+ ion peak at m/z 566.8. 
 
Bispidine ethyl ester derivative B11 
 
Derivatives B11’ and B11 were synthesized to analyze the effect ethyl esters on the 
pharmacokinetics of the system compared to the usual dimethyl ester substituents 
present at C1/5 positions of all possible C9-modified derivatives. B11’ and B11 were 
synthesized by using diethyl-1,3-acetonedicarboxylate following the double Mannich 
reactions (dimethyl-1,3-acetonedicarboxylate used B1’ and B1) (Scheme 3.1.13). The 
preliminary characterization of the product B11 was performed by ESI-MS with [M+H]+ 
ion peak at an m/z value of 621.2 (calculated m/z 620.27) (Figure 3.1.16). 
 
 
Scheme 3.1.13: Synthesis of B11’ and B11 via double Mannich reactions. 
The red bonds represent the difference from derivative B1’ and B1. 
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Figure 3.1.16: ESI-MS spectra of B11 showing the [M+H]+ and [M+2H]++ ion peak at m/z 621.27 and 
311.25. 
 
Table 3.1.1: Representation of the mass spectrometry calculated vs experimental m/z values of 
derivatives B1−B11 (including the intermediates B1‘, B3‘, B8‘, B9‘, B11‘). 
Compound MS [M+H]+ 
Calculated m/z 
MS [M+H]+ 
Experimental m/z 
B1‘ 460.17 461.3 
B1 592.24 611.6 
B2 594.26 596.2 
B3‘ 751.37 751.8 
B3 651.32 651.4 
B4 843.30 843.3 
B5 938.41 939.1 
B6 753.35 736.2 
B7 725.50 725.3 
B8‘ 899.43 899.3 
B8 799.38 799.5 
B9‘ 1044.45 1045.4 
B9 822.38 822.6 
B10 566.23 566.8 
B11‘ 488.21 489.1 
B11 620.27 621.2 
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3.1.2 Radiochemistry of modified bispidine derivatives 
 
3.1.2.1 Radiolabeling of precursors B1 and B2, and BFCAs B3 – B5 
 
The conjugation of the synthesized bispidine-based BFCA to a targeting agent is a 
pivotal step in the generation of high quality imaging tracers and therapeutic agents. To 
ensure this, the investigation of the radiolabeling properties and distribution behavior of 
the BFCAs are performed prior to its bioconjugation. The precursors B1 and B2 were 
examined on these parameters to obtain comparative radiochemical data and study the 
effects of derivatization on compounds B3 – B5. 
 
As discussed earlier, bispidines are excellent 64Cu radionuclide binding agents. The 
complexation of bispidines with radiocopper occurs at ambient temperature and 
physiological pH, to form thermodynamically stable and kinetically inert complexes, 
which makes them an exceptional radiochelator of choice. Another peculiar feature of 
the complexation is that the radiolabeling is independent of the different kinds of buffer 
system (acetate, succinate, citrate, and 2-[N-morpholino] ethanesulfonic acid (MES) 
buffer). MES buffer was used for this set of experiments to eliminate any traces of 
complex formed between 64Cu(II) and the buffer salts in the reaction solution. 
 
The synthesized bispidine derivatives B1-B5 (Scheme 3.1.5, Table 3.1.2) were 
radiolabeled using [64Cu]CuCl2 in 0.1 M MES/NaOH buffer (pH 5.5) at room temperature. 
The radioligands [64Cu]Cu-B1, [64Cu]Cu-B2, [64Cu]Cu-B3, [64Cu]Cu-B4 and [64Cu]Cu-B5 
showed a high radiochemical yield (RCY) of ≥ 99% within 2 minutes of the reaction which 
is a characteristic feature of 64Cu(II)-bispidine complexes. The aforementioned 
complexes also demonstrated high resistance towards transchelation and demetalation 
processes which was confirmed by performing challenge experiments against 10,000 
folds excess of competitive ligands such as EDTA (log KCu(II)-L = 18.8) or cyclam (log 
KCu(II)-L = 27.2) for up to 24 hours. 
The radiolabeling and competition reactions of the complexes [64Cu]Cu-B1–B5 were 
monitored via radio-TLC system (“Method II” section 5.3). A comparative radio-TLC of 
the 64Cu(II)- bispidine complexes for the challenge experiments is displayed in Figure 
3.1.17 (above). The 64Cu(II)-bispidine complexes move on the TLC plate with a retention 
factor (Rf) of 0.6–0.7. EDTA also complexes any excess or non-specifically bound 
64CuCl2 radionuclide to the bispidines. From the TLC analysis it was clear that negligible 
amount (< 5%) of [64Cu]Cu-EDTA (Rf = 0) were detected in all the five complex solutions, 
which supports the characteristic feature of high radiolabeling efficiency, radiochemical 
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purity and lack of transchelation for [64Cu]Cu-B1–B5. A reference TLC for [64Cu]Cu-
EDTA is shown in Figure 3.1.17 (below). 
 
 
 
Figure 3.1.17: Comparative Radio-TLC chromatograms of [64Cu]Cu-B1 − [64Cu]Cu-B5 (EDTA 
challenged) (Above); Radio-TLC of [64Cu]Cu-EDTA (standard) (Below).  
TLC plotted after 30 min reaction, (TLC system: neutral Alox plates, Mobile phase: 2M NH4OAc:MeOH (1:1, 
v/v), (Method II) Retention factor values (Rf). 
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3.1.3 Conclusions 
 
Working towards the aim of developing bispidine-based radiocopper chelating agents, 
this chapter dealt with the synthetic optimization of a series of novel C9-functionalized 
BFCA B3−B9. A summary of the synthesized ligands with the respective substituents is 
presented in Table 3.1.2. The derivatives were prepared via facile synthetic routes in 
high chemical yields. The reverse phase preparative HPLC technique was employed to 
isolate the ligands in high purity suitable for biological applications. The structure 
elucidation, identification, and characterization of the compounds were done by 
techniques like NMR, FTIR and mass spectrometry. The synthesized bispidines form 
hexadentate mononuclear coordination complexes with 64Cu with high thermodynamic 
stability and kinetic inertness. Like reported bispidine systems, these conjugates also 
undergo fast complexation (< 5 minutes) with the radiometal at ambient temperature. 
Copper-64 based experimental radiochemical studies of the conjugates B1−B5 
determined the radiolabeling efficiency and radiochemical purity of the complexes. A 
detailed description of the bioconjugation of ligands B4 and B5 is reported in the next 
chapter (Chapter 3.2).  
  
Results and Discussion 
 
62 
 
 
Table 3.1.2: Summary of hexadentate bispidine derivatives B1−B11 and their substituents.  
(C9 modified B2−B9 and C1/5 modified B10−B11).
L R1 
(C2/4) 
R2 = R3 
(N3/7) 
R4 
(C1/5) 
X 
(C9) 
 Y 
(C9) 
B1 
   
 
 
 
B2 
   
 
 
 
B3 
   
 
 
 
B4 
   
 
 
 
 
B5 
   
 
 
 
B6 
   
 
 
 
B7 
   
 
 
 
B8 
   
 
 
 
B9 
   
 
 
 
B10 
   
 
 
 
B11 
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3.2 Design and synthesis of Bispidine-based TATE and sd antibody 
bioconjugates  
 
Bispidines being exceptional radiochelators with excellent radiolabeling efficiency and 
biocompatibility have been studied in detail over the years, for their development as 
potential PET imaging agents. Although, very limited data is available in the literature of 
bioconjugated bispidines for in vivo cancer tumor targeting. An in vivo biodistribution 
study of bispidine-bombesin (BBN) peptide bioconjugate was reported by Stephan, 
Comba and coworkers and showed significant amount of active tumor accumulation in 
human prostate tumor (PC-3) bearing mice. Recent studies report that bispidines have 
also been conjugated to amino acids (lysine) [77] and fluorophores (BODIPY) to aid 
disease targeting and imaging. However, there are no animal experiment data available 
that can be used to assess the success with such conjugates in vivo.  
This chapter deals with the synthesis of bispidine bioconjugates designed for 64Cu-based 
targeted PET imaging of cancerous tumors. Specifically, the isothiocyanate- and 
dibenzocyclooctyne-terminated bispidines, B4 and B5 (Chapter 3.1) have been suitably 
bioconjugated to allow targeting of the somatostatin (SST) and epidermal growth factor 
(EGF) receptors employing TATE peptide and sdAb respectively. These receptors are 
highly overexpressed in neuroendocrine cancer tumors and numerous epithelial cancer 
cells. 
 
3.2.1 Bispidine-based bioconjugates of somatostatin agonist TATE 
 
Somatostatin receptors (SSTR) are known to be overexpressed in a variety of human 
neuroendocrine tumors. Out of the five receptor subtypes, somatostatin receptor subtype 
2 (SSTR-2) is found in several types of malignancies and has become a popular receptor 
target for modified somatostatin analogues radiolabeled probes for disease detection by 
nuclear imaging techniques [238, 240, 253]. TATE (Tyr3-Octreaotate or Y3-TATE) is a 
derivative of somatostatin with a long biological half-life and high affinity for SSTR-2 
receptors. 
The choice of BFCA and radiometal has shown to have a direct effect on the 
pharmacokinetics of SSTR-targeted imaging agents. Lin et al. showed that 68Ga-labeled 
TATE modified with a NOTA analogue bearing three carboxylates has greater 
accumulation in SSTR-positive xenograft, and shows superior pharmacokinetics than the 
analogues with more carboxylates (Figure 3.2.1) [239]. Likewise, NOTA analogues also 
demonstrated superior pharmacokinetics and a higher liver clearance when compared 
with the DOTA analogue. 
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Fani et al. compared the effect of radionuclides 64Cu and 68Ga on the in vivo 
biodistribution behavior using the radiolabel-modified somatostatin antagonist, 
NODAGA-LM3 [253]. The 64Cu and 68Ga-labeled agents exhibited similar accumulation 
in the SSTR-positive xenograft, however, there were significant differences in the 
clearance from the kidneys and pancreas. 
 
An instructive comparison of commercially available chelators, p-SCN-Bn-NOTA and 
NODAGA, conjugated to TATE and radiolabeled with 64Cu and 68Ga, respectively, has 
also been reported. According to the data, the size of linkers and method of conjugation 
had a significant impact on the performance of the SSTR2-targeted PET imaging agents 
[237, 253, 254]. For example, directly conjugated BFCA demonstrated superior in vivo 
performance for both 64Cu- as well as 68Ga-labeled analogues compared to chelators 
conjugated to Y3-TATE with PEG linkages. The choice of radiometal used for the 
experiments, in this case, was determined to be insignificant. 
 
 
Figure 3.2.1: Representation of NOTA and NODAGA derivatives of Y3-TATE bioconjugates for PET 
imaging. 
 
Radiochemistry of B4 
 
Prior to the bioconjugation of B4, the molar activity and radiochemical purity were 
assessed to ensure the stability of the radiolabeled complex [64Cu]Cu-B4. 
For the determination of molar activity, five samples of 0.1, 0.5, 1, 5 and 10 µg of B4 
were dissolved in 100 µL MES buffer. To these samples, [64Cu]CuCl2 (~100 MBq) was 
added and the reaction mixture was stirred for 60 minutes at room temperature. The 
reaction was followed by radio-TLC (“Method II” Section 5.3) at 5, 30 and 60 minute 
time points. The complex [64Cu]Cu-B4 was purified by reverse phase-HPLC system with 
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a RCY of > 95% (“Method A” Section 5.2). The HPLC chromatogram for [64Cu]Cu-B4 
(Figure 3.2.2) displayed the elution of radiolabeled complex at a retention time (Rt) of 
18.5 minutes. The molar activity of B4 was calculated to be 181 GBq/µmol which is 
optimum for a chelator to be employed for bioimaging purposes. 
 
 
Figure 3.2.2: Radio-HPLC chromatogram of [64Cu]Cu-B4 reaction mixture and [64Cu]CuCl2 (inset). 
(HPLC system: Gradient 0% to 70% B in 20 min (A = H2O + 0.1 Vol. % TFA, B = CH3CN + 0.1 Vol. % TFA) 
flow rate = 1 mL/min, λ = 220 nm; [64Cu]Cu-B4 Rt = 18.5 min and [64Cu]CuCl2 Rt = 6.6 min (Method A). 
 
Distribution ratio (log Do/w) of B47 
 
The distribution ratio helps in determining the relative hydrophilicity of the compounds, 
which govern the factors like biodistribution and pharmacokinetic properties of the 
complex at physiological pH, which is a crucial parameter to be considered prior to 
associated biological applications. The experiments performed in 1-octanol/water 
system at pH 7.2, 7.4 and 7.6 gives also an idea about the aqueous solubility of the 
complex. The obtained negative log D values for the [64Cu]Cu-B1 and [64Cu]Cu-B4 
reported in Table 3.2.1 confirm the hydrophilic behavior of the complexes. 
  
                                                          
7 The radiolabeling experiments were performed by Ms. Karin Landrock, Institute of Radiopharmaceutical 
Cancer Research at HZDR.  
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Table 3.2.1: Distribution ratio (log Do/w) values of [64Cu]Cu-B1 and [64Cu]Cu-B4 complexes at different 
pH values.
 log Do/w log Do/w 
pH [64Cu]Cu-B1 [64Cu]Cu-B4 
7.2 -2.90 -1.25 
7.4 -2.88 -1.27 
7.6 -2.85 -1.40 
 
 
3.2.1.1 Synthesis and characterization of B4-TATE bioconjugate 
 
To synthesize the bispidine-based TATE bioconjugate, commercially available Boc-tert-
butyl-protected TATE peptide with a free terminal amine of the phenylalanine amino acid 
was coupled with the isothiocyanate-functionalized bispidine B4. The two-step synthesis 
of the conjugate is displayed as Scheme 3.2.1. 
 
 
Scheme 3.2.1: Scheme representing two-step synthesis of B4-TATE bioconjugate. 
 Step i) Peptide coupling reaction yielding Boc-tert-butyl-protected B4-TATE, ii) TFA deprotection reaction 
yielding B4-TATE. 
 
The TATE peptide precursor solution was sctivated by DIPEA prior to the addition of B4 
for conjugation. After the addition of B4, the reaction solution was stirred overnight at 
room temperature. The deprotection of the Boc-TATE-B4 bioconjugate was performed 
Results and Discussion 
 
67 
 
in situ. TFA was employed to cleave the tert-butyloxycarbonyl groups on the amine and 
the tertiary butyl residues on hydroxyl groups. Tri-isopropylsilane (TIPS) was used as a 
scavenging agent to provide milder conditions for the deprotection reaction to form B4-
TATE. 
 
Purification and Characterization of B4-TATE 
 
The crude B4-TATE was purified by RP-HPLC (“Method B” Section 5.2) in 25% yield 
and analyzed by MALDI-TOF mass spectroscopy. The [M+H]+ ion peak at m/z 1921.4 
confirms the identity of the product B4-TATE (Figure 3.2.3). Interestingly, along with the 
molecular ion peak for B4-TATE, an additional peak at m/z 903.4 (Figure 3.2.3) was 
also observed in the spectrum. This indicated the presence of an unexpected secondary 
product in the sample isolated after HPLC purification. 
 
 
Figure 3.2.3: MALDI-TOF spectrum of B4-TATE with calculated and experimental m/z values. 
 
It was inferred that the thiourea bond formed in the B4-TATE bioconjugate is unstable 
under acidic conditions. The reason for the instability is the placement of the thiourea 
bond directly on the α-amine of peptide that leads to Edman’s degradation of the product, 
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resulting in removal of the conjugated amino acid of the peptide (Scheme 3.2.2) [240]. 
Of note, in general, such degradation requires acidic conditions for it to occur. 
 
 
Scheme 3.2.2: Mechanism of Edman degradation of B4-TATE conjugate leading to the loss of 
phenylalanine. 
 
B4-TATE in this case also undergoes Edman’s degradation reaction, which leads to the 
loss of phenylalanine amino acid conjugated directly to B4 and the formation of a 
thiohydantoin derivative (experimental m/z 988.8; calculated m/z 990.3) of the bispidine. 
The mechanism of the degradation reaction is displayed in Scheme 3.2.2. 
 
The movement of the thiourea away from the α-amino group can increase the stability of 
the thiourea when conjugated to a peptide. Banks and Paquette demonstrated that the 
conjugation through the ε-amine of a lysine versus the α-amine was more stable after 10 
days at 37°C. Therefore, to eliminate the possibility for Edman’s degradation to take 
place, the B4-TATE construct was redesigned to avoid positioning of the thiourea bond 
at the α-amine of the peptide (Section 3.2.1.2). 
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3.2.1.2 Synthesis and characterization of B4-EG-TATE8 
 
To avoid the Edman degradation, a short linker in the form of diethylene glycol, was then 
used to connect TATE and B4. The commercial availability of the modified peptide EG-
TATE was useful in reducing the number of reaction steps and obtaining the 
bioconjugate in reasonable yields. The two-step reaction between the commercially 
available EG-TATE and B4 was performed under similar conditions as for B4-TATE 
using acetonitrile as solvent. The reaction was facile with a simple RP-HPLC purification 
of the product B4-EG-TATE in 33% yield (Scheme 3.2.3). 
 
 
Scheme 3.2.3: Two-step synthesis of B4-EG-TATE bioconjugate. 
Step i) Reaction of isothiocyanate terminated B4 with glycolated TATE peptide (Yield 37%), ii) TFA 
deprotection to yield B4-EG-TATE (Yield 33%). 
 
  
                                                          
8 EG refers to diethylene glycol. 
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The MALDI-TOF mass spectrometry analysis of the B4-EG-TATE confirmed the reaction 
success. The MALDI-TOF mass spectra displayed [M+H]+ ion peak at m/z 2407.1 
(calculated m/z 2407.1) for the Boc-protected B4-EG-TATE (first step) (Annex Figure 
7.20) and m/z 2038.5 (calculated m/z 2036.7) for the deprotected B4-EG-TATE (second 
step) (Figure 3.2.4). Compared to the B4-TATE conjugates, B4-EG-TATE bioconjugate 
showed no signs of degradation when stored under inert conditions at freezing 
temperature. 
 
 
Figure 3.2.4: MALDI-TOF spectra of B4-EG-TATE with [M+H]+ at m/z 2038.5 (calculated m/z 2036.7). 
 
Radiolabeling of the [64Cu]Cu-B4-EG-TATE 
 
B4-EG-TATE conjugate was complexed with [64Cu]CuCl2 to determine the radiolabeling 
efficiency and stability of the [64Cu]Cu-B4-EG-TATE complex. For the experiment, 10 µg 
of the conjugate was dissolved in a solution of 10% DMSO and 185 µL 0.05 M MES 
buffer (pH 5.6). Roughly 30 MBq of [64Cu]CuCl2 were added to this solution and stirred 
for 20 minutes. The reaction progress was monitored by radio-TLC (“Method II” Section 
5.3) and the radiochemical yield (RCY) was calculated to be ~98% with the Rf of 
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[64Cu]Cu-B4-EG-TATE = 0.8 and Rf of [64Cu]CuCl2 = 0.0. The radiolabeled conjugate 
was purified by HPLC (“Method A” Section 5.2) with a radiochemical purity of > 95% 
(Figure 3.2.5). 
  
 
Figure 3.2.5: Radio-HPLC chromatogram of [64Cu]Cu-B4-EG-TATE reaction mixture with Rt = 14.8 
min. 
(HPLC system: Gradient 0% to 70% B in 20 min; Mobile phase: A = H2O + 0.1 Vol. % TFA, B = CH3CN + 
0.1 Vol. % TFA; Flow rate = 1 mL/min, λ = 220 nm; [64Cu]CuCl2 Rt = 6.6 min (Method A)). 
 
The B4-EG-TATE bioconjugate is currently under investigation for the in vivo PET 
analysis, the biodistribution behavior and tumor targeting for the SSTR2 tumor bearing 
mice. 
 
3.2.2 Bispidine-based EGFR targeting sdAb conjugates B5-sdAb9 
 
For the development of bispidine-based EGFR targeting conjugates, a generic 
chemoenzymatic strategy of sortase-A (SrtA)-mediated site-specific labeling of camelid 
single-domain antibody-fragments (sdAbs) was applied. The key advantages of this 
system are the simple production of the recombinant enzyme in substantial amounts, its 
flexibility towards its substrates, and the required presence of only very short peptides in 
these substrates (the sortag in the target protein and a nucleophilic N-terminal 
oligoglycine within the biorthogonal probe). The mechanism of the two-step 
transpeptidation is displayed in Figure 3.2.6. 
In the first step, the polypeptide backbone of the substrate protein is cleaved by the SrtA 
at the position where the SrtA recognition motif sortag (Leu-Pro-Glu-Thr-Gly: LPETG) is 
incorporated. This leads to the formation of an acyl-enzyme intermediate. Subsequently, 
a new peptide bond is formed between the threonine residue in the sortag and the N-
                                                          
9 Results reported in Section 3.2.2 (synthesis, purification and characterization of B4-sdAb) were 
performed by Dr. Kristof Zarschler, Helmholtz-Zentrum Dresden – Rossendorf. The resulting sdAb 
derivative was used for the experiment in the frame of this work. 
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terminal glycine of a nucleophilic probe (for imaging purposes), containing the 
bioorthogonal functionality. Besides the conjugated sdAb, the reaction mixture still 
contains unreacted sdAb and imaging probe, SrtA, as well as acyl-enzyme intermediate 
and released His-tag that result from the first step of the conjugation reaction. Therefore 
the purification protocol consisted of (i) immobilized metal affinity chromatography 
(IMAC) to remove all undesired His-tagged products, (ii) EDTA competition, to prevent 
occupation of the chelating agents by Ca2+ or Ni2+ ions, and (iii) size-exclusion 
chromatography (SEC), to separate the conjugated sdAb from the unreacted imaging 
probe (Figure 3.2.6 B). 
 
In this part of the thesis, the site-specific labeling of the EGFR-specific single domain 
antibody (sdAb) 7C12 with DBCO-functionalized bispidine B5 for non-invasive cancer 
imaging is reported.  
 
To develop this conjugate, the sdAb was first functionalized with an azide residue to 
render a bioorthogonal reaction platform to the DBCO terminated bispidine, B5. 
Therefore, a short peptide (Gly)3-Lys-N3, composed of three glycine residues linked 
through a lysine residue to a terminal azide was used (Scheme 3.2.4).  
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Figure 3.2.6: General representation of Sortase-A mediated conjugation and purification strategies. 
A) SrtA-mediated conjugation is a generic conjugation method. First, SrtA recognizes the C-terminal sortag 
of the sdAb and cleaves the peptide bond between T and G, with release of the downstream His-tag. Next, 
a nucleophilic attack of the triglycine-functionalized imaging probe on the acyl-enzyme intermediate leads to 
the formation of a new peptide bond with the sdAb, resulting in the site-specifically conjugated sdAb. 
B) Schematic overview of the purification strategy. After SrtA-mediated conjugation the reaction mixture 
contains, apart from the product-of-interest (conjugated sdAb), also unreacted sdAb, acyl-enzyme 
intermediate, imaging probe, SrtA and processed His-tags. Except for the imaging probe, all other undesired 
products contain a His-tag. This allows to capture all His-tagged products via IMAC with Ni-sepharose beads 
on an FPLC system in a first purification step. Next, the collected flow-through (composed of conjugated 
sdAb and imaging probe) was incubated with an excess of EDTA to remove Ca2+ ions, that were present as 
a cofactor of SrtA in the reaction buffer, and Ni2+ ions, that could leak from the Ni-sepharose beads, and 
prevent them from occupying the chelating agents. After sample volume reduction by concentration, the final 
purification step consisted of SEC on an FPLC system to separate the product-of-interest from the excess 
of nucleophilic imaging probe. Adapted from [232] 
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Scheme 3.2.4: Overview of the two-step site-specific antibody modification and conjugation using a 
combination of enzyme-mediated bioconjugation and cycloaddition click reaction.  
The first step uses enzymatic bioconjugation with the transpeptidase sortase-A for site-specific incorporation 
of a functional azide group, whereas the second step involves the azide-alkyne cycloaddition click reaction. 
(SPAAC: Strain-promoted azide–alkyne cycloadditions) 
 
3.2.2.1 Sortase-A-mediated azide functionalization 
 
The chemoenzymatic functionalization was performed using EGFR-specific single 
domain antibody 7C12 and (Gly)3-Lys-N3 as a substrate. The sdAb 7C12 was produced 
with a terminal hexahistidine purification tag. As successful sortase-A-mediated 
conjugation leads to the elimination of the hexahistidine tag, this design allows the 
removal of the unreacted sdAb as well as of the His6-tagged enzyme by immobilized 
metal affinity chromatography. The reaction was optimized by varying the molar ratios of 
SrtA, sdAb and (Gly)3-Lys-N3 (Figure 3.2.7). A 4 h reaction at 30°C with a molar ratio 
SrtA:sdAb:(Gly)3-Lys-N3 of 1:1:10 was identified as being ideal. After purification of the 
reaction mixture by affinity chromatography, the obtained azide-functionalized sdAb was 
analyzed by MALDI-TOF mass spectroscopy (Figure 3.2.8). 
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The mass spectra of the purified product showed a homogeneous product of a single-
conjugated, azide-functionalized sdAb with an m/z ~16.6 kDa. 
 
 
Figure 3.2.7: SDS-PAGE analysis of Sortase-A mediated azide-functionalization of the single-domain 
antibody 7C12.  
The molar amount of (Gly)3-Lys-N3 was varied (50-500 nmol) while the amount of the sdAb as well as the 
enzyme was kept constant (50 nmol).  
 
 
Figure 3.2.8: MALDI-TOF mass spectra of (A) sdAb-Leu-Pro-Glu-Thr-Gly-Gly-His6 and (B) purified 
azide-functionalized sdAb-Leu-Pro-Glu-Thr-N3 (calculated m/z  ~ 16.6 kDa) 
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3.2.2.2 Strain-promoted azide-alkyne cycloaddition (SPAAC) [118] 
 
The site-specifically azide-modified sdAb was reacted with the DBCO-containing 
Bispidine (B5) for up to 4 h at 25°C. After several optimization reactions, the molar ratios 
of modified sdAb:B5 of 1:5 yielded the desired bioconjugate in satisfactory yields (Figure 
3.2.9). The crude sdAb-Leu-Pro-Glu-Thr-B5 (sdAb-B5) conjugate was purified by size 
exclusion chromatography and analyzed by MALDI-TOF mass spectroscopy (Figure 
3.2.10). The mass spectra of the final purified product showed a homogeneous product 
of a single-conjugated, bispidine-functionalized sdAb (B5-sdAb) with a molecular ion 
peak at m/z ~17.6 kDa. 
 
 
Figure 3.2.9: SDS-PAGE analysis of strain-promoted azide-alkyne cycloaddition between DBCO-
containing bispidine and azide-functionalized single-domain antibody 7C12.  
The molar amount of DBCO-Bispidine was varied (1-10 nmol) while the amount of the sdAb was kept 
constant (1 nmol) (Standards on left and right side of the gel). 
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Figure 3.2.10: MALDI-TOF mass spectra of purified, single-conjugated sdAb functionalized with the 
radiometal chelator B5 (calculated m/z  ~ 17.6 kDa). 
 
3.2.2.3 Radiolabeling of sdAb-B5 with [64Cu]CuCl2 
 
sdAb-B5 (1 nmol) was radiolabeled with 64Cu with activities ranging from 0.5 MBq to 10 
MBq and the extent of radiometal complexation was assessed by radio-TLC (Figure 
3.2.11). As expected, the amount of protein radiolabeled correlates with the activity of 
[64Cu]CuCl2 added. The reaction mixture also contains free [64Cu]CuCl2 that migrates as 
[64Cu]Cu-EDTA complex at the solvent front which was subsequently purified by spin 
filtration. The [64Cu]Cu-sdAb-B5 bioconjugate was obtained with a radiochemical purity 
of ~99%. 
In addition to radio-TLC, 64Cu-labeling of sdAb-Leu-Pro-Glu-Thr-B5 was also confirmed 
by SDS-PAGE and subsequent radioluminography (Figure 3.2.12). A single 
predominant protein species corresponding to the monomeric 64Cu-labeled sdAb was 
easily detectable in the Coomassie stained gels as well as in the autoradiographic 
images. Free [64Cu]CuCl2 was present at the origin of the gel, whereas [64Cu]Cu-B5 
migrated to the gel front. 
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Figure 3.2.11: Radio-TLC analysis of 64Cu-labeled bispidine-conjugated sdAb [64Cu]Cu-sdAb-B5After 
conjugation of the sdAb with the chelating agent, the conjugate was labeled with [64Cu]CuCl2 and analyzed 
by radio-TLC. Radiolabeled sdAb-Leu-Pro-Glu-Thr-B5 remains at the origin (Rf = 0), whereas [64Cu]Cu-
EDTA migrates with the solvent front (Rf = 1). [64Cu]Cu-B5 has an Rf of ~0.7. Noteworthy, any excess of 
[64Cu]CuCl2 is complexed by the addition of EDTA.
 
 
 
Figure 3.2.12: (A) Discontinuous SDS-PAGE and (B) Autoradiography analysis of [64Cu]Cu-sdAb-B5.  
After radiolabeling, aliquots of each reaction were separated using a 15% SDS-polyacrylamide gel, and prior 
to staining with Coomassie staining (A), an electronic autoradiographic image of the gel was recorded using 
imaging plates/radioluminography laser scanner (B). 
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3.2.2.4 Cell binding studies 
 
In order to investigate the targeting ability of the functionalized sdAb to EGFR, binding 
to the human epithelial cell line A431 originating from an epidermoid carcinoma of the 
skin was examined. These squamous carcinoma cells express approximately 2 x 106 
EGFR molecules per cell, which represents a high expression level [255, 256]. In a 
saturation binding assay, where the amount of radioligand required to saturate these 
receptors is measured, the equilibrium dissociation constant Kd and the total number of 
receptors expressed on the cell surface Bmax can be determined (Figure 3.2.13). 
 
 
 
Figure 3.2.13: Analysis of binding affinity bispidine-functionalized sdAbs to human EGFR-presenting 
cells.  
Total binding was measured in the absence of and nonspecific binding in the presence of 1 mM unlabeled 
sdAb. Specific binding was calculated as the difference between total and nonspecific binding.  
 
The binding studies on the A431 cells showed promising results and directed the 
conjugate towards the in vivo analysis and biodistribution studies. The active targeting 
and pharmacokinetics studies of sdAb-B5 bioconjugates for the EGFR-specific A431 
tumor bearing xenografts are not a part of this work. 
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3.2.3 Conclusions 
 
In this chapter, the synthesis of two novel bispidine-based imaging agents has been 
reported, which will be employed for the active targeting of tumors. The receptor-specific 
PET imaging agents can potentially be a useful tool for early diagnosis of malignant 
tumors. 
 
The first conjugate B4-EG-TATE involves the coupling of EG-TATE to B4 in a 
straightforward manner leading to a stable bioconjugate in high yields with efficient 
radiolabeling tendency, which is a crucial feature for determining the prospect of short-
lived contrast agents. The isothiocyanate-terminated radiochelator B4 was coupled to a 
diethylene glycol-modified TATE peptide via stable thiourea bond. The radiolabeling 
experiments of the conjugate displayed satisfactory results and therefore, [64Cu]Cu-B4-
EG-TATE was directed for in vivo analysis targeting the SSTR-2 cancer tumor receptors. 
 
The second conjugate, sdAb-B5 was developed by taking advantage of the 
chemoenzymatic Sortase-A–mediated labeling of the sdAb followed by the strain 
promoted alkyne-azide coupling (SPAAC) with B5. The reaction resulted in a 
homogeneous, site-specifically single-conjugated sdAb with an uncompromised 
functionality. The introduction of the azide handle at the C-terminal end of the sdAb 
makes it complementary to the DBCO-functionalized B5. The cell binding studies of 
sdAb-B5 were also performed to ensure their tumor cell targeting efficiency. 
 
The strategies represent an important contribution to expand the application of the two 
bispidine derivatives conjugated to different targeting vectors (TATE and sdAb) for 
different cancer types. This successful synthesis expands the use of bispidines as 
BFCAs for future preclinical studies. 
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3.3 Synthesis and characterization of amine-terminated ultrasmall Si NPs10 
 
The research community assumes that the Si NPs will leave great potential for 
application in the future due to properties such as excellent physico-chemical behavior, 
extraordinary biocompatibility and low cytotoxicity. The surface-termination of the Si NPs 
by various functionalities like amines and esters has proved to be a beneficial strategy 
for developing multifunctional NPs with accessible surface groups [28, 152, 257, 258] 
(Chapter 2.2.1). 
 
This chapter focuses on the synthesis, purification, and characterization of ultrasmall (~4 
nm) amine-terminated Si NPs with large surface-to-volume ratio, and various 
functionalization strategies for further decoration with modular ligands. 
 
3.3.1 Synthesis of amine-terminated Si NPs 
 
The method used in this thesis for the hydrothermal synthesis of the ultrasmall NPs is a 
slight modification of the protocol reported in the literature [259]. Specifically, an aqueous 
solution of (3-aminopropyl)-trimethoxysilane and trisodium citrate was heated under 
microwave conditions for about 5 hours at 160 OC. This lead to the production of blue 
emitting spherical Si NP in with reasonable photoluminescent quantum yields (PLQY) 
(~15%). The synthesis of the Si NPs is presented in Figure 3.3.1 [260]. Although the 
mechanism for this reaction is not yet fully understood, it is hypothesized that it is follows 
Ostwald ripening method [259]. A large scale synthesis (400 mg Si NPs batch) was 
purified by dialysis against millipore water. Si NPs were stored protected from light at 4 
°C and were stable up to 2 months with almost no aggregation and minor lowering of 
photoluminescence. 
 
                                                          
10 The synthesis and characterization of the Si NPs was performed in collaboration with Prof. Luisa De Cola 
at University of Strasbourg with the assistance of Dr. Angélique Faramus and Mr. John Ddungu. 
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Figure 3.3.1: Synthesis of amine-terminated Si NPs by hydrothermal method bottom-up strategy. 
Adapted from [259] 
 
3.3.2 Characterization of Si NPs 
 
Transmission electron microscopy (TEM) 
 
TEM images displayed monodispersed Si NPs in the size range of 2 to 5 nm (Figure 
3.3.2). According to the size distribution histogram, the average size of Si NP is 4.3 ± 1.3 
nm. High resolution TEM images of a single Si NP shows a crystal lattice of silicon with 
a distance of 2.0 Å between fringes, which is a characteristic lattice spacing of the (220) 
planes of crystalline silicon [261]. 
 
 
Figure 3.3.2: TEM and HR-TEM of Si NPs (left); size distribution graph of Si NPs with an average size 
of 4.3 ± 1.3 nm (right) [262] 
 
UV-Visible spectroscopy 
 
The water dispersed Si NPs displayed a stable absorbance and photoluminescence (PL) 
mainly in the blue region of the electromagnetic spectrum with the maximum absorbance 
(λabs,max) at 353 nm (Figure 3.3.3). 
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Figure 3.3.3: Absorption spectrum of water dispersed Si NPs (λabs = 353 nm). 
 
The emission maxima (λems) for Si NP, when excited at λ = 355 nm is centered at 446 
nm indicating that the Si NPs possess good optical properties with clearly resolved 
absorption peaks and symmetrical photoluminescence peaks. A slight red shift is 
observed when the spectra were recorded at higher excitation wavelengths from 290 to 
390 nm (Figure 3.3.4) [169, 263]. In comparison to previously reported red- emitting Si 
NPs (λmax = 660 nm), these blue emitting Si NPs exhibit distinctly shorter λmax (∼446 
nm) due to quantum-size effect. Also, the fluorescence of the Si NPs (PLQY: 2−15%) is 
attributable to both quantum-size and ligand-related effects, upon excitation. 
 
 
Figure 3.3.4: Emission spectra of water dispersed Si NPs at different excitation wavelengths in nm 
(exc). 
 
Fourier-transform infrared spectroscopy (FTIR) 
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The FTIR spectrum (Figure 3.3.5) was in agreement with the vibration bands reported 
in the literature for amine-terminated Si NPs [54, 143, 155, 264]. The spectral region 
from 3342 cm−1 to 2965 cm−1 corresponds to the C-H stretching from the propyl groups 
and the N-H stretching from the propyl amine. The peaks observed from 1650 cm−1 to 
1550 cm−1 refer to the bending vibrations of the primary amine. The peaks in the region 
1400 cm−1 to 1270 cm−1 relate to the vibrational modes of Si-CH2 bond.  
 
The fingerprint region displayed characteristic bending vibrations of the covalent bonds. 
Band observed at 1568 cm−1 is due to N-H bending vibrations from the amine. The 
vibration band at 1390 cm−1 refers to the Si-C bond, which confirms that the carbon is 
linked covalently to the silicon atom. A characteristic band from extending from 1100 to 
1000 cm−1 confirms the presence of Si-O bonds, which are also present on the surface 
of NPs along with Si-C bonds. Weak bands near 1100 cm−1 and 1000 cm−1 are 
characteristic for silicon oxide vibration modes. 
 
 
Figure 3.3.5: FTIR spectra of amine-terminated Si NPs with highlighted characteristic bands. 
 
3.3.3 Surface characterization of Si NPs 
 
The number of available amine groups per Si NP was estimated by thermogravimetric 
analysis (TGA) (Annex Figure 7.23) and Kaiser (Ninhydrin) test which follows the Beer-
Lambert’s Law. These experiments revealed that approximately 162 freely accessible 
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amine groups (from TGA measurements) are present on the surface of one Si NPs that 
corresponds to 6.8 µmol of amines per mg Si NP (from Kaiser test). (Experimental 
section 5.4.3) [265]. 
 
For the NPs to be biocompatible and show a uniform biodistribution and favorable 
pharmacokinetics (ADME), the surface charge of the particle plays a major role. Neutrally 
charged NPs are a preferred choice for biological studies as they show minimum 
cytotoxicity and rapid elimination from the body with reduced accumulation in body 
organs [266]. Water-dispersed amine-terminated Si NPs can be assumed to exist as 
protonated ammonium species. In the presence of citric acid, they have a zeta potential 
of (−1.1 ± 3.9 mV) at room temperature and physiological pH 7.4. The results suggest 
that despite being amine-terminated, the NPs possess a zwitterionic nature at 
physiological pH. This can be explained by the presence of a citrate shell around the 
surface of the Si NPs. The cationic ammonium groups of Si NPs tend to get neutralized 
by the negatively charged carboxylates of the citrate present on the surface of the NPs. 
This explanation was confirmed by NMR spectroscopy (Annex Figure 7.21). 
Temperature-dependent 1H NMR spectroscopy (range: 10–45 °C) also showed no 
significant difference in the chemical shifts confirming the temperature independence on 
the binding of citrate to the NPs. 
 
3.3.4 Conclusions 
 
The hydrothermal method of synthesis leads to the successful production of ultrasmall 
amine-terminated, water-dispersible Si NPs. Using this method, the NPs were obtained 
in high yields and with a good reproducibility. The accessible amino groups on the 
surface will allow for further functionalization with different moieties. The hydrophilicity of 
the Si NPs ensures the biocompatibility for in vivo studies and the ultrasmall size and 
neutral charge possibly facilitate the rapid renal clearance from the body. Altogether, the 
physico-chemical and surface properties of Si NPs suggest that they can be used as 
platform for the development of multifunctional imaging agents for further investigation 
in vivo mouse. 
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3.4 Synthesis, characterization, and biodistribution studies of Si NP-based 
mono-labeled PET and optical imaging agents11 
 
The Si NPs have been investigated as molecular imaging probes. The literature review 
displays preliminary cytotoxicity and cellular studies of Si NPs that show their potential 
as biomedical agents. Yet, the development of a suitable Si NP conjugate for multimodal 
imaging in vivo has not been achieved. This section shows the efforts towards the 
construction of Si NP-based mono-labeled imaging probes to overcome the existing 
limitations related to their biodistribution and small-animal studies. 
 
The good dispersibility in water and ease of functionalization of the Si NPs allowed the 
decoration of the NPs with ligands for either PET or OI. A summary of the mono-labeled 
PET/optical imaging probes synthesized in this work is presented in Scheme 3.4.1. 
 
After the successful synthesis of the mono-labeled Si NPs conjugates, radiolabeling 
studies were performed to quantify the amount of BFCAs attached to the surface of Si 
NPs. Further, the conjugates were assessed for their cytotoxicity and then directed 
towards the preclinical studies. These included the in vivo biodistribution studies, 
followed by the ex vivo autoradiography studies on healthy rats as well as A431 tumor 
bearing mice to determine the fate of the nanoobjects. 
 
Similarly, the OI probes were prepared by modifying the Si NPs with IR 800 fluorophore 
The NP conjugates were examined for their biocompatibility and toxicity, and further 
subjected to in vivo and ex vivo evaluation. 
 
                                                          
11 A few sections of this chapter are an excerpt of the published article: 
Licciardello, N., Hunoldt S; Bergmann, R.; Singh, G.; Mamat, M.; Faramus, A.; Ddungu, J.L.Z.; Silvestrini,S.; 
Maggini, M.; Cola, L. De; Stephan, H. Biodistribution studies of ultrasmall silicon nanoparticles and 
carbon dots in experimental rats and tumor mice 
DOI: 10.1039/c8nr01063c. 
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Scheme 3.4.1: Scheme of the synthesis of mono-labeled Si NP-based imaging agents. 
  
Results and Discussion 
 
88 
 
3.4.1 Si NP-NOTA derived PET imaging agent12 
 
3.4.1.1 Synthesis and radiolabeling studies of Si NP-NOTA 
 
The Si NPs were reacted with the NOTA-Bn-SCN (0.1 µmol / mg Si NPs) in aqueous 
medium to produce Si NP-NOTA conjugates. The synthetic scheme for the production 
of the Si NP-NOTA conjugate is shown as Scheme 3.4.2. The Si NP-NOTA conjugates 
were purified by dialysis followed by SEC with 0.9% NaCl solution (w/v) as eluent to 
remove the retaining impurities. Small (~100 µL) fractions of the Si NP-NOTA sample 
were collected from SEC. 
 
 
Scheme 3.4.2: Reaction of amine-terminated Si NPs with NOTA-Bn-SCN to produce Si NP-NOTA. 
 
Si NP-NOTA conjugates were labeled with [64Cu]CuCl2 in MES/NaOH buffer (pH 5.2) at 
room temperature for 30 minutes. Radio-iTLC (radio instant thin layer chromatography) 
confirmed complete complexation of [64Cu]Cu-Si NP-NOTA with an Rf = 0 and no trace 
of free 64Cu(II) (Rf = 1) (“Method III” Section 5.3). The stability of the 64Cu-labeled NPs 
was tested in challenge experiments using EDTA (Figure 3.4.1). Radiolabeling studies 
exhibited that Si NP-NOTA readily complexes 64Cu(II), forming a thermodynamically 
stable and kinetically inert [64Cu]Cu-Si NP-NOTA under mild conditions conserving its 
radiolabeling efficiency even after NP conjugation. 
                                                          
12 The synthesis, characterization and PET studies of Si NP-NOTA were performed by Dr. Nadia Licciardello 
and Sebastian Hunoldt and published in [262] Licciardello, N., et al., Biodistribution studies of 
ultrasmall silicon nanoparticles and carbon dots in experimental rats and tumor mice. Nanoscale. 10 
(2018) 9880-9891. 
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Figure 3.4.1: Radiochemical purity of purified 64Cu-labeled Si NP-NOTA conjugate.  
EDTA incubated and SEC purified [64Cu]Cu-Si NP-NOTA; Radio-TLC system: iTLC-SG in NH4OAc:MeOH 
1:1 (v/v); [64Cu]Cu-Si NP-NOTA Rf = 0, [64Cu]Cu-EDTA Rf = 1 (Method III). 
 
Quantification of the chelator NOTA on Si NPs 
 
Radiometric titrations of Si NP-NOTA was performed to determine the amount of NOTA 
conjugated to the Si NPs. Radionuclides, such as 57Co and 64Cu, have been employed 
in the past to determine the number of radiometal chelating ligands attached to the 
biomolecules or NPs [267-269]. The major advantage of this procedure is the extremely 
low amount of sample (μg) required for detection. The radiometric titration method 
exploits the fact that the Si NP scaffold itself does not bind Cu(II) ions. To confirm this, 
an excess of EDTA was added after complex formation. 
 
For this experiment, increasing amounts of a mixture of radioactive ([64Cu]CuCl2) and 
non-radioactive (CuSO4) Cu(II) was added to five different batches of Si NP-NOTA. The 
amount of the conjugate was kept the same for all the five samples. Subsequently, an 
excess of EDTA was added to remove any radionuclide non-specifically bound to the Si 
NPs. The amount of 64Cu(II) bound to the Si NP-NOTA complex relates to the number of 
bound chelator per chelate (Section 5.5). The complexation between Cu(II) and NOTA 
follows a stoichiometry of 1:1 according to which only one copper can complex to each 
NOTA chelator. The process of chelation was followed via radio-TLC analysis (“Method 
III” Section 5.3). Figure 3.4.2 illustrates the plot of the percentage of 64Cu(II) bound 
against the total amount of nonradioactive Cu(II) added. 0.09 µmol NOTA chelator was 
calculated bound per mg Si NP-NOTA. 
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Figure 3.4.2: Radiometric titration curve for 64Cu(II) and Cu(II) labeled Si NP-NOTA conjugate. 
(Experimental value: ~0.09 µmol NOTA/mg Si NP-NOTA) 
 
3.4.1.2 In vitro cytotoxicity and cell viability studies of Si NP-NOTA13 
 
After the characterization of the Si NP-NOTA, it was important to test its biocompatibility. 
Previous studies demonstrated that the amine-terminated Si NPs prepared by the 
hydrothermal method have very low cytotoxicity in human epithelial cervical cancer cells 
(HeLa) even after 48 hours of exposure [259]. In addition, it is also reported that the 
toxicity of amine-terminated Si NPs increases in the presence of serum [157] and this 
was ascribed to the fact that serum proteins facilitate the cellular uptake of NPs and thus 
cause higher toxicity [270-272]. To determine the affect of Si NP-NOTA conjugates on 
cellular viability, the human embryonic kidney (HEK 293) cell line was chosen. The 
literature suggests that the preferred mode of elimination of ultrasmall NPs is renal and 
therefore, it was important to ensure the lack of any nephrotoxic effects of these 
nanoconjugates on the kidney cells. 
 
For the cell viability and cytotoxicity measurements, the HEK 293 cells were incubated 
with varying concentrations of Si NP-NOTA and analyzed for up to 72 hours. The viability 
and cytotoxicity of the cells were plotted against the concentration of the Si NP-NOTA 
conjugates. From both the assays, it was inferred by visual detections (490 nm) that the 
modified Si NPs do not induce any substantial changes in the cellular metabolism of the 
experimental cell culture. 
                                                          
13 Cell experiments of Si NPs were performed by Mrs. Utta Herzog assisted by Ms. Neena Patel, Institute 
of Radiopharmaceutical Cancer Research, HZDR. 
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The CyQ assay demonstrated > 90% viability and < 5% cytotoxicity for 1, 10, 50 and 100 
µg/mL Si NP-NOTA concentrations after 24, 48 and 72 hours, respectively (Figure 
3.4.3). 
 
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) and LDH (lactate dehydrogenase) calorimetric assays also illustrated no 
negative influence of the nanoconjugates on the metabolism and viability (> 95%) of the 
system over a period of 72 hours (Figure 3.4.4). The intact cell membranes of the cells 
after 72 hours of incubation assured the negligible amount of nanotoxicity (< 10%) 
caused by the Si NP-NOTA. 
 
 
Figure 3.4.3: In vitro cell viability and membrane integration studies of Si NP-NOTA by CyQuant 
assay in human embryonic kidney (HEK293) cell lines after incubation up to 72 h. 
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Figure 3.4.4: In vitro toxicity evaluation of Si NP-NOTA conjugate by MTS and LDH assay after 48 
hours in HEK293 cells. 
Cell viability (mitochondrial activity) of Si NP-NOTA in HEK 293 cells at different concentration. Triton-X was 
used as positive control. The percentage of cell viability is calculated relative to untreated cells (triplicate), 
which served as a negative control. The membrane integrity is measured as lactate dehydrogenase (LDH) 
release into the media relating to necrosis at different time points (data shown after 48 h incubation). BSA 
served as a negative control and a triplicate set of wells were treated with supplied lysis buffer for maximum 
LDH release and regarded as a positive control. A triplicate of wells with cells treated with conjugates with 
no MTT added was used as blank for any interference of the fluorescence. The percentage of cytotoxicity 
and LDH release is relative to that of the controls.  
 
3.4.1. Biodistribution of [64Cu]Cu-Si NP-NOTA by small animal PET  
 
Si NP-NOTA showed rapid clearance from the body with 84.5% ID14 in the urine 5 
minutes post injection (Figure 3.4.5). The rapidly transferred activity in the urine confirms 
the renal filtration of the conjugates in the in vivo system. The particles thus confer to be 
neutral, nanosized and biocompatible with favorable pharmacokinetics.[262] 
 
                                                          
14 Accumulated activity amount (% ID = % injected dose). 
Standardized uptake value (SUV) = activity concentration in tissue [Bq/g] × body weight [g] / injected dose 
[Bq]) at a certain time point p.i 
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Figure 3.4.5: In vivo PET imaging of [64Cu]Cu-Si NP-NOTA at different time points. 
Maximum intensity projections obtained from a PET study after a single intravenous injection of [64Cu]Cu-Si 
NP-NOTA (n = 2) in A431 tumor-bearing mice after 1 min (A, E), 5 min (B, F), 30 min (C, G), and 60 min (D, 
H) after injection. The images A–D were scaled to the maximum activity and the images E–H were rescaled 
to visualize the tumor (bl = bladder, he = heart, in = intestine, ki = kidney, li = liver, tu = tumor). 
 
The radiolabeled particles were also observed to rapidly diffuse in the tumor with 
visualization under optimized imaging conditions. The maximum tumor uptake is 
detected within 5 min of the intravenous administration. However, the activity was quickly 
washed out from the tumor, as is expected for such small sized particles, with the 
exception of NPs equipped with tumor-specific moieties, which resided longer in the 
tumors. This infers the passive targeting that occurs for the first 5-10 minutes. However, 
the size of the particles is too small (< 30 nm) to observe any significant EPR effect and 
therefore, the signal is again under the limit of detection. [225] 
 
3.4.2 Synthesis and characterization of Si NP-Bispidine (Si NP-B4) 
 
Bispidines being excellent 64Cu chelators were used as a BFCA for the development of 
Si NP-based PET imaging agent. A general scheme for the synthesis of Si NP-B4 is 
represented as Scheme 3.4.3. For the preparation of Si NP-B4, a series of solvent 
mixtures were tested in order to optimize the reaction conditions. In contrast to NOTA, 
B4 possesses a lower solubility in aqueous medium, leading to a decrease in the extent 
of conjugation due to aggregate formation. Table 3.4.1 shows the different tested 
conditions for the conjugation reaction between B4 (0.1 µmol / mg Si NPs) and Si NPs. 
Initial trial reactions with solvent mixtures (water/ethanol, water/ACN) inferred that the 
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reaction works best when heated up to 35 °C and run for 12 hours. Although, in some 
cases, the reaction turned turbid immediately after the addition of B4 ligand, which later 
(1-2 hours) forms a clear solution. With solvents like DMSO, a large amount of 
aggregation was observed in the reaction mixture. Reactions between B4 (0.1 µmol / mg 
Si NPs) and Si NPs in H2O/ACN (9:1) v/v yielded Si NP-B4 when stirred at 35 °C and 
run for 12 hours. 
 
Scheme 3.4.3: Reaction of amine-terminated Si NPs with B4 to produce Si NP-B4 
 
Table 3.4.1: Optimization of the synthesis of Si NP-B4 at pH 7−7.5. 
Solvents used Observation 
Water + Ethanol (9:1 v/v) Clear 
Water + 0.1% DMSO Aggregation 
Water + ACN (9:1) Clear 
Phosphate buffer + Ethanol (9:1) Turbid 
Phosphate buffer + ACN (9:1) Turbid 
 
 
For purification of the crude Si NP-B4, SEC was repeated twice to yield the product. Of 
note, dialysis techniques did not work well for the purification of Si NP-B4 conjugates. 
The reaction yield of Si NP-B4 was lower compared to other more hydrophilic conjugates 
(Si NP-NOTA) due to the loss of NPs in form of aggregates. 
The process of radiolabeling was monitored by radio-iTLC SG using 2M NH4OAc:MeOH 
1:1(v/v) solvent system (“Method III” Section 5.3). The 64Cu(II)-labeled Si NP-B4 was 
detected at the origin with Rf = 0 while the free 64Cu(II) moves to the front with an Rf = 1 
(Annex Figure 7.22). 
 
Radiometric titration of Si NP-B4 
 
Radiometric titration was performed to calculate the amount of bispidine conjugated per 
milligram of Si NP. Bispidines also forms mononuclear Cu(II) complexes, therefore, the 
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number of moles of nonradioactive copper can be quantified to calculate the conjugated 
B4 to the Si NPs. The radiolabeling reaction was performed as mentioned in Section 
3.4.1.1 for Si NP-NOTA conjugates. The amount of conjugated B4 to the Si NPs derived 
from Figure 3.4.6 was calculated to be ~0.052 µmol/mg Si NPs. Compared to Si NP-
NOTA conjugate (0.09 µmol/mg Si NPs) the amount of bispidine present per milligram 
of Si NP is much less, which clearly was due to the lower hydrophilicity of B4. The 
solubility differences lead to lower radiolabeling efficiency and radiochemical purity of 
the Si NP-B4 conjugates. Due to these reasons, the experiments on the Si NP-B4 
conjugates were discontinued and no further studies were performed. 
 
 
Figure 3.4.6: Radiometric titration curve for 64Cu(II) and Cu(II) labeled Si NP-B4 conjugate. 
Experimental value: ~0.052 µmol B4/mg Si NP-B4 determined by radio-TLC analysis (Method III)  
 
3.4.3 Synthesis, characterization, in vitro and in vivo evaluation of Si NP-IR800 
as an optical imaging probe 
 
The Si NPs were coupled to IR 800 infrared dye to develop them as potential optical 
imaging agents. Presence of an optical label in the form of IR 800 dye should allow the 
study of in vivo biodistribution and pharmacokinetic behavior of the Si NP-IR800 via 
fluorescence imaging. Keeping in mind our long- term goal of developing such probes 
for clinical applications, IR 800 dye was chosen as it has successfully passed all animal 
toxicity studies and recently been approved by FDA. Its characteristic emission lies in 
the red region of the visible spectrum (λem = 789 nm when excited at λ = 774 nm, in water) 
that circumvents the possibility of the overlap with the auto-fluorescence caused by the 
living cells. 
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3.4.3.1 Synthesis of Si NP-IR800 
 
The Si NPs were reacted with the NHS-activated IR800 dye in aqueous medium to 
produce Si NP-IR800 conjugates (0.5 µmol NHS-IR800 per mg Si NPs). The synthetic 
scheme for the production of the Si NP-IR800 conjugate is shown as Scheme 3.4.4. 
Variations in reaction conditions like the reaction time and temperature showed 
significant differences in the efficiency of the reactions. Table 3.4.2 shows the different 
reaction conditions explored along with the solvent system. 
 
 
Scheme 3.4.4: Reaction of amine-terminated Si NPs with NHS-IR 800 to produce Si NP-IR800. 
 
The reaction of Si NPs and NHS-IR800 showed better results when stirred for longer 
hours (~12 hours) as analyzed by UV-Vis spectroscopy. Because water and the 
phosphate buffer delivered similar results, it was more feasible to select water as the 
solvent to avoid the desalting of the sample while purification (Table 3.4.2). 
 
Table 3.4.2: Optimization of the synthesis of Si NP-IR800 reaction. 
Solvent Temperature (oC) Time (h) pH 
Water 25 6 7−7.5 
Water 25 12 7−7.5 
Water 35 12 7−7.5 
Phosphate buffer 25 12 7.4 
Phosphate buffer 35 12 7.4 
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3.4.3.2 Purification and characterization of Si NP-IR800 
 
The Si NP-IR800 conjugates were purified by dialysis followed by SEC with 0.9% NaCl 
solution (w/v) as eluent to remove the retaining impurities. Small (~100 µL) fractions of 
the Si NP-IR800 sample were collected from SEC and analyzed by RP-TLC plates using 
methanol as eluent. The TLC was read under the IR short channel (710 – 730 nm) and 
IR long channel (810 – 840 nm) of the scanner (300-900 nm) that yielded similar results. 
A representation of the TLC chromatogram of an impure sample (containing Si NP-IR800 
and IR800 dye) and a pure sample (Si NP-IR800) is represented as Figure 3.4.7. 
Optimization of the purification strategy leads to a faster analysis with reproducible 
uniform Si NP-NOTA. Fluorescence TLC and UV-Vis measurements effectively detected 
the purity of the conjugates, demanding only nanograms of the sample. 
 
 
Figure 3.4.7: Comparative Fluorescence TLC chromatograms to detect the purity of Si NP-IR800. 
A: TLC plate of crude Si NP-IR800 sample (left) and the chromatogram showing Si NP-IR800 (Rf = 0) and 
free IR 800 dye (Rf = 1) (right). B: TLC plate after dialysis and SEC purified Si NP-IR800 sample (left) and 
the chromatogram showing Si NP-IR800 (Rf = 0). TLC system RP-TLC plate, Solvent system: Methanol. 
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Absorption/Emission properties of Si NP-IR800 
 
After its conjugation to the Si NPs, a huge hypsochromic shift (λabs 775 nm to 612 nm) is 
observed for the Si NP-IR800. The probable reasons for this massive shift in the 
absorbance maxima could be ascribed to the disruption in the extended conjugation of 
the conjugated IR800 dye (trans to cis configuration). The profile broadening observed 
in this case could be due to the increased heterogeneity in the sample induced by 
chemical interaction among the dye molecules and with the Si NPs. 
 
Anisotropy studies, NMR and Raman spectroscopy could be employed to deduce the 
exact reason for this behavior which is not a part of this work [273-276]. Nonetheless, 
the Si NP-IR800 conjugates remain in the NIR region (600−900 nm) and thus, can be 
applied for the in vitro and in vivo trials as potential imaging agents. 
A comparative normalized absorption and emission spectra of Si NP-IR800 and IR 800 
fluorophore are displayed as Figure 3.4.8. The emission spectrum of the Si NP-IR800 
exhibited a smaller blue shift from λem 792 nm (IR800) to 754 nm with a typical shoulder 
peak which is a characteristic feature of cyanine dyes. 
 
 
Figure 3.4.8: A comparative absorption (A) and emission spectra (B) of Si NP-IR800 and NHS-IR 800 
dye in water. 
 
The absorption and emission maxima of Si NPs, IR 800 dye and the Si NP-IR800 
conjugate is reported in Table 3.4.3. The photoluminiscent quantum yield (PLQY) for Si 
NPs and Si NP-IR800 was calculated from the respective normalized absorption-
emission spectra. NHS-IR 800 dye in water (PLQY = 14.2%) was used as a reference 
for calculating the PLQY of Si NP-IR800 conjugate.[277] 
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Table 3.4.3 Photophysical characterization of Si NP-IR800 vs Si NPs and IR 800 dye. 
 IR800 dye (nm) Si NPs (nm) Si NP-IR800 (nm) 
Absorbance (λabs) 775 355 612 
Absorbance (shoulder) 700 - 470 
Fluorescence (λems) 792 456 754 
PLQY 14.2% 15% 22.5% 
 
Size and surface charge determination 
 
Due to the extremely small size, metalloid behavior and the organic functionalization on 
the Si NPs, techniques like DLS to determine the size as hydrodynamic diameter are 
fairly challenging and do not work properly. The physicochemical properties, the surface 
charge studies and the functionalization, on the other hand, provide adequate details 
about the behavior and characterization of the conjugates. 
 
Surface charge determination 
 
The zeta potential (ζ) measurements were conducted to measure the surface charge of 
the Si NP-IR800 conjugates. A value of −5.4 ± 4.1 mV (water, pH 7) deduced from the 
experiments for IR800 conjugates was comparable to that of nonconjugated Si NPs (−1.1 
± 3.9 mV). This infers to fact that the IR800 functionalization of the Si NPs does not 
remarkably influence the surface properties for the NPs. This was done to preserve the 
ultrasmall and zwitterionic behavior of the conjugates, which is crucial for its biomedical 
applications. It was achieved by limiting the surface functionalization of the NPs by 
employing a small amount of dye (0.05 µmol/mg Si NPs), which makes it a suitable 
optical imaging yet conserving its inherent properties. 
 
Quantification of IR800 dye conjugated to Si NPs 
 
The amount of dye conjugated to the Si NPs was determined by UV spectroscopy. For 
this, the absorbance of parent IR 800 dye was measured at different concentrations to 
obtain a calibration curve, which was then used to obtain the dye concentration in the Si 
NP-IR800 particles (Figure 3.4.9). A weighted sample of Si NP-IR800 was checked for 
the absorbance and plotted on the same graph to know the concentration of the dye 
attached to the Si NPs. 
The experimental value was calculated as ~0.013 µmol IR 800 dye per mg Si NPs.  
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Figure 3.4. 9: Quantification of IR 800 dye present on Si NP-IR800 by UV-Vis spectroscopy 
(Experimental value ~0.013 µmol IR 800 dye per mg Si NPs). 
 
3.4.3.3 Cell studies of Si NP-IR800 
 
As discussed earlier, for a nanoobject to be developed for pre-clinical and clinical 
imaging trials, it is of utmost importance to understand its cellular behavior and 
biocompatibility [210, 266, 278]. The viability of the human embryonic kidney (HEK 293) 
cell line was determined for Si NP-IR800 over a time frame of 72 hours (Section 3.4.1.2). 
The assessment was performed using MTS calorimetric assay, LDH assay and the 
CyQUANT® Direct Cell Proliferation Assay. The data obtained from the CyQ assay for 
Si NP-IR800 presented > 95% viability of the cell lines for all the four tested 
concentrations over a period of 72 hours (Figure 3.4.10) which is similar to data obtained 
for Si NP-NOTA conjugates. Interestingly, negligible amount of toxicity was recorded 
even at the highest concentration of 100 µg/mL of Si NP-IR800, which inferred that the 
Si NP functionalization did not induce any substantial changes in the cellular metabolism 
of the in vitro system.  
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Figure 3.4.10: In vitro cell studies of Si NP-IR800 by CyQuant assay in HEK293 cell lines. 
 
The MTS assay also depicted viability and proliferation values comparable to the CyQ 
assay. The LDH assay performed to test the necrosis and cytotoxicity, revealed that even 
after 48 hours of incubation of 1, 10, 50 and 100 µg/ml nanoconjugates with the cell lines, 
the cellular membrane remains integrated, and the release of LDH is in the range of the 
negative control with a value < 5% (Figure 3.4.11). 
 
 
Figure 3.4.11: In vitro toxicity evaluation of Si NP-IR800 by MTS and LDH assay after 48 h. 
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3.4.3.4 Determination of in vivo behavior of Si NP-IR800 in mice15 
 
The successful in vitro analysis of the Si NP-IR800 conjugates with convincing 
biocompatibility instigated us to evaluate the in vivo potential of the fluorescent NPs. The 
fluorophore conjugated to the Si NPs allows the imaging of the mice with acceptable 
resolution. For the biodistribution experiments, ~ 100 µg (200 µL) of the Si NP-IR800 
sample was administered intravenously to four healthy nu/nu murine mice. The mice 
were analyzed at different time points (1 minute, 10 minutes and 2 hours) by whole body 
fluorescence scanners to detect the fluorescence intensity in each organ. Exemplary 
images of the mice after the intravenous injections at different time points are displayed 
as Figure 3.4.12. 
The 2 h time frame is best suited for these ultrasmall Si NPs as they are anticipated to 
undergo a fast renal elimination within this duration. The optical image recorded 
immediately (1 minute) after the administration, displayed a uniform distribution of the Si 
NP-IR800, all over the body of the mice, via the blood circulation. Within 10 minutes of 
injection, the particles started to pass through the kidneys, reaching the bladder and 
rapidly eliminated via urine. 
  
 
Figure 3.4.12: In vivo optical imaging of Si NP-IR800 at different time points.  
Optical imaging scans of after 1 min, 10 min and 2 h of intravenous injection in healthy NMR nu/nu mice. 
The scans show a rapid clearance of the particles via kidneys into the urine after uniform distribution of the 
Si NP-IR800 throughout the body (R: Reference, injected sample). 
                                                          
15 Biodistribution studies were conducted by Dr. Ralf Bergmann and Ms. Regina Herrlich in the group of 
Prof. Jens Pietzsch, Institute of Radiopharmaceutical Cancer Research at HZDR. 
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The later time point (2 hours p.i.) showed that most of the fluorescence intensity from Si 
NP-IR800 has already been excreted from the body with traces found in the kidneys 
which could be visualized only with high intensity projections. 
 
3.4.3.5 Ex vivo analysis of Si NP-IR800 
 
After the whole body fluorescence scan of the Si NP-IR800 injected to mice 2 hours p.i., 
the mice was excised for a semi-quantitative analysis. The main visceral organs of the 
mice along with the urine sample were scanned for fluorescence intensities and draw a 
conclusion regarding the fate of the NPs. The ex vivo analysis of the excised mice is 
displayed in Figure 3.4.13. The ex vivo biodistribution studies of the dissected organs 
confirmed that the majority of the injected sample is excreted from the body in the form 
of urine exhibiting maximum fluorescence and slight distribution of fluorescence in 
organs like kidneys, lungs and spleen. 
 
 
Figure 3.4.13: Ex vivo optical imaging of Si NP-IR800 2 h p.i.  
Optical imaging scans of excised body organs 1-11, after 2 h of intravenous injection of Si NP/IR800 in 
healthy mice. 
 
For a comprehensive analysis of the fate of Si NP-IR800 conjugates, urine from the mice 
was collected and analyzed (1 hour p.i.). The urine samples were analyzed by TLC 
(eluent: methanol, water) and compared to the reference sample (injected Si NP-IR800) 
Figure 3.4.14. The TLC system displayed a single spot at the origin (Rf = 0) 
corresponding to the Si NP-IR800 and no free/detached fluorescence (IR800) was 
observed at the TLC (Rf = 1). This concludes that the Si NP conjugate was rapidly 
eliminated from the in vivo system via renal pathway and confirms the integrity of the Si 
NP-IR800 in presence of complex biological milieu. 
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Figure 3.4.14: TLC analysis of urine of experimental healthy mice 1 h p.i. of Si NP-IR800.  
The urine sample collected 1 h p.i. displays a single fluorescent peak from Si NP-IR800 at the origin (Rf = 0) 
and no traces of cleaved IR 800 dye. TLC chromatogram of free IR8 00 dye at the front (Rf = 1) (inset) TLC 
system: RP-TLC plates, Solvent system: Methanol.
 
From the biodistribution and pharmacokinetic studies of Si NP-NOTA and Si NP-IR800, 
it is verified that both the mono-labeled imaging agents show similar behavior for the in 
vitro (non-cytotoxic) and in vivo (rapid renal elimination, uniform biodistribution) analysis. 
These favorable results, therefore, directed us towards the development of Si NP-based 
dual modal imaging agent with NOTA (PET imaging) and IR 800 (optical imaging) for the 
simultaneous in vivo analysis by the combination of two imaging modalities on a single 
Si NP core. The development of the dual-labeled imaging agents is illustrated in Chapter 
3.5. 
 
3.4.5 Conclusions 
 
Chapter 3.4 describes an elaborate synthesis and preclinical studies of ultrasmall Si NP-
based mono-labeled imaging agents. The nanohybrids can be synthesized on a large 
scale (~ 100 mg batches)  using reliable methods. The synthesis of the nanoobjects was 
performed in an aqueous solution at physiological conditions. Afterwards, the purification 
of the mono-labeled Si NPs was optimized by dialysis and size exclusion 
chromatography. The physico-chemical characterization confirmed neutral surface 
charge (zeta potential) and hydrophilicity (distribution constant) optimal for in vitro and in 
vivo applications.  
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Cell studies of the Si NP conjugates have shown no signs of cytotoxicity. Both in vivo 
PET and OI conducted for the two nanohybrids displayed comparable results. The 
conjugates (Si NP-NOTA and Si NP-IR800) after intravenous administration in mice were 
observed to be uniformly distributed for 10 minutes and eventually eliminated from the 
renal pathway to the bladder and urine within 60 minutes of injection. The rapid renal 
clearance profile and no liver accumulation makes these Si NPs exceptional candidates 
for imaging applications. These results thus pave a way towards the synthesis of dual-
labeled imaging agents. Figure 3.4.15 summarizes the biological studies of the mono-
labeled Si NP based imaging agents. 
 
 
Figure 3.4.15: Summary of synthesis, characterization and in vitro and in vivo behavior of mono-
labeled Si NP conjugates.  
The mono-labeled nanoconjugates, Si NP-NOTA and Si NP-IR800 show high cell viability (top) as 
determined by MTS and LDH assay up to 72 h. The PET and OI scans for Si NP-NOTA and Si NP-IR800, 
respectively, exhibit rapid renal clearance with minor liver accumulation. 
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3.5 Development of dual-labeled Si NPs an its in vitro and in vivo evaluation 
 
To design an efficient dual-labeled probe, it is of significant value to analyze the probes 
at unimodal level first. As reported in Chapter 3.3 and 3.4, Si NPs were functionalized 
with a chelator and dye respectively, which fulfills the prerequisites for imaging studies. 
Here, the aim was to decorate the Si NP platform with modular ligands for PET (NOTA-
Bn-SCN) and OI (IR 800) simultaneously to attain dual-modality and exploit the 
properties of the bimodal nanoconjugates synergistically. Figure 3.5.1 shows the 
stepwise synthesis of Si NP-IR800-NOTA. 
 
 
Figure 3.5.1: Synthesis of dual-labeled Si NP-based imaging agents with 64Cu binding NOTA for PET 
and IRDye 800CW for OI. 
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3.5.1 Synthesis and characterization of Si NP-IR800-NOTA conjugate 
 
To attain bimodality, the amine-terminated Si NPs were reacted simultaneously with a 
BFCA and a fluorescent marker. The ligands (NOTA-Bn-SCN and NHS-IR 800) 
evaluated for the development of mono-labeled imaging agents (Chapter 3.4) with 
satisfactory pharmacokinetic behavior for in vivo systems, were a suitable choice for this 
synthesis. To analyze the degree of functionalization and produce uniformly 
functionalized Si NPs via a thiourea and amide linkage, respectively, two synthesis 
strategies were carried out: one pot synthesis and stepwise reaction. 
 
One-pot synthesis of Si NP-IR800-NOTA conjugate 
 
For one pot synthesis, 1 mg (500 µL) water-dispersed amine-terminated Si NPs were 
adjusted to pH 7.5. The ligands NOTA (~ 60 µg, 0.1 µmol/mg Si NP in 20 µL) and IR 800 
(~ 75 µg, 0.05 µmol/mg Si NP in 20 µL) were simultaneously added to the reaction 
mixture and stirred overnight at 35 OC. (Scheme 3.5.1). The resulting Si NP-IR800-
NOTA solution was purified by dialysis and SEC. The SEC fractions were analyzed by 
TLC, UV spectroscopy and radiolabeling experiments as performed for mono-labeled 
conjugates (Section 3.4.1.1 and 3.4.3.2).  
 
The straightforward unimodal approach of modification was not applicable for the 
bimodal Si NPs as it resulted into a mixture of SiNP-IR800-NOTA, Si NP-IR800 and Si 
NP-NOTA conjugates. A probable reason for this variation owes to the different 
reactivities of the isothiocyanate group present on NOTA-Bn-SCN and the active 
succinimide ester on the NHS-IR800 that compete for the amines on the Si NP surface. 
To this end, a new stepwise synthesis strategy was applied for synthesizing Si NP-
IR800-NOTA. 
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Scheme 3.5.1: One-pot and stepwise synthesis method for the synthesis of Si NP-IR800-NOTA. 
 
Stepwise synthesis of Si NP-IR800-NOTA conjugate 
 
The stepwise synthesis of Si NP-IR800-NOTA could evade the disadvantages of the 
one-pot method of synthesis. In this method, the amine-terminated Si NP (pH 7.4) were 
first reacted to activated NHS-IR 800 (70 µg, 0.05 µmol/mg Si NP in 100 µL) and stirred 
for 8 hours at 35 OC (Scheme 3.5.1). The unreacted IR800 dye hydrolyzes in aqueous 
medium and does not interferes with further reactions. NOTA-Bn-SCN (60 µg) was then 
added next to the Si NP-IR800 solution and stirred overnight. The second reaction was 
performed in situ. This assures the dual labeling of all the Si NPs sustaining the uniformity 
of the Si NP-IR800-NOTA conjugates. 
Fluorescence and radiolabeling studies of the SEC fractions confirmed the covalent 
attachment of the IR 800 and NOTA respectively to the Si NP core (Figure 3.5.2). 
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Figure 3.5.2: Complementary radio-TLC and fluorescence-TLC of Si NP-IR800-NOTA.  
A) EDTA incubated 64Cu(II)-labeled Si NP-IR800-NOTA. (Radio-iTLC SG; Mobile phase: NH4OAc:MeOH 
1:1 (v/v); [64Cu]Cu-Si NP-IR800-NOTA Rf = 0, [64Cu]Cu-EDTA Rf = 1.) B) Fluorescence TLC of Si NP-IR800-
NOTA measured under IR short channel (710 – 730 nm). (RP-TLC; Mobile phase: Methanol; Si NP-IR800-
NOTA Rf = 0). 
 
3.5.2 Photophysical characterization of Si NP-IR800-NOTA and comparison with 
mono-labeled imaging agents 
 
A comparative analysis of the UV-Vis photophysical characterization of Si NP-IR800 and 
Si NP-IR800-NOTA is demonstrated in Figure 3.5.3. The absorbance maxima (λabs) for 
both Si NP-IR800 and Si NP-IR800-NOTA are observed at 611 nm with typical cyanine 
shoulders at 470 nm for both, which confirms the conjugation of the IR 800 dye (λabs 792 
nm) to the Si NPs (Section 3.4.3.2). The maximum emission (λem) on the other hand, for 
Si NP-IR800 and Si NP-IR800-NOTA is observed at 754 nm and 748 nm respectively. 
The data represents that the fluorescence intensity of the mono-labeled Si NP-IR800 to 
be higher than the dual-labeled Si NP-IR800-NOTA conjugate. It is assumed that the 
difference could be due to the presence of additional ligand NOTA which tends to quench 
the emission to certain extent. Table 3.5.1 presents the absorbance (λabs) and emission 
(λabs) and the photoluminescent quantum yields calculated for the Si NPs and its 
conjugates. The quantum yield calculation of the dual-labeled Si NP conjugates was 
performed similar to mono-labeled Si NP-IR800, using standard NHS-IR800 dye as a 
reference. Table 3.5.1 comprises of collective data of the photophysical behavior of the 
Si NP conjugates. 
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Figure 3.5.3: Comparative absorption (A) and emission spectra (B) of Si NP-IR800-NOTA, Si NP-IR800 
and NHS-IR 800 dye in water. 
Normalized spectra for comparison between the absorbance and emission of dual-labeled Si NP-IR800-
NOTA and mono-labeled Si NP-IR800 using standard IR 800 dye as reference. 
 
Table 3.5.1: Comparative analysis of photophysical properties of mono-labeled vs dual babeled Si 
NPs 
 IR800 dye 
(nm) 
Si NPs 
(nm) 
Si NP-IR800 
(nm) 
Si NP-IR800-NOTA 
(nm) 
Absorbance (λabs) 775 355 612 611 
Absorbance (shoulder) 700 - 470 470 
Fluorescence (λems) 792 456 754 748 
PLQY 14.2% 15% 22.5% 15.7% 
 
Surface charge 
 
The zeta potential (ζ) value of −5.1 mV ± 3.5 mV obtained for the Si NP-IR800-NOTA 
confirms its zwitterionic behavior of the dual-labeled conjugate. The values show slight 
variations from the mono-labeled Si NPs (Table 3.5.2) which depends on the chemical 
structure and the influence of functionalities present on the NOTA and IR 800 ligands. 
But the nearly zero values for all the Si NP conjugates owes to the limited surface 
functionalization performed which is detectable by imaging techniques yet not hampers 
the surface properties of the conjugates. 
 
3.5.3 Radiolabeling studies of dual-labeled Si NP-IR800-NOTA 
 
The radiolabeling experiments were performed according to the standard protocol 
followed in Section 3.4.11. The Si NP-IR800-NOTA conjugates were labeled with 
[64Cu]CuCl2 radionuclide at pH 5.2 at room temperature for 30 minutes. [64Cu]Cu-Si NP-
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IR800-NOTA was obtained in > 90% RCY with a specific activity of ~2 MBq/ 100 µg. The 
variation in the parameters like increasing the reaction time and slight elevation of the 
temperature (35 OC) did not potentially affect the radiolabeling of the Si NP conjugate. 
The radio-labeled Si NPs were purified by SEC to obtain ~98% radiochemical purity. 
 
An effect of pH on the radiolabeling efficiency of Si NP-IR800-NOTA was also 
determined. The percentage 64Cu(II) bound to the Si NP conjugate was plotted against 
the pH and is represented as Figure 3.5.4. The results show that highest radiolabeling 
is achieved at pH 4−6 for [64Cu]Cu-Si NP-IR800-NOTA. 
 
 
Figure 3.5.4: pH dependent 64Cu(II) radiolabeling studies of Si NP-IR800-NOTA.  
The extent of radiolabeling was determined by radio-iTLC after 30 min of reaction and Radio-HPLC 
purification. The results were plotted as pH vs percentage 64Cu(II) bound to Si NP-IR800-NOTA.
 
3.5.4 Quantitative estimation of the amount of fluorophore and the radiolabel on 
the Si NP conjugate 
 
Radiometric titration of Si NP-IR800-NOTA 
 
To determine the amount of NOTA chelator attached to the dual-labeled Si NP-IR800-
NOTA, radiometric titrations were performed with 64Cu(II). The protocol followed was 
same as for Si NP-NOTA (Figure 3.5.5). 
The calculations yielded ~0.091 µmol of NOTA conjugates per mg of Si NP-IR800-
NOTA, which is almost the same as obtained for mono-labeled Si NP-NOTA conjugate 
(0.09 µmol/mg Si NP-NOTA). 
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Figure 3.5.5: Radiometric titration curve for 64Cu(II) and Cu(II) labeled Si NP-IR800-NOTA. 
(Experimental value: ~0.091 µmol of NOTA /mg Si NP-IR800-NOTA determined by radio-TLC analysis 
(Method III)). 
 
Determination of lipophilicity of Si NP-IR800-NOTA 
 
1-octanol/water distribution experiments examined the hydrophilicity of [64Cu]Cu-Si NP-
IR800-NOTA to determine the biological behavior of the conjugate under physiological 
conditions. A negative log D7.4 value of −3.84 ± 0.10 assures the hydrophilicity and 
preserved biocompatibility of the dual-labeled Si NPs. The distribution ratio varies slightly 
from the mono-labeled Si NP-NOTA (−4.12 ± 0.04) which is probably due to the 
additional IR 800 ligand in the case (Table 3.5.2). 
The studies suggest that the Si NP conjugates are highly soluble under aqueous 
conditions, an important requisite for further in vitro/in vivo studies. 
 
Table 3.5.2: Zeta potential and distribution constants of Si NP conjugates. 
(Zeta potential was measured in water and distribution ratios for 1-octanol/water system) 
Si NP conjugates Zeta potential ζ (mV) log D7.4 
Si NPs −1.1 ± 3.9 mV − 
[64Cu]Cu-Si NP-NOTA −2.9 ± 4.7 mV −4.12 ± 0.04 
Si NP-IR800 −5.4 ± 4.1 mV − 
[64Cu]Cu-Si NP-IR800-NOTA −5.1 ± 3.5 mV −3.84 ± 0.10 
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Estimation of amount of IR800 conjugated to Si NPs 
 
The amount of dye conjugated to the NPs was determined by UV spectroscopy analysis 
based on Beer-Lambert’s Law. For the experiment, known samples of free IR 800 dye 
were prepared and measured for their absorbance and plotted on a graph against the 
concentration. A known amount of Si NP-IR800-NOTA solution was then measured and 
compared for the detection of the amount of the conjugated IR 800 dye (Figure 3.5.6). 
The results reveal an estimate IR 800 dye as 0.009 µmol/mg Si NP-IR800-NOTA which 
in this case is less compared to its mono-labeled analogue (0.013 µmol/mg Si NP-
IR800). 
 
 
Figure 3.5.6: Quantification of IR 800 dye conjugated to Si NP-IR800-NOTA (Experimental value ~ 
0.013 µmol IR800 / mg Si NP-IR800). 
 
A comparative summary of the conjugated ligands (NOTA and IR 800 dye) to the surface 
amine groups of Si NPs (Table 3.5.3).  
 
Table 3.5.3: Quantification of ligands bound to Si NP conjugates. 
Si NP conjugate Ligand Amount (µmol/mg Si NP conjugates) 
Si NP-NOTA NOTA ~0.09 
Si NP-IR800-NOTA NOTA ~0.091 
Si NP-IR800 IR 800 0.013 
Si NP-IR800-NOTA IR 800 0.009 
Si NP-B4 Bispidine (B4) ~0.052 
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3.5.5 Cell Cytotoxicity Studies of the Si NP-IR800-NOTA 
 
Biocompatibility studies for Si NP-IR800-NOTA were performed to assess the cellular 
toxicity related to the multifunctionalization of the NPs. The in vitro studies were 
performed following the same protocol utilized for the mono-labeled Si NPs to attain a 
comparative cytotoxicity data. The CyQ viability assay for the HEK 293 cells incubated 
with Si NP-IR800-NOTA portrays a permissible value of > 95% for 24, 48 and 72 hour 
time points, even at the higher concentrations (100 µgm/mL) of the conjugate (Figure 
3.5.7). 
 
 
Figure 3.5.7: In vitro cell studies of Si NP-IR800-NOTA in HEK293 cell lines. 
 
LDH assay results of ~5% cell death demonstrated that the dual modal Si NP conjugates 
show negligible LDH leakage into the cell media due to cell membrane disintegration for 
all four concentrations up to 3 days. A value considered to be well below the toxic 
threshold according to the Iso Norm 10993–5:2009 was retained for the bimodal Si NP-
IR800-NOTA. There was no statistical difference when comparing the toxic effects 
between mono-labeled and dual-labeled Si NP conjugates. The MTS viability assay 
supported the CyQuant and LDH results presenting the lack of any significant 
nephrotoxicity with ≥ 97% viability of the cells after 24, 48 and 72 hours (Figure 3.5.8). 
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Figure 3.5.8: Comparative in vitro analysis of Si NP conjugates. 
The cell viability and membrane lysis studies (MTS and LDH assay) for Si NP-NOTA, Si NP-IR800 and Si 
NP-IR800-NOTA upon 48 h of incubation in HEK293 cells. 
 
Based on these results, it is apparent that the dual modal conjugate does not lead to any 
substantial modifications in the cellular morphology and that the cellular metabolism is in 
the range of the negative controls. There are no toxic effects under the examined 
conditions. Thus, it is confirmed that the Si NPs are biocompatible and ready for the in 
vivo trials with its bimodal functionality. 
 
3.5.6 In vivo PET analysis and biodistribution studies, urine analysis and ex vivo 
examination of [64Cu]Cu-Si NP-IR800-NOTA 
 
3.5.6.1 Small animal PET studies and urine analysis of dual-labeled [64Cu]Cu-Si NP-
IR800-NOTA 
 
The [64Cu]CuCl2 radiolabeled and purified [64Cu]Cu-Si NP-IR800-NOTA was injected 
intravenously (~10 MBq each) to a set of 4 NMRI nu/nu healthy mice (standard deviation 
= 4). The biodistribution of the dual-labeled [64Cu]Cu-Si NP-IR800-NOTA was recorded 
by whole body PET scans at 5, 20, 30 and 60 minute time points. The Figure 3.5.9 
shows a fast clearance of the majority of the radiolabeled Si NP bioconjugates from the 
kidneys to bladder. The scan suggests that the bimodal Si NPs, after intravenous 
administration distribute uniformly in the whole body within the first 5−10 minutes and 
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then start eliminating from the body after glomerular filtration attributing to their ultrasmall 
size and zwitterionic surface charge. 
 
 
Figure 3.5.9: In vivo PET imaging of [64Cu]Cu-Si NP-IR800-NOTA at different time points. 
Whole body PET scans after a single intravenous injection of [64Cu]Cu-Si NP-NOTA (n = 4) in NMRI nu/nu 
mice after 5, 20, 30, 60 min p.i. 
 
The urine from the experimental mice was collected 5 min and 1 h p.i. and the activity 
was examined by radio-TLC system (“Method I” Section 5.2). The [64Cu]Cu-Si NP-
IR800-NOTA remains at the origin (Rf = 0) on the radio RP-TLC and the [64Cu]Cu-EDTA 
moves to the solvent front (Rf = 0.9) (Figure 3.5.10). The results show no significant 
differences in the three chromatograms with most of the radioactive compounds present 
at the origin corresponding to the bimodal Si NPs (Rf = 0). [64Cu]Cu-EDTA is observed 
in the injected sample and the urine 1 hour p.i. This data confirms the stability of the 
radiolabeled nanoconjugates in the physiological system of the mice with intact PET 
imaging modality. Additionally, no signs of demetalation of 64Cu(II) or cleavage of 
[64Cu]Cu-NOTA were observed within the biological system. This proves the covalent 
attachment of the radioactive chelating moiety, NOTA to the Si NPs via metabolically 
stable thiourea bonds. 
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Figure 3.5.10: Radio-TLC analysis of the urine sample of [64Cu]Cu-Si NP-IR800-NOTA injected mice. 
EDTA incubated SEC purified [64Cu]Cu-Si NP-IR800-NOTA was injected in a NMRI nu/nu. The urine 
samples (red) 5 min and 1 h p.i. were analyzed by Radio-TLC. TLC system: RP-TLC plates, 2M NH4OAc : 
MeOH (1:1, v:v), [64Cu]Cu-Si NP-IR800-NOTA Rf = 0. 
 
3.5.6.2 Ex vivo biodistribution and autoradiography studies of [64Cu]Cu-Si NP-
IR800-NOTA 
 
The [64Cu]Cu-Si NP-IR800-NOTA injected (~10 MBq) 4 NMRI nu/nu healthy mice were 
excised 5 min, 1 hour and 24 hour post injection respectively for the ex vivo 
autoradiography studies. The standardized uptake value (SUVBD) and the percent 
injected dose (%ID) values were used to evaluate the preferred mode of elimination of 
the particles from the body and the accumulation of these particles in different tissues 
and organs. The data were also used to compare the biodistribution of the dual-labeled 
imaging agent to that of previously studied and published mono-labeled agent [64Cu]Cu-
Si NP-NOTA, which lacks the fluorophore in its structure. 
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%ID values based analysis of [64Cu]Cu-Si NP-IR800-NOTA 
 
After 5 minutes of injection, the organs distribution studies depicted that the majority of 
the radioactive NPs constituting ~40% [64Cu]Cu-Si NP-IR800-NOTA was eliminated via 
the urine with kidneys, liver and intestine accounting for 5%, 5% and 3% respectively 
(Figure 3.5.11). After 1 hour, the radioactive content in the urine showed upto 85% and 
less than 5% was detected in the kidneys, liver and intestine. The other organs show 
negligible amount of activity confirming the extremely fast complete renal clearance of 
these hydrophilic Si NPs from the in vivo system within 1 hour time post injection. The 
24 hour p.i. study showed the presence of ~ 99% activity in the urine with 1% in the 
kidney and liver and negligible in other body parts. 
 
SUV based PET analysis of [64Cu]Cu-Si NP-IR800-NOTA 
 
The SUV data analysis after 5 minutes of administration of [64Cu]Cu-Si NP-IR800-NOTA 
showed major amount of activity concentration in the kidneys whereas all the other 
organs showed a SUV of 0.5–2, which refers to a smooth whole body biodistribution 
pattern (Figure 3.5.11). In 1 hour, the SUV in the kidney, liver and spleen were observed 
to be around 1.5, 0.7 and 0.3. The SUV in other organs were substantially lower, which 
further went down to 0.3 and 0.1 for kidneys and liver and negligible for all the other 
organs. 
Having a closer look at the data and evaluating the mode of elimination of the Si NPs, 
we compared the %ID and SUV values of the kidneys (to check renal excretion) and the 
liver (to check hepatobiliary mode of elimination) (Figure 3.5.12). 
The values clearly state that the mode of elimination for [64Cu]Cu-Si NP-IR800-NOTA is 
renal. The particles show no sign of sticking in the renal medulla and are easily passing 
through the glomerular pores in as short as 1 hour time post injection. 
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Figure 3.5.11: Biodistribution and autoradiography studies of [64Cu]Cu-Si NP-IR800-NOTA in NMRI 
nu/nu mice. 
Quantitative analysis of time-activity curves as %ID (mean ± SEM) (left) and SUV (mean ± SEM) (right) (n = 
4) A: 5 min, B: 1 h and C: 24 h after single intravenous administration. (%ID: Highest amount of activity in 
urine after 5 min, 1 h and 24 h). 
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Figure 3.5.12: Comparative quantification of renal versus hepatobiliary mode of elimination for 
[64Cu]Cu-Si NP-IR800-NOTA in NMRI nu/nu mice.  
Si NP-IR800-NOTA prefer renal mode of elimination over hepatobiliary excretion. 
 
3.5.6.3 Optical imaging ex vivo biodistribution studies of Si NP-IR800-NOTA 
 
The Si NP-IR800-NOTA (~120 µg) were injected intravenously in NMRI nu/nu healthy 
mice (n=4). The mice were excised after 5 min, 1 h and 24 h p.i. The fluorescence was 
studied semi-quantitatively for different organs. Zhe results show that the majority of the 
Si NP conjugates were excreted into the urine via bladder. The maximum fluorescence 
intensity projections as after the elimination of the majority of the injected sample via 
urine detects only traces of fluorescence in the organs. Figure 3.5.13 demonstrates the 
organs of the excised mice 5 minutes, 1 hour and 24 hour post injection of the bimodal 
Si NP conjugate. 
In the first 5 minutes, the fluorescence is observed uniformly distributed in the whole 
body and also actively filtered through the kidneys which shows prominent signals for 
the urine sample. In 1 hour, the activity has gone down quite low and major signal is 
observed in the urine, stomach and intestine. For 24 hour post injection excision sample, 
traces of fluorescence from the Si NPs are detected majorly in the urine with traces in 
the stomach.  
 
Results and Discussion 
 
121 
 
 
Figure 3.5.13: Ex vivo optical imaging of Si NP-IR800-NOTA at different time points p.i.  
Optical imaging scans of excised body organs numbered 1-21, after 5 min, 1 h and 24 p.i. in NMRI nu/nu 
mice.
 
The complementary biocompatibility and rapid renal clearance of the Si NP-IR800-NOTA 
achieved by PET and optical imaging, confirms the bimodality of the Si NP system. The 
results also displayed excellent pharmacokinetics and extraordinary biocompatibility of 
the system, which is prerequisite for any NP platform adapted for in vivo studies. The 
most acceptable reason for this behavior is the minimum required surface modification 
performed on the Si NP surface to achieve the imaging goals without hampering the 
hydrodynamic diameter and surface charge of the particles. 
 
3.5.7 Comparative analysis of [68Ga]Ga-Si NP-IR800-NOTA and [64Cu]Cu-Si NP-
IR800-NOTA in A431 tumor bearing mice 
 
To discover the effect of radiometals on the pharmacokinetics of the novel dual-labeled 
Si NP-IR800-NOTA conjugate, in vivo PET and biodistribution experiments were 
performed with two different radionuclides. NOTA being an efficient chelator for 68Ga as 
well as for 64Cu, provided us the opportunity to develop a correlation between the in vivo 
behavior and examine the effect of different radionuclides on the biodistribution pattern 
of the conjugates. The time frame for the two biodistribution experiments (64Cu and 68Ga) 
was set for up to 24 hours which was optimized while investigating the mono-labeled 
conjugates. 64Cu (t1/2 = 12.7 hours) radionuclide has an added advantage to measure the 
PET for a longer period compared to 68Ga, (t1/2 = 68 minutes) due to substantial 
differences in their half-lives. In this section, we present the quantitative (PET imaging) 
and semi-quantitative (optical imaging) results obtained after the in vivo biodistribution, 
pharmacokinetics and the ex vivo examination of the [68Ga]Ga-Si NP-IR800-NOTA and 
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[64Cu]Cu-Si NP-IR800-NOTA administered mice. The tumor mice were used to study the 
pharmacokinetics of the Si NP conjugates and to check the nonspecific tumor binding. 
 
3.5.7.1 In vivo PET results of [68Ga]Ga-Si NP-IR800-NOTA in A431 tumor bearing 
mice16 
 
The Si NP-IR800-NOTA were radiolabeled in MES buffer at room temperature with 68Ga 
radionuclide in ~ 95% RCY and purified by SEC Sephadex G-25 in 80% radiochemical 
purity, for the in vivo experiments. The preliminary small animal experiments were 
performed by intravenous administration of ~23 MBq of [68Ga]Ga-Si NP-IR800-NOTA (~ 
60 µg in 200 µL) to a set of two NMRI nu/nu mice with A431 tumor in the right hind leg 
(n = 2). As a minimal prerequisite, the in vivo studies were carried out via intravenous 
injections rather than local injection in order to get reliable pharmacokinetic profiles of 
the NPs. 
The chosen time points for recording the PET and fluorescence imaging for [68Ga]Ga-Si 
NP-IR800-NOTA was 30 minutes, 2 and 24 hours. The whole body PET image of the 
[68Ga]Ga-Si NP-IR800-NOTA recorded after 30 minutes of administration is displayed in 
Figure 3.5.14. The semi-quantitative PET scan clearly portrays the maximum 
radioactivity from the [68Ga]Ga-Si NP-IR800-NOTA in the heart of the mice and in the 
circulatory system with a little amount detected in other vital organs and tissues. 
The time-activity graph (Figure 3.5.14 A) displays a comparative biodistribution analysis 
of the bimodal [68Ga]Ga-Si NP-IR800-NOTA in the blood, heart, kidneys, muscles and 
tumor. The Si NPs are distributed in the whole body through the blood circulation at all 
points of time and eliminate via the designated renal pathway. No significant liver 
accumulation validates the renal clearance of the Si NPs and thus the biocompatible 
hydrodynamic diameter and the zwitterionic nature of the system. The values obtained 
are in accordance with the data attained for dual-labeled and mono-labeled 64Cu(II) 
ligated [64Cu]Cu-Si NP-IR800-NOTA and [64Cu]Cu-Si NP-NOTA. 
 
                                                          
16 68Ga radiolabeling of Si NP-IR800-NOTA and the animal experiments were performed by Dr. Ralf 
Bergmann at the Institute of Radiopharmaceutical Cancer Research, HZDR. 
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Figure 3.5.14: PET scan of [68Ga]Ga-Si NP-IR800-NOTA 30 min p.i. 
Whole body PET scan, A) Time-activity curve B) Tumor to muscle ratio of [68Ga]Ga-Si NP-IR800-NOTA in 
NMRI nu/nu mice. 
 
The high tumor to muscle ratio and tumor to blood ratio (Figure 3.5.14 B) suggest the 
non-specific targeting of the tumor tissue, occurring by the perfusion of the ultrasmall Si 
NPs in the tumor cells. Due to the crucial < 10 nm size of the imaging agent, the chances 
of EPR is eradicated. The graph shows that the maximum passive targeting was 
achieved 20−30 minutes post injection of the [68Ga]Ga-Si NP-IR800-NOTA. The 
radioactivity tends to wash away quickly from the tumor and the particles are again in 
the blood vessels making their way towards the kidneys. 
Another interesting and valuable data from this set of experiments was the determination 
of the complementarity of the dual-labeled Si NP system. The Figure 3.5.15 displays the 
maximum intensity projections of the simultaneous PET and fluorescence detection of 
the 64Cu(II) positrons emissions and the fluorescence from the IR 800 present on the Si 
NP surface. The complementary dual modal detection of [68Ga]Ga-Si NP-IR800-NOTA 
in the bladder 2 hours post injection confirmed the uniformity of the system and the 
presence of both the imaging modalities on a single Si NP platform. 
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Figure 3.5.15: PET/CT and OI/CT whole body scans of [68Ga]Ga-Si NP-IR800-NOTA injected mice. 
Similar PET (A) and OI (B) images of [68Ga]Ga-Si NP-IR800-NOTA injected in A431 tumor bearing NMRI 
nu/nu mice validates the dual modality of the Si NP conjugate with maximum detected activity in the urinary 
bladder.  
 
3.5.7.2 In vivo biodistribution studies [64Cu]Cu-Si NP-IR800-NOTA in A431 tumor 
bearing mice by small animal PET 
 
The second set of experiments on A431 tumor bearing mice was performed by the 
intravenous injection of 64Cu labeled Si NP-IR800-NOTA followed by the in vivo and ex 
vivo analysis. The whole body PET scan of the mice 2 hours post injection is presented 
in Figure 3.5.16. Similar to the other data, the [64Cu]Cu-Si NP-IR800-NOTA conjugates 
in this case are also visualized passing through the kidneys and ending up in the bladder 
and eliminated by the urine. Due to the absence of a tumor targeting moiety, no 
significant tumor accumulation is observed for the mono as well as dual-labeled Si NPs 
as in the case of healthy mice. 
A simultaneous comparative PET and fluorescence read out study of the [64Cu]Cu-Si 
NP-IR800-NOTA 1, 2 and 24 hour post injection, demonstrated the complementarity of 
the system for the tumor bearing mice, too (Figure 3.5.17). The results are also in 
agreement with the 68Ga labeled dual-labeled nanoconjugates with a similar 
pharmacokinetic behavior. 
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Figure 3.5.16: Whole body PET scan of A431 right hind leg tumor bearing NMRI nu/nu mice 2 h p.i. 
of [64Cu]Cu-Si NP-IR800-NOTA. 
 
 
Figure 3.5.17: PET and OI scans of [64Cu]Cu-Si NP-IR800-NOTA injected A431 tumor bearing mice. 
PET (A) and OI (B) images of [64Cu]Cu-Si NP-IR800-NOTA in NMRI nu/nu mice 1 h and 24 h p.i. The 
maximum activity is already eliminated within 1 h via bladder. MIP analysis detects traces of radioactivity 
and fluorescence in the kidneys.
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3.5.7.3 Ex vivo and autoradiography studies of [64Cu]Cu-Si NP-IR800-NOTA 
 
Due to the longer half-life of 64Cu, unlike 68Ga, an ex vivo analysis was also possible for 
the system along with the fluorescence measurements. As expected, the maximum 
activity and fluorescence from [64Cu]Cu-Si NP-IR800-NOTA was detected in the kidneys 
and the urine, followed by minor quantities in the intestine, stomach and liver (Figure 
3.5.18). The data obtained are consistent to their [68Ga]Ga-Si NP-IR800-NOTA labeled 
counterparts. 
 
 
Figure 3.5.18: Ex vivo PET (A) and optical imaging (B) scans of excised organs for [64Cu]Cu-Si NP-
IR800-NOTA injected A431 tumor xenograft mice 24 h p.i. 
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3.5.8 Conclusions 
 
The dual-labeled Si NPs were prepared by stepwise synthesis method and obtained in 
high purity after several optimizations. Si NP-IR800-NOTA was characterized for its 
surface properties which shows comparable values to its mono-labeled analogues. The 
cell studies also displays no signs of cytotoxicity and cell damage. Therefore, the bimodal 
conjugate was assessed for its in vivo behavior. 
 
The most interesting conclusion drawn from the small animal experiments was that no 
significant effect of the radionuclide 64Cu or 68Ga was observed on the pharmacokinetics, 
elimination behavior, and fate of Si NPs. Another important aspect was the 
complementary data obtained from the dual imaging modalities, NOTA and IR 800, 
present on Si NP-IR800-NOTA, confirming the successful synthesis of a silicon-based 
dual-labeled system. The preclinical trials on the healthy and tumor bearing mice 
demonstrated pharmacokinetics similar to the mono-labeled conjugates Si NP-IR800 
and Si NP-NOTA. The slight non-specific tumor accumulation of the Si NP conjugate 
detected was also quickly washed away by the blood circulation not leading to any 
significant differences in the elimination pattern. The comparable conduct of the mono-
labeled as well as dual-labeled Si NP-based nanohybrids in the living system can be 
explained by the physicochemical properties possessed by the modified Si NPs. 
 
Si NP-IR800-NOTA displays excellent pharmacokinetics with high biocompatibility. The 
low unspecific binding and fast renal clearance makes it ideal for labeled Si NPs with 
targeting moieties and their use for in vivo imaging. With these characteristic properties, 
the bimodal conjugate can be used as a potential diagnostic tool for cancer imaging. 
After the successful synthesis of the dual-labeled core, the next step was to investigate 
their potential with a tumor-targeting agent that is reported in Chapter 3.6.  
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3.6 Investigation of mono-labeled and dual-labeled Si NPs as targeted 
imaging agents 
 
The successful synthesis of non-targeting Si NP-based mono and dual-labeled agents 
and the promising small animal biodistribution results directed us towards the 
development of targeting Si NPs. This chapter deals with the synthesis, purification, 
photophysical and physico-chemical characterization of the targeting Si NP-based 
nanohybrids. 
 
The initial coupling reactions were performed with the peptide 5B9 to analyze the extent 
of fabrication and stability of the NPs as multimodal systems. The peptide 5B9 is the first 
known chimeric anti-platelet factor 4/heparin complexes IgG1 antibody that has a human 
Fc fragment. It fully mimics the effect of Heparin-induced thrombocytopenia (HIT) human 
antibodies. This property leads to  a detailed study of this disease HIT [279-281].  
 
The biological vector conjugations to the Si NP-IR800 and Si NP-IR800-NOTA lead to a 
viable analysis and characterization of the Si NP bioconjugates. Hexaethylene glycol 
was used as a bifunctional linker with an active-NHS ester on one end and maleimide on 
the other to couple amine-terminated Si NPs and thiol-terminated 5B9 peptide, 
respectively. The advantage of using such linkers is that it does not deeply affects the 
crucial properties of the NPs, like the size and surface charge and thus, the 
biocompatibility of the system. Ethylene glycols are renowned linkers for biological 
applications, as they tend to increase the blood retention time of the bioconjugates with 
no significant drawbacks. 
 
3.6.1 Synthesis of Si NP-PEG-5B9 peptide conjugates17 
 
For the synthesis of Si NP-IR800-PEG-5B9 and Si NP-IR800-NOTA-PEG-5B9, Si NP-
IR800 (mono-labeled) and Si NP-IR800-NOTA (dual-labeled) (Chapter 3.4 and 3.5) 
were used as precursors. The PEG moieties further allow the modification of the Si NPs 
to the peptide through the thiol-maleimide coupling. 
The first step in this synthesis was the addition of the linker, consisting of oxyethylene 
groups to the Si NPs to gain maleimide-functionalized NPs (Figure 5.6.1). The second 
reaction of the 5B9 addition was performed in situ for both the fluorescent conjugates. 
The thiol-terminal 5B9 peptide was stirred in an aqueous solution with a reducing agent, 
                                                          
17 PEG in Chapter 3.6 refers to Hexaethylene glycol. 
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TCEP to break the disulfide linkages and to get free the sulfhydryl groups. The reactions 
were run in aqueous environment at physiological pH for 8 hours. 
Upon multifunctionalization, due to no major differences in the molecular masses of Si 
NP conjugates, the purification, as well as the characterization of the samples was 
challenging. The NPs were dialyzed against water, followed by SEC. The fractions 
collected from SEC were further analyzed by measuring the DLS, Zeta potential, 
photophysical properties and electrophoresis. 
 
3.6.2 Characterization of the targeted Si NP conjugates 
 
The absorption and emission properties of the purified samples, Si NP-IR800-PEG-5B9 
and Si NP-IR800-NOTA-PEG-5B9 were compared to their non-targeted counterparts Si 
NP-IR800 and Si NP-IR800-NOTA. A comparative study of absorption and emission 
spectra of the conjugates is represented in Figure 5.6.2. 
 
The results reveal no changes in the spectral band positions of the bioconjugates upon 
coupling the 5B9 peptide via the PEG linker. However, an increase in the PLQY of the 
Si NP bioconjugates is observed compared to its non-targeted analogues. 
The absorption, emission and calculated photoluminescent quantum yields of the 
fluorescent Si NP conjugates (Si NP-IR800, Si NP-IR800-NOTA, Si NP-IR800-PEG-5B9 
and Si NP-IR800-NOTA-PEG-5B9) along with Si NPs and IR 800 dye are summarized 
in Table 5.6.1. 
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Figure 5.6.1: Synthesis of Si NP-IR800-PEG-5B9 and Si NP-IR800-NOTA-PEG-5B9. 
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Figure 5.6.2: Absorption (A) and emission spectra (B) of Si NP conjugates and IR 800 dye. 
 
Table 3.6.1: Photophysical properties of non-targeted and targeted Si NPs. 
 IR800 
dye 
Si NPs Si NP-
IR800 
Si NP-IR800-
NOTA 
Si NP-IR800-
PEG-5B9 
Si NP-IR800-NOTA-
PEG-5B9 
 (nm) (nm) (nm) (nm) (nm) (nm) 
λabs 775 355 612 611 619 619 
λabs 
(shoulder) 
700 - 470 470 470 470 
λem 792 456 754 748 753 753 
PLQY 14.2% 15% 22.5% 15.7% 29.82% 26.29% 
 
 
Zeta potential measurements of the fluorescent, targeted and non-targeted Si NPs was 
measured in water between pH 7.2−7.5. A comparative analysis of the surface charge 
of Si NP conjugates is reported in Table 3.6.2. The zeta potential values of Si NP-IR800-
PEG-5B9 (−19.1 ± 6.6) and Si NP-IR800-NOTA-PEG-5B9 (−8.3 ± 5.3) do not display 
huge deviations from the non-targeting Si NP conjugates. As discussed earlier, the low 
surface modification, helps in retaining the inherent and surface properties of the Si NPs, 
therefore, no huge deflections were observed from the nearly zero surface charge for all 
the nanoconjugates. The conservation of the surface charge and size of the modified Si 
NPs play a major role in the noncytotoxic behavior and favorable pharmacokinetic 
patterns attained by the conjugates. 
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Table 3.6.2: Summary of surface charge (Zeta potentials) of Si NPs and its conjugates. 
Si NP conjugates Zeta potential ζ (mV) 
Si NPs −1.1 ± 3.9 
Si NP-NOTA −2.9 ± 4.7 
Si NP-IR800 −5.4 ± 4.1 
Si NP-IR800-NOTA −5.1 ± 3.5 
Si NP-IR800-PEG-5B9 −19.1 ± 6.6 
Si NP-IR800-NOTA-PEG-5B9 −8.3 ± 5.3 
 
SDS-PAGE and Agarose gel analysis 
 
The charge, size and mass dependent mobility of the synthesized conjugates was 
verified by two kinds of gel electrophoresis techniques, the sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and agarose gel electrophoresis. 
Previous experiments confirmed the mobility of the Si NPs in the gel but the particle with 
or without 5B9 peptide could not be stained. Therefore, only fluorescence read out was 
possible for the preliminary studies. 
 
The two peptide conjugates Si NP-IR800-PEG-5B9 and (1) Si NP-IR800-NOTA-PEG-
5B9 (2) (Figure 5.6.3) were loaded on 10% agarose gel and run in an electric field. The 
gels were read under two wavelength categories, IR short channel (710 – 730 nm) and 
IR long channel (810 – 840 nm). The results were overlaid for better analysis. 
The major interpretations and conclusions drawn from the two kinds of gel 
electrophoresis are: 
 
The free IRDye 800CW (λab/λem = 775/792 nm) is seen in the IR long wavelength detector 
and moves to the front in both the gels (Figure 5.6.3). The Si NP conjugates with higher 
molecular mass, show less mobility. It is also evident that the IR 800 dye bears higher 
charge compared to Si NP conjugates. 
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Figure 5.6.3: Agarose gel for Si NP-IR800-PEG-5B9 (1a, 1b) and Si NP-IR800-NOTA-PEG-5B9 (2a, 2b). 
IR short channel (710-730 nm) IR long channel (810-840 nm) 
 
The peptide conjugates Si NP-IR800-PEG-5B9 (1a and 1b) and Si NP-IR800-NOTA-
PEG-5B9 (2a and 2b) are observed in the both the IR short and IR long channels and 
therefore, can be observed in the overlaid images too. 
An interesting finding is the presence of two consistent populations of fluorescent Si NPs 
in each sample which might be due to the non-uniformity of conjugation on the surface 
of Si NPs (Figure 5.6.3 and 5.6.4). The two bands differ slightly in their mobility and 
therefore, in the charge, mass and size. The presence of the two populations even after 
purification steps (dialysis and SEC) confirms that they bear similar retention times with 
comparable mass and size. 
 
 
Figure 5.6.4: Agarose (left) and SDS PAGE (right) gel for Si NP-IR800-PEG-5B9 and Si NP-IR800-
NOTA-PEG-5B9. 
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3.6.3 Conclusions 
 
Fluorescent Si NP conjugates Si NP-IR800 and Si NP-IR800-NOTA were grafted by a 
bifunctional linker (PEG) to couple a receptor targeting peptide onto the Si NP surface. 
The Si NP bioconjugates were synthesized in aqueous medium and purified by dialysis 
and SEC. The analysis was performed by fluorescence measurements. Preliminary 
studies confirmed the attachment of the peptide 5B9 to the Si NPs via thioether bonds. 
The electrophoresis studies revealed a non-uniform surface modification of both the Si 
NP bioconjugates leading to two distinct populations in the solution. 
The investigations of the targeting Si NPs, Si NP-IR800-PEG-5B9 and Si NP-IR800-
NOTA-PEG-5B9 are currently under progress and not a part of this work. 
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Chapter 4 Conclusions and Outlook 
 
 
4.1 Conclusions 
 
The major goals achieved during the course of this dissertation are: 
 
Development of novel bispidine bioconjugates as 64Cu chelators for PET imaging: 
 
The facile and cheap synthesis, excellent chelating efficiency, possibility to form highly 
stable complexes under mild conditions with favorable biodistribution patterns was an 
instigation to work towards the development of bifunctional bispidines as novel chelators 
for PET applications. A series of bispidine derivatives (B4 − B9) with varying terminal 
functional groups were synthesized and thoroughly characterized. 
 
 
 
Bispidine-Bn-SCN (B4) and Bispidine-DBCO (B5) forming excellent thermodynamically 
stable and kinetically inert complexes were selected for the development of targeted PET 
imaging agents. 
The novel derivative B4 was conjugated to amine-terminated TATE peptide via a two-
step coupling/deprotection reaction to produce B4-EG-TATE (EG: diethylene glycol). 
TATE peptide is a somatostatin analogue and is expected to efficiently target 
Somatostatin type-2 receptors overexpressed in cancer malignancies of neuroendocrine 
origin. 
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Bispidine coupled to SSTR-specific EG-TATE peptide 
 
The [64Cu]Cu-B4-EG-TATE complex was delivered in high RCY and radiochemical 
purity. This also proved the preservation of the labeling efficiency of B4 after its 
bioconjugation. 
A Sortase-A (Srt-A) mediated approach was applied for the site-specific labeling of single 
domain antibody 7C12 (sdAB 7C12) to generate an azide terminal complementary 
biomolecule to the dibenzocyclooctyne functionality present on B5. This 
chemoenzymatic strategy leads to a facile and convenient modification of the single 
domain antibody. The strain promoted azide-alkyne cycloaddition between B5 and sdAb 
7C12 produced a stable triazole derivative B5-sdAb-7C12 via Cu-free click reaction. 
Preliminary studies provided a high radiolabeling efficiency and stability of the complex 
[64Cu]Cu-B5-sdAb-7C12. Cell binding studies performed with A431 cancer cell lines 
revealed a specific binding to the epidermal growth factor receptors and allowed further 
investigation in the direction of small animal PET experiments. 
 
 
Bispidine coupled to EGFR-specific sdAb 7C12 via azide-cyclooctyne click chemistry 
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Modification of ultrasmall silicon nanoparticles as PET/OI imaging agents: 
 
Hydrothermal method was employed to yield extremely hydrophilic, multifunctional, 
zwitterionic amine-terminated Si NPs with a size of ~ 4 nm. Novel Si NP-IR800 and Si 
NP-bispidine conjugates were developed as positron emission tomography and optical 
imaging agents. A comprehensive characterization of the nanoconjugates confirmed the 
preservation of ‘ultrasmall’ hydrodynamic diameter and ‘zwitterionic‘ surface charge of 
the Si NPs even upon its functionalization. After successful synthesis, analysis and 
characterization, it was concluded that the Si based nanoparticles; Si NP-NOTA and Si 
NP-IR800 (Figure) bear optimal intrinsic and surface properties to be applicable for cell 
studies and preclinical trials in mice. 
 
 
Cell viability and proliferation analysis of Si NP-IR800 on human embryonic kidney cells 
(HEK 293) showed no cytotoxicity. 
The biodistribution studies from both kinds of nanoparticles; Si NP-IR800 and [64Cu]Cu-
Si NP-NOTA performed in NMRI nu/nu healthy mice, displayed comparable results. The 
Si NPs tend to distribute uniformly in the whole body within the first 5−10 min after 
intravenous injection. The detected activity from [64Cu]Cu-Si NP-NOTA and fluorescence 
from Si NP-IR800 showed that the Si NPs take the renal elimination pathway. Majority 
of the radioactive NPs (> 90%) are eliminated from the body within 30 min of 
administration and the rest is gradually cleared over time with no liver accumulation. The 
ex vivo fluorescence analysis of Si NP-IR800 2 h p.i. exhibited the maximum 
fluorescence signals in the urine followed by kidneys. Urine analysis of Si NP-IR800 
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confirms the covalent attachment of the ligand to the Si NPs, which is stable even within 
the complex biological system. 
 
Development of bimodal Si NPs for PET-OI: 
 
Using mono-labeled Si NPs as a precursor, efforts were made towards the synthesis of 
bimodal Si NP-IR800-NOTA. The stepwise synthesis method was adapted for a 
reproducible synthesis after several optimizations. The characterizations were 
performed by adapting combined methodologies (radiolabeling to determine the 
chelator; fluorescence studies for fluorophores). 
 
 
The cell studies of Si NP-IR800-NOTA exhibited extremely low cytotoxicity and thus, a 
high biocompatibility. The small animal experiment for complementary OI and PET 
distribution studies of Si NP-IR800-NOTA and its 64Cu-labeled analogue delivered 
promising results. The ultrasmall sized, nearly neutral Si NP conjugates portrayed 
excellent pharmacological properties with no accumulation in the body organs. The mode 
of elimination of the Si NP conjugate was renal. The full body PET and fluorescence 
scans infer the conjugation of the labeling agents (IR 800 and NOTA) to a single Si NP 
core with covalent bonds. The urine analysis of the bimodal Si NPs displayed no 
cleavage of the radiolabel and fluorophore, thus, confirming the stability of the dual-
labeled system. Another interesting data observed was the similar pharmacokinetic 
behavior for both, 64Cu and 68Ga labeled Si NP-IR800-NOTA depicting no influence of 
the radionuclide on in vivo biodistribution and fate of Si NPs. The ex vivo studies also 
showed comparable data to the unimodal imaging agents with majority of the 
radioactivity and fluorescence expelled into the urine and kidneys at all time-points. A 
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summary of results obtained by bimodal Si NP-IR800-NOTA is shown in the Figure 
below. 
 
 
Figure: A i) In vivo PET scan of [64Cu]Cu-Si NP-IR800-NOTA injected in healthy NMRI nu/nu mice 5, 20, 
30 and 60 min p.i.; A ii) Urine analysis by radio-TLC 5 and 60 min p.i. B) Complementary PET and OI images 
1 h and 24 h p.i. D) Structure of [64Cu]Cu-Si NP-IR800-NOTA. 
 
As a conclusion, Si NPs bear an extremely versatile and functionalizable platform. The 
convenient and cost-effective synthesis along with superior pharmacokinetics of the 
mono- and dual-labeled Si NPs make them distinguished multifunctional candidates for 
the development of targeting agents. These exceedingly biocompatible imaging probes 
can build a strong foundation in the field of multimodal molecular imaging due to their 
unmatched physico-chemical characteristic properties. 
The results presented in the thesis, therefore, successfully addressed the scientific goals 
towards targeted and non-targeted molecular imaging. Bispidines and ultrasmall silicon 
nanoparticles can serve as potential candidates in the field of cancer diagnostics and 
imaging in future. 
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4.2 Outlook 
 
Molecular imaging is an important and envisaged research area with a broad space for 
further developments. The personalized approach relying on the incorporation of 
appropriate molecular species to target particular cancer cells is the major aspect of the 
molecularly targeted therapy. In this direction, the overall outlook of the functionalized 
bispidines and Si NPs with variable component system looks very promising. 
 
The novel bispidine derivatives developed in the thesis opens up new opportunities to 
conjugate efficiently to biological vector molecules, capable of targeting variable cancer 
types and progress towards the evolvement of personalized cancer theranostics. The 
rigid bicyclic structure with inherent biocompatibility and acquired radiochelation 
tendency can be exploited comprehensively in the field of multimodal imaging. 
 
The ultrasmall silicon nanoparticles on the other hand, exhibit promising characteristics 
with easily accessible terminal groups, facile coupling tendency and excellent 
pharmacokinetics. The synthesized novel dual-labeled Si NPs, in future, can be 
decorated with cancer tumor specific vectors to target a diverse range of tumors for 
personalized therapeutics. 
 
In summary, multimodal molecular imaging applying the NPs may have a bright future. 
The cost-effective, reproducible and convenient synthesis of the bispidine and Si NP-
based imaging probes with high biocompatibility can definitely bring a major 
breakthrough in medical imaging. 
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Chapter 5 Experimental Section 
 
5.1 Chemicals and Materials 
 
All chemicals and solvents for synthesis and analysis were purchased from Fisher 
Scientific, Fluka, Merck, VWE, Lumiprobe and Sigma-Aldrich with reagent, analytical 
grade and used without any further purification. Dry solvents were purchased from 
Sigma-Aldrich along with corresponding drying agents. Reactions demanding inert 
conditions were performed under argon or nitrogen atmosphere in flame-dried 
glassware. Ultrapure water with resistivity 18 MΩ.cm (25°C) obtained from Millipore 
RiOs/Origin System (Millipore Corporation, USA) was used throughout the synthesis 
and analysis. 
 
Table 1 Specifications of Chemicals and Materials used. 
 Chemicals and Materials Manufacturer Specifications 
 Acetonitrile Fisher HPLC grade 
 Ammonium acetate (NH4OAc) Fluka® Bioultra 
 Anatop filters (0.02 μm) filter GE Healthcare  
 3-Bromopropylamine hydrobromide Sigma-Aldrich 98.0 % 
 Copper nitrate pentahydrate Sigma-Aldrich 99.0 % 
 DBCO-NHS Ester Lumiprobe  
 Dichloromethane Fisher HPLC grade 
 Diethyl ether Sigma-Aldrich 99.8% 
 Diethyl-1,3-acetonedicarboxylate Sigma-Aldrich 96.0% 
 Dimethyl-1,3-acetonedicarboxylate Sigma-Aldrich 96.0% 
  1,4-Dioxane Sigma-Aldrich 99.8% 
 Disodium hydrogen phosphate (Na2HPO4) Fluka® Anhydrous,≥  
   99.5% 
 Ethanol Fisher HPLC grade 
 Ethyl acetate Merck  
 N,N-Dimethyl Formamide Sigma-Aldrich Anhydrous,≥ 
   99.8% 
 N,N-Diisopropylethyl amine (DIPEA) Sigma-Aldrich 99.0 % 
 Dimethyl sulfoxide (DMSO) Sigma-Aldrich Anhydrous,≥ 
   99.7% 
 dMal-PEG4-NHS Celares GmBH 98.0 % 
 N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide Sigma-Aldrich > 99.0 % 
 hydrochloride (EDC)   
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 Di-tert-butyl dicarbonate Sigma-Aldrich  
 Ethylene diamine Tetraacetic acid (EDTA) Fluka® ≥ 99.0 % 
 Float-A-Lyzer Spectrum labs  
 Formaldehyde Sigma-Aldrich 37.0% 
 HBTU (N,N,N’,N’-Tetramethyl-O-(1H-benzotriazol- Sigma-Aldrich ≥ 98.0% 
 1-yl)uranium hexafluorophosphate)   
 His60 Ni Column Clontech  
 Hydrochloric acid Merck 30.0% 
 2-Iminothiolane Hydrochloride Sigma-Aldrich ≥ 98.0 % 
 IRCW 800-NHS ester Lumiprobe  
 S-2-(4-Isothiocyanatobenzyl)-1,4,7- Macrocyclics ≥ 94.0 % 
 triazacyclononane-1,4,7-triacetic acid   
 (p-SCN-Bn-NOTA)   
 Maleic anhydride Merck ≥ 99.0% 
 Methanol Fisher HPLC grade 
 Microfilter (0.2 μm) VWR  
 2-Morpholino-ethansulfonic acid monohydrate Applichem ≥ 99.0% 
 (MES)   
 NAP-5 columns GE Healthcare  
 Octylamine Sigma-Aldrich 99.0% 
 PD 10 Sephadex G25 GE Healthcare  
 1,3 Phenylene diisothiocyanate Sigma-Aldrich 97.0% 
 2-Picolylamine Sigma-Aldrich 99.0% 
 Potassium Chloride (KCl) Fisher  
 Potassium hydroxide Merck ≥ 88.0% 
 Pyridine Sigma-Aldrich > 99.0% 
 Pyridine-2-aldehyde Sigma-Aldrich 99.0% 
 Sephadex G25 fine resin GE Healthcare  
 Sodium borohydride Sigma/Aldrich 98.5% 
 Sodium Chloride (NaCl) Fluka® Analytical 
   ≥99.5% 
 Sodium dodecyl Sulfate (SDS) Sigma-Aldrich  
 Sodium Carbonate Roth ≥ 99.5% 
 Sodium bicarbonate (NaHCO3) Sigma-Aldrich ≥ 99.5% 
 Sodium Hydroxide (NaOH) Sigma-Aldrich 99.9% 
 Tetrahydrofuran Fisher HPLC grade 
 Triethyl amine (TEA) Sigma-Aldrich ≥ 99.5% 
 Tris (2-carboxyethyl)phosphine hydrochloride (TCEP) Sigma-Aldrich ≥ 98.0% 
 Trifluoroacetic acid Fluka 99.0 % 
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5.2 Analysis, characterization and purification techniques and methods 
 
Dynamic Light Scattering (DLS) 
Hydrodynamic size and zeta potential measurement were performed using the dynamic 
light scattering (DLS) using Zetasizer NanoZS (Malvern Instruments, UK) with an angle 
detection of 173° at 25° C with a beam wavelength of 632.8 nm. Particle size 
determination as well as zeta potential measurements were conducted at a concentration 
of 2 mg/mL in 10 mM phosphate buffer saline (pH 7.4) in disposable plastic cuvettes with 
a square aperture (Malvern Instruments Ltd.). Prior to each experiment, the solutions 
were filtered through 0.02 µm or 0.2 µm syringe filters (GE Healthcare, Germany) and 
equilibrated for 2 mins. The stated value is a mean of three independent measurements. 
Zeta potential measurements were performed in a universal dip cell (Malvern 
Instruments Ltd.). The stated values are a mean of three independent measurements 
using the Smoluchowski model. Data were evaluated with Malvern Zetasizer Software 
7.11 version.  
 
Ultraviolet-Visible Spectroscopy (UV-Vis) 
UV-Vis spectroscopy was conducted on Specord® S50 from Analytik Jena 
(Germany).The samples were measured on quartz micro cuvettes (d=1cm) with 400-500 
μL with a wavelength range from 190-1100 nm.  
The standard calibration curves and the molar extinction coefficient of dPG were 
calculated using the Beer-Lambert equation: A= ε x l x c where A is the absorbance at 
λmax, ε denotes the extinction coefficient, c denotes the concentration and l denote the 
path length of the cuvette (1 cm). For quantum yield experiments, the absorbance was 
kept between 0.01-0.1. The measurements were set relative to the blank solution 
(reference).Data were processed using the WinASPECT® software. 
 
Fluorescence Spectrometry (FS) 
Quantum Yield (QY) and fluorescence measurements were done using a PerkinEimer 
LS55 using a black cuvette of 100 µL with a light path 10 x 2 mm (105.250, QS). Settings: 
Split with 10nm and speed record. 
Fluorescence emission measurements and quantum yield experiments were done using 
an LS 55 (230V) luminescence spectrometer from PerkinElmer equipped with a xenon 
flash lamp source for excitation. Samples were measured in transparent disposable 
cuvettes of 2 mL with a wavelength range of 200-900 nm and the slit width of 10 nm. FL 
UV WinLab® software was used for Data analysis and acquisition 
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Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier transform infrared (FTIR) spectra were recorded on a Perkin Elmer 1600 Series 
FTIR spectrometer in the range 4000-400 cm-1, with a resolution of 4 cm-1. Solid samples 
were prepared as KBr disks. Oils were analyzed using NaCl discs. 
 
Mass spectrometry (MS) 
Electron spray Ionization-MS (ESI-MS) was conducted on high-performance compact 
mass spectrometer ‘expression CMS’ (Advion, Germany) in either positive or negative 
mode. The samples 0.1 mg/mL were dissolved in acetonitrile: water (1:1) and a diluted 
5 μL sample of 1:100 dilution was injected manually with a flow rate of 0.1 mL min-1. 
Software Mass express and data express version 3.0 were used for data analysis. 
 
Matrix-assisted laser desorption/ionization (MALDI-TOF) was conducted to determine 
the PEG conjugation on the sdAbs on a Daltonic Autoflex II TOF/TOF (Bruker, Germany). 
3-hydroxypicolinic acid (HPA) was used as the matrix for measurement 
 
Nuclear magnetic resonance spectroscopy (NMR) 
1H-NMR and 13C spectra were recorded on a 400 MHz and 101 MHz Varian Inova 400 
spectrometer. Chemical shifts were recorded on a δ scale in parts per million (ppm). The 
samples were dissolved in deuterated solvents as indicated. Tetramethylsilane (TMS) 
was used as an internal calibration standard (δ 0 ppm). MeOD (δ 3.31 ppm), CDCl3 (δ 
7.26 ppm) or D2O (δ 4.79 pm) were used for calibration standard for 1H spectra. The 
abbreviations used to describe the resonances are: s (singlet), d (doublet), dd (doublet 
of doublets), t (triplet), q (quartet), m (multiplet), and br (broad). The data analysis was 
done using Mestronova software. 
 
Elemental analysis (EA) 
It was used to determine the content of C, N, S and H were measured on an Elemental 
Analyzer EuroEA 3000 from EuroVector (Milan, Italy). The used software was Callidus 
5.1. As standards 2,5-(Bis(5-tert-butyl-2-benzo-oxazol-2-yl) thiophene (BBOT) and 
Sulphanilamide were used. 
 
Dialysis 
Dialysis was performed on with regenerated cellulose membranes with ultra-pure 
cellulose ester Float-A-Lyzer membranes from Spectrum Labs, Germany with various 
molecular weight cut-off (MWCO: 1 kDa, 3.5-5 kDa) against appropriate solvents as 
indicated in the results and discussion section. 
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Ultracentrifugation 
Amicon® Ultra-0.5 centrifugal filter devices with a molecular weight cutoff of 3K 
(Amicon® Ultra 3K device, Merck-Millipore) were used to purify single domain antibodies 
before and after its coupling to the chelators. 
 
Size exclusion chromatography (SEC) 
Size Exclusion Chromatography was performed using different resins and columns 
depending on the compounds and the sample volume. The eluents used were Millipore 
water or 0.9% NaCl (v/v) as indicated in the experiment section.  
 
System SEC column Method Mobile phase 
A PD-10 Desalting G25 column 
(Sephadex, G25 medium) 
Gravity flow 0.9 % NaCl or water 
B NAP-5 DNA grade column 
(Sephadex, G25 fine) 
Gravity flow 0.9 % NaCl or water 
 
 
High-Performance Liquid Chromatography (HPLC) 
Purification of the bispidine derivaties was performed by the Äkta explorer 
chromatography system (GE Healthcare, Germany) and Knauer HPLC systems on 
different columns with detection at 220 and 254 nm. The columns used, injection 
volume, solvents, flow rates and solvent gradient and UV detection wavelength can be 
found in the Table below. 
Äkta explorer uses the Unicorn 5.11 software was applied for peak analysis and Knauer 
system uses the ChromGate software for data processing and analysis. 
Solvent System A = H2O + 0.1 Vol. % TFA, B = CH3CN + 0.1 Vol. % TFA 
Method HPLC column Solvent gradient 
Analytical HPLC 
A Phenomenex Aqua C-18 125 Å 
(250 × 4.6 mm, 5 μm) 
0% to 70% B in 20 min 
70% to 100% B in 2 min 
f = 1 mL/min, λ = 220 nm 
Semipreparative HPLC 
B Phenomenex Gemini C-18 110 Å 
(250 10 mm, 5µm) 
 
i) 30% to 70% B in 30 min 
70% to 100% B in 15 min 
f = 1 mL/min, λ = 220 nm 
ii) 30% to 50% B in 20 min 
50% to 70% B in 10 min 
f = 1 mL/min, λ = 220 nm 
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C Synergi Hydro RP 80 Å 
(250 x 21,2 mm, 4µm) 
60% B to 40% B in 15 min 
f = 10 mL/min, λ = 220 nm 
Preparative HPLC 
D Phenomenex Gemini C-18 110 Å 
(250 x 30 mm, 5µm) 
i) 30% B to 70% B in 15 min 
70% B to 100% B in 15 min 
f = 10 mL/min, λ = 220 nm 
ii) 30% B to 70% B in 40 min 
70% B to 100% B in 20 min 
f = 10 mL/min, λ = 220 nm 
iii) 30% B to 70% B in 
70% B to 100% B in 
f = 10 mL/min, λ = 220 nm 
 
 
Thin Layer Chromatography (TLC) 
Thin layer chromatography was conducted on various stationary phases such as silica 
gel (reverse phase, RP-TLC) and neutral aluminum oxide (Alox) plates using different 
mobile phase systems in a vertical chamber for elution. UV lamp (254 nm) and 
Amersham Typhoon 5 Scanner (300-900 nm) were used for analysis of fluorescence 
labeled nanoparticles. 
 
5.3 Radionuclide production (68Ga and 64Cu) 
 
68Ga was eluted from a 68Ge/68Ga generator from iThemba LABS (Faure, South Africa) 
in as [68Ga]GaCl3 by using 0.6-0.8 M HCl. The concentration of the eluate is usually in a 
range of 2-4 MBq /mL depending on the age of the generator. The [68Ga]GaCl3 was 
purified by ion exchange chromatography and then concentrated. 
64Cu was produced as [64Cu]CuCl2 by the cyclotron “Cyclone 18/9” (IBA molecular) at the 
Helmholtz-Zentrum Dresden–Rossendorf by a 64Ni(p,n)64Cu nuclear reaction. The yields 
of the nuclear reaction were between 3.6–5.2 GBq (EOB) with molar activities between 
150–250 GBq/μmol Cu [64]. 
 
Radio-Thin Layer Chromatography (Radio-TLC) 
Radiochemical analysis of the yields and kinetics of the experiments was determined 
using different stationary phase and eluent systems. iTLC plates were purchased from 
Agilent Technologies. The air-dried TLC strips are exposed to a high-resolution 
phosphorimaging plate (GE Healthcare). The exposed plates are scanned with an 
Amersham Typhoon 5 Scanner (GE Healthcare) or read by a radioluminography laser 
scanner BAS-1800II (Raytest). Aida Image Analyzer version 4.0 software was used for 
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data analysis and conversion of data to ASCII before graph-plotting in Origin. The TLC 
systems used are: 
 
Method TLC plate Mobile phase 
I Reverse phase silica gel (RP C-18) 2M NH4OAc : MeOH (1:1, v:v) 
II Neutral aluminium oxide (Alox) 2M NH4OAc : MeOH (1:1, v:v) 
III iTLC - SG 2M NH4OAc : MeOH (1:1, v:v) 
 
Sample Method I Method II Method III Method IV 
[64Cu]CuCl2 0.0 0.0 1.0 0.0 
[64Cu]Cu-Si NP conjugates 0.0 0.0 0.0 0.0 
[64Cu]Cu-NOTA 0.0 ~ 0.5 ~ 0.7 1.0 
[64Cu]Cu-EDTA 1.0 0.0 1.0 1.0 
[64Cu]Cu-Bispidine 0.0 ~ 0.6 ~ 0.5 ~ 0.8 
 
Radio-Size Exclusion Chromatography (Radio-SEC) 
Radio-SEC was performed using the high performances columns used for the analysis 
of the non-radioactive compounds on a Knauer HPLC system fitted with a UV detector 
and a Gabi radio-detector (Raytest). ChromeGate 3.3.2 software was used for peak 
analysis and interpretation. 
 
Radio High Performance Liquid Chromatography (Radio-HPLC) 
Same columns and HPLC systems as for non-radioactive samples were used but 
connected to a radioactive detector (Raytest, Ramona Start, and Software Chromgate 
2.8) 
 
Design Software methods 
All graphs were plot in OriginLab 9.0. Chemical Structures were created using 
ChemBioDraw Ultra 12.0. Figures were done using Adobe Photoshop CS2, Adobe 
ImageReady CS2 or CorelDrawX. 
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5.4 Syntheses 
 
5.4.1 Synthesis of bispidines derivatives (B1-B11), intermediates (B1’, B3’, B8’, 
B9’, B11’) and bifunctional linkers (L1, L2) 
 
Dimethyl-4-oxo-2,6-di(pyridin-2-yl)-1-(pyridin-2-ylmethyl)piperidine-3,5-
dicarboxylate (B1’) 
 
The piperidone precursor (B1’) was obtained by drop-wise addition of pyridine-2-
aldehyde (9.56 mL, 100 mmol) and picolylamine (5.1 mL, 50 mmol) to an ice-cold 
solution of dimethyl acetonedicarbocylate (7.2 mL, 50 mmol) dissolved in methanol (30 
mL). After 30 min, the solidified orange solution was stored in the freezer overnight, 
washed with cold ethanol, and recrystallized from ethanol. [282]. 
Yield: 18.62 g, 81% 
ESI MS (m/z): [M+H]+ 461.3 
 
Dimethyl-9-oxo-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo 
[3.3.1]-nonane-1,5-dicarboxylate (B1) 
 
To a solution of B1’ (15.00 g, 32.6 mmol) in 25 mL THF, 2(aminomethyl) pyridine (4.23 
g, 39.1 mmol) and formaldehyde (37%, 6.4 mL, 78.3 mmol) were added. This solution 
run under reflux for 4 h until a deep brown solution was formed. The solvent was removed 
under low pressure and the remaining dark brown solid was recrystallized from ethanol 
[282]. 
Yield: 4.81 g, 25% 
ESI MS (m/z): [M+TFA]+ 611.6 
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1H NMR: 
(CDCl3) 
δ 8.59 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.44 – 8.36 (m, 2H), 7.86 (d, J 
= 7.9 Hz, 1H), 7.65 (td, J = 7.7, 1.8 Hz, 1H), 7.49 – 7.39 (m, 2H), 7.37 
(td, J = 7.6, 1.9 Hz, 1H), 7.20 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 7.04 
(ddd, J = 7.5, 4.8, 1.2 Hz, 2H), 6.95 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 
6.75 (dt, J = 7.8, 1.1 Hz, 1H), 5.32 (s, 2H), 3.67 (d, J = 2.5 Hz, 6H), 
3.62 (s, 2H), 3.47 – 3.40 (m, 1H), 2.87 (d, J = 11.9 Hz, 1H) 
13C NMR: 
(CDCl3) 
δ 203.39, 168.90, 158.08, 157.17 (d, J = 27.0 Hz), 149.29, 149.02 (d, 
J = 2.1 Hz), 136.27, 135.68 (d, J = 24.1 Hz), 124.92, 124.22, 123.80, 
122.65, 122.28, 121.59, 70.48, 63.43, 62.98, 58.60, 56.72, 52.45 
 
Dimethyl-9-hydroxy-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-
diazabicyclo [3.3.1]-nonane-1,5-dicarboxylate (B2) 
 
B1 (1.5 g, 2.5 mmol) was dissolved in a 3:1 mixture of 1,4-dioxane/water (170 mL) and 
cooled to -5 °C with a ice/acetone bath. Sodium borohydride (124.5 mg, 3.3 mmol) 
suspended in an ice/water mixture (20 mL) was added dropwise over 2 h. The reaction 
was run for 12 h. The pH of the solution was adjusted to 3 with 1 M hydrochloric acid and 
then to pH 8 by addition of 1 M sodium hydroxide solution. The reaction mixture was 
extracted with DCM. The organic layer was dried over sodium sulfate. The solvent was 
removed under reduced pressure and the crude product was purified by preparative RP-
HPLC. B3 was obtained as a white solid [76]. 
Yield: 88 mg, 59 % 
ESI MS (m/z): [M+H]+ 596.2 
1H NMR: 
(CDCl3) 
δ 8.66 – 8.58 (m, 1H), 8.45 – 8.34 (m, 2H), 7.87 (d, J = 7.9 Hz, 1H), 
7.74 – 7.53 (m, 1H), 7.48 – 7.27 (m, 3H), 7.27 – 7.15 (m, 1H), 7.02 
(ddd, J = 7.3, 4.9, 1.2 Hz, 2H), 6.98 – 6.84 (m, 1H), 6.68 (d, J = 7.7 
Hz, 1H), 4.76 (s, 1H), 4.67 (d, J = 5.8 Hz, 1H), 4.17 – 3.96 (m, 1H), 
3.65 (s, 1H), 3.54 (d, J = 10.9 Hz, 6H), 2.70 – 2.49 (m, 3H) 
13C NMR: 
(CDCl3) 
δ 172.67, 159.42, 157.74, 156.62, 149.28 (d, J = 18.0 Hz), 148.38 (d, 
J = 14.9 Hz), 136.09, 135.53 (d, J = 16.7 Hz), 124.73, 124.39, 124.17, 
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122.20 (d, J = 18.7 Hz), 121.59 (d, J = 10.4 Hz), 70.88, 65.17, 57.64, 
52.98, 52.03, 49.21, 30.89 
FTIR : > 3000 (O-H, N-H, C-H), 1720 (C=O), 1670 (C=N), 1210 (C-O) 
 
Tert-butyl (3-bromopropyl)carbamate (L1) 
 
To a solution of 3-bromopropylamine hydrobromide (2.0 g, 9.1 mmol) in DCM (30 mL), 
TEA (5 mL, 36.5 mmol) was added and the reaction solution was stirred at room 
temperature for 30 min before di-tert-butyl-dicarbonate (2.4 g, 10.9 mmol) was added. 
After 12 h of continuous stirring at room temperature under nitrogen atmosphere, 20 mL 
ethyl acetate and 20 mL water were added to the solution. The organic phase was 
separated, washed with brine and the solvent was removed under reduced pressure. 
The product L1 was obtained as a white solid by after purification by column 
chromatography (silica gel, ethyl acetate:hexane = 1:5) [283]. 
Yield: 1.52 g, 70% 
1H NMR: 
(CDCl3) 
δ 3.37 (t, J = 6.5 Hz, 2H), 3.19 (q, J = 4.7, 4.0 Hz, 2H), 1.97 (p, J = 
6.6 Hz, 2H), 1.37 (s, 9H) 
13C NMR: δ 155.99, 39.69, 30.74, 28.71 – 27.90 (m) 
 
Dimethyl-9-(3-((tert-butoxycarbonyl)amino)propoxy)-2,4-di(pyridin-2-yl)-3,7-bis 
(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylate (B3’) 
 
Sodium hydride (311.2 mg, 1.3 mmol) was added to a solution of B2 (300 mg, 504 μmol) 
in dry THF (50 mL) and the resulting mixture was stirred for 1.5 h at 50 °C. Tert-butyl (3-
bromopropyl)carbamate (238.1 mg, 1.0 mmol) was then added to the solution and stirred 
for another 20 h at 50 °C. The reaction was quenched by adding saturated sodium 
hydrogen carbonate solution (50 mL, pH = 8). The aqueous layer was extracted with 
DCM and ethyl acetate. The organic fractions were combined, washed with brine and 
dried over sodium sulfate. Finally, the organic solvent was removed to obtain crude B3’. 
The product was used for the next step in situ [284, 285]. 
Experimental Section 
 
151 
 
Yield: 131 mg, 35% 
ESI MS (m/z): [M+H]+ 751.8 
1H NMR: 
(CDCl3) 
δ 8.66 (d, J = 4.9 Hz, 2H), 8.44 (dd, J = 5.0, 1.7 Hz, 2H), 8.41 – 8.35 
(m, 4H), 7.89 (d, J = 7.9 Hz, 3H), 7.68 (td, J = 7.6, 1.8 Hz, 2H), 7.56 
– 7.45 (m, 2H), 7.37 (dtd, J = 9.8, 7.6, 1.8 Hz, 8H), 7.28 – 7.21 (m, 
3H), 6.99 (ddd, J = 15.3, 7.5, 5.0 Hz, 7H), 6.68 (d, J = 7.7 Hz, 2H), 
5.26 (s, 2H), 4.90 (d, J = 6.6 Hz, 2H), 4.80 (s, 3H), 4.70 (s, 1H), 4.36 
(s, 2H), 3.70 (dq, J = 6.5, 3.3, 2.9 Hz, 2H), 3.58 (s, 9H), 3.55 – 3.45 
(m, 9H), 3.41 (dd, J = 14.6, 8.1 Hz, 8H), 3.23 (q, J = 6.3 Hz, 5H), 2.99 
(q, J = 6.6, 6.0 Hz, 4H), 2.55 – 2.43 (m, 7H), 2.42 (s, 1H), 2.06 – 1.87 
(m, 6H), 1.51 (h, J = 6.3, 5.5 Hz, 4H), 1.24 – 1.20 (m, 3H), 0.86 – 0.77 
(m, 3H) 
 
Dimethyl-9-(3-aminopropoxy)-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-
diazabicyclo[3.3.1]nonane-1,5-dicarboxylate (B3) 
 
The Boc-protected amine (100 mg, 153 μmol) was dissolved in DCM (3 mL), to which 
trifluoroacetic acid (3 mL) was added. The resulting reaction mixture was stirred for 24 h 
at room temperature. After addition of chloroform (10 mL), the solvent was removed 
under reduced pressure. The product B3 was purified by RP-HPLC and obtained as a 
yellow-brown oil [285]. 
Yield: 86.5 mg, 100 % 
RP-HPLC: Rt = 11 min (Method D/i) 
ESI MS (m/z): [M+H]+ 651.4 
1H NMR: 
(CD3CN) 
δ 9.12 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 8.79 (dd, J = 6.0, 1.6 Hz, 1H), 
8.15 – 8.05 (m, 3H), 8.05 – 7.97 (m, 2H), 7.82 – 7.75 (m, 3H), 7.75 – 
7.67 (m, 2H), 7.63 (dt, J = 7.8, 1.0 Hz, 2H), 7.31 (dt, J = 7.8, 1.1 Hz, 
2H), 7.26 – 7.18 (m, 3H), 7.11 (d, J = 8.1 Hz, 2H), 6.97 (s, 1H) 
13C NMR: 
(CD3CN) 
δ 167.45, 125.12 – 150.90, 125.33, 80.74, 72.64, 65.12, 55.01, 53.20, 
52.14  
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FTIR: > 3000 (N-H, C-H), 1727 (C=O), 1670 (C=N), 1200 (C-O), 1126 (N-
H) 
 
Dimethyl-9-(3-(3-(4-isothiocyanatophenyl)thioureido)propoxy)-2,4-di(pyridin-2-yl)-
3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylate (B4) 
 
B3 (250 mg, 0.307 mmol) was dissolved in DCM (25 mL). p-Phenylene diisothiocyanate 
(80 mg, 416 μmol) alongwith TEA (1 mL, 7.1 mmol) was added to this solution. The 
reaction mixture turned yellow in 5−10 min. The reaction was stirred at room temperature 
for 16 h. The reaction solvent was evaporated under reduced pressure. The p-phenylene 
diisothiocyanate was extracted from the mixture by dissolving it in dietyl ether. The crude 
solid B4 was then purified by RP-HPLC. 
Yield: 194 mg, ~60% 
RP-HPLC: Rt = 19 min (Method D/i) 
ESI MS (m/z): [M+H]+ 843.3 
1H NMR: 
(CDCl3) 
δ 8.90 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.63 (d, J = 8.1 Hz, 1H), 8.23 – 
8.12 (m, 2H), 7.93 (ddd, J = 4.9, 1.8, 0.8 Hz, 2H), 7.82 (td, J = 7.7, 
1.8 Hz, 1H), 7.71 – 7.53 (m, 5H), 7.45 (ddd, J = 7.4, 5.8, 1.2 Hz, 2H), 
7.27 – 7.17 (m, 7H), 7.15 – 7.05 (m, 4H), 4.69 – 4.60 (m, 5H), 4.01 
(d, J = 12.5 Hz, 2H), 3.92 (d, J = 12.7 Hz, 2H), 3.80 (s, 2H), 3.66 (t, J 
= 5.3 Hz, 4H), 3.53 (s, 6H), 1.84 (p, J = 5.6 Hz, 2H) 
13C NMR: δ 149.34, 138.00, 126.02, 125.76, 123.87, 28.60 
FTIR: > 3000 (N-H, C-H), 2140 (N=C=S), 1727-1675 (C=O), 1200 (C-O), 
1140 (N-H) 
EA: C 53.75%, N 11.14%, H 4.61%, S 5.46%  
 
Dimethyl-9-(5,8(8-dibenzocyclooctyne)diamido)octoxy)-2,4-di(pyridin-2-yl)-3,7-
bis(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylate (B5) 
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B3 (2.5 g, 2.86 mmol) and TEA (2.5 mL, 17.8 mmol) were dissolved in DCM (40 mL). 
DBCO-NHS ester (1.0 g, 2.5 mmol) dissolved in 10 mL DCM was added to this solution. 
The reaction mixture was stirred for 2 h at room temperature. The product B5 was 
concentrated under reduced pressure, and purified by RP-HPLC [286]. 
Yield: 1.63 g, 56 % 
RP-HPLC: Rt = 22 min (Method D/i) 
ESI MS (m/z): [M+H]+ 939.1 
1H NMR: 
(CDCl3) 
δ 8.89 – 8.82 (m, 1H), 8.49 (s, 1H), 8.26 (s, 1H), 8.23 (d, J = 8.1 Hz, 
1H), 8.11 (d, J = 5.2 Hz, 2H), 8.02 (d, J = 8.9 Hz, 2H), 7.97 – 7.82 (m, 
2H), 7.70 – 7.60 (m, 4H), 7.60 – 7.47 (m, 4H), 7.47 – 7.40 (m, 2H), 
7.40 – 7.32 (m, 5H), 7.29 (d, J = 8.1 Hz, 6H), 7.14 – 7.04 (m, 3H), 
5.14 (s, 1H), 5.12 – 5.02 (m, 1H), 5.00 (s, 1H), 4.73 – 4.64 (m, 2H), 
4.62 (s, 1H), 4.07 (d, J = 9.6 Hz, 3H), 4.00 (d, J = 13.3 Hz, 2H), 3.90 
(d, J = 10.4 Hz, 3H), 3.68 – 3.59 (m, 3H), 3.50 (t, J = 4.1 Hz, 8H), 
3.27 (d, J = 9.1 Hz, 1H), 3.08 (t, J = 6.0 Hz, 3H), 2.80 – 2.66 (m, 8H), 
2.46 (dt, J = 14.6, 7.3 Hz, 5H), 2.29 (ddt, J = 21.6, 14.4, 7.1 Hz, 4H), 
2.15 (s, 1H), 1.95 (dt, J = 16.6, 7.1 Hz, 2H), 1.58 (s, 1H), 1.52 (s, 1H), 
1.24 (s, 2H), 0.82 (s, 1H). 
FTIR: > 3000 (N-H, C-H), 1740-1600 (C=O), 1200 (C-O), 1140 (N-H) 
 
 
Dimethyl-9-(3-(4-mercaptobutanimidamido)propoxy)-2,4-di(pyridin-2-yl)-3,7-bis 
(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylate (B6) 
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B3 (1.2 g, 1.8 mmol) was dissolved in 10 mL acetonitrile and methanol (4 mL) to which 
iminothiolane hydrochloride (250 mg, 1.8 mmol) and TEA (280 µL,1.9 mmol) were 
added. The solution was stirred at room temperature for 4 h and the solvent was removed 
under reduced pressure. The product B6 was purified by RP-HPLC and obtained as a 
white solid. It was stored under inert conditions at -20 °C [287]. 
Yield: 50% 
RP-HPLC: Rt = 15 min (Method D/ii) 
ESI MS (m/z): [M+H-17]+ 736.2 
1H NMR: 
(CDCl3) 
δ 8.07 (d, J = 4.8 Hz, 3H), 7.97 (t, J = 7.6 Hz, 3H), 7.78 – 7.63 (m, 
6H), 7.62 (s, 2H), 7.29 (d, J = 7.6 Hz, 2H), 7.25 (s, 62H), 7.18 – 7.10 
(m, 4H), 4.87 (d, J = 9.0 Hz, 5H), 4.78 (s, 2H), 4.01 (d, J = 12.9 Hz, 
3H), 3.92 (d, J = 10.4 Hz, 5H), 3.85 (d, J = 10.7 Hz, 2H), 3.71 (d, J = 
15.5 Hz, 4H), 3.62 (s, 6H), 3.60 – 3.54 (m, 4H), 3.53 (d, J = 6.6 Hz, 
5H), 3.38 (dt, J = 14.8, 7.0 Hz, 4H), 3.29 (s, 2H), 3.20 – 3.13 (m, 3H), 
2.41 (dt, J = 13.8, 7.0 Hz, 10H), 2.17 (d, J = 0.8 Hz, 44H), 2.10 (d, J 
= 0.9 Hz, 22H), 2.08 (s, 10H), 2.00 (d, J = 0.9 Hz, 7H), 1.34 (t, J = 7.3 
Hz, 4H), 1.29 – 1.21 (m, 3H) 
 
Dimethyl-9-(3-(2-mercaptoacetamido)propoxy)-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-
2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylate (B7) 
 
B7 is formed in a two-step reaction. In the first reaction step, B3 (1.3 g, 2 mmol), S-
Acetylthioglycolic acid NHS ester (4.6 g, 2 mmol) and trimethylamine (50 µL, 300 μmol) 
Experimental Section 
 
155 
 
were dissolved in acetonitrile (10 mL). The solution was stirred at room temperature for 
2.5 h. The solvent was then removed under reduced pressure. The second step of the 
reaction was performed in situ. 
In the second step, the thioester formed was hydrolyzed by suspending in hydroxylamine 
hydrochloride, ethylenediaminetetraacetic and sodium hydrogen carbonate in a mixture 
of water and methanol (10 mL, 1:1 v/v). The pH was adjusted to pH 7 and the suspension 
was stirred at room temperature for 3 h. The product B7 was extracted with DCM. The 
organic phases were combined and dried with anhydrous sodium sulfate and the solvent 
was removed under reduced pressure. The product was purified via RP-HPLC as a 
colorless solid. B7 was stored under inert gas at -20 °C [287]. 
Yield: 0.94 g, 68% 
ESI MS (m/z): [M+H]+ 725.3 
 
Tert-butyl (4-(2-bromoacetamido)phenyl)carbamate (L2) 
 
Bromoacetate succinimdyl ester (39 mg, 0.12 mmol) was dissolved in dry acetonitrile (4 
mL) and a solution of p-amino-Boc-aniline (36 mg, 160 μmol) in dry acetonitrile (4 mL) 
added. The mixture was stirred under nitrogen atmosphere for 24 h, whereupon a solid 
precipitated. The solvent was removed under vacuum and the residue was dissolved in 
chloroform (10 mL) and washed thrice with water (10 mL each). The organic phase was 
separated, dried over anhydrous sodium sulfate, filtered and evaporated to yield the 
product L1 as a powder [196]. 
Yield: 46 mg, 90% 
1H NMR: 
(CDCl3) 
δ 8.17 (s, 1H), 7.42 (d, J = 6.7 Hz, 1H), 7.41 – 7.17 (m, 4H), 6.60 (s, 
1H), 3.99 (s, 1H), 2.64 (s, 2H), 1.49 (s, 9H), 1.47 – 1.39 (m, 1H) 
13C NMR: δ 115.79, 28.35, 25.31 
 
Dimethyl-9-(3-((2-((4-((tert-butoxycarbonyl)amino)phenyl)amino)-2-oxoethyl) 
amino)propoxy)-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo 
[3.3.1]nonane-1,5-dicarboxylate (B8’) 
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L1 (10 mg, 0.03 mmol) was dissolved in dry acetonitrile (5 mL) and a solution of B3 (19.5 
mg, 0.03 mmol) in dry acetonitrile (5 mL) was added, followed by K2CO3 (17 mg, 0.13 
mmol) and KI (4 mg, 0.02 mmol). The mixture was stirred at room temperature for 1 h 
and then refluxed for 24 h. After cooling to room temperature, the solution was filtered 
and the solvent evaporated to yield the product B8’ as a brown oil [196]. 
Yield: 12 mg, 42% 
ESI MS (m/z): [M+H]+ 899.3 
 
Dimethyl-9-(3-((2-((4-aminophenyl)amino)-2-oxoethyl)amino)propoxy)-2,4-di 
(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-
dicarboxylate (B8) 
 
B8’ (10 mg, 0.01 mmol) was dissolved in a 1:1 (v/v) mixture of chloroform and TFA (2 
mL). The mixture was stirred for 4 h and then the solvent was evaporated to obtain the 
crude product B8 as dark brown red oil [196, 288]. 
Yield: ~2 mg, 19% 
ESI MS (m/z): [M+H]+ 799.5 
 
Dimethyl-9-((1-(9H-fluoren-9-yl)-3,6,9,12-tetraoxo-2-oxa-4,7,10,13-tetraaza 
hexadecan-16-yl)oxy)-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-
diazabicyclo [3.3.1]-nonane-1,5-dicarboxylate (B9’) 
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Fmoc-(Gly)3-OH (22.9 mg, 56 μmol) was dissolved in 560 µl anhydrous DMF solvent. To 
this solution, PyBOP (29.4 mg, 56 μmol), HOBT (7.57 mg, 56 μmol) and DIPEA (19 µl, 
0.11 mmol) were added to generate the active ester. The solution was stirred at room 
temperature for 5 min when it turns brown in color. At this point, B3 (48.5 mg, 55 μmol) 
dissolved in 560 µl anhydrous DMF was added to the active ester solution. The mixture 
was stirred overnight at room temperature under inert (Argon) conditions. The solvent 
was then removed under low pressure and the crude product was purified by RP-HPLC 
[232]. 
Yield: 16,8 mg, 30% 
RP-HPLC: Rt = 11 min (Method C) 
ESI MS (m/z): [M+H]+ 1045.4 
1H NMR: 
(CD3CN) 
δ 9.00 – 8.94 (m, 1H), 8.50 (d, J = 5.5 Hz, 1H), 8.13 – 8.06 (m, 1H), 
7.99 (td, J = 7.7, 1.7 Hz, 1H), 7.86 (dd, J = 17.0, 7.8 Hz, 2H), 7.73 – 
7.60 (m, 4H), 7.44 (dt, J = 10.8, 6.4 Hz, 2H), 7.36 (d, J = 7.1 Hz, 1H), 
7.35 – 7.29 (m, 1H), 7.27 (s, 1H), 7.20 (dd, J = 7.9, 3.9 Hz, 3H), 6.73 
(t, J = 5.6 Hz, 1H), 6.34 (s, 1H), 4.90 (s, 1H), 4.63 (s, 1H), 4.56 (s, 
1H), 4.33 (d, J = 7.0 Hz, 2H), 4.24 (t, J = 7.1 Hz, 1H), 3.97 (d, J = 
12.6 Hz, 2H), 3.81 – 3.63 (m, 5H), 3.59 (d, J = 11.1 Hz, 6H), 3.52 (t, 
J = 6.0 Hz, 2H), 3.10 (d, J = 13.1 Hz, 2H), 1.85 – 1.77 (m, 1H), 1.59 
(p, J = 6.4 Hz, 2H), 1.09 (d, J = 6.3 Hz, 1H) 
 
Dimethyl-9-(3-(2-(2-(2-aminoacetamido)acetamido)acetamido)propoxy)-2,4-
di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-
dicarboxylate (B9) 
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B9‘ (2.3 mg, 2.2 mmol) was dissolved in 500 µl 20 % Piperidine/DMF solution and stirred 
at room temperature for 20 min at room temperature. The crude product was then 
lyophilized and purified by RP-HPLC [232]. 
Yield: 1.2 mg, 66% 
RP-HPLC: Rt = 15 min (Method C) 
ESI MS (m/z): [M+H]+ 822.6 
1H NMR: 
(CD3CN) 
δ 7.80 – 7.65 (m, 4H), 3.96 – 3.81 (m, 4H), 3.75 – 3.69 (m, 4H), 3.65 
(d, J = 1.1 Hz, 6H), 3.59 (t, J = 6.0 Hz, 2H), 3.15 (q, J = 6.6 Hz, 3H), 
1.99 – 1.93 (m, 72H), 1.65 (p, J = 6.4 Hz, 2H) 
 
9-oxo-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo [3.3.1]-
nonane-1,5-dicarboxylic acid (B10) 
 
A solution of B2 (200 mg, 0.336 mmol) was prepared by dissolving it in 6 mL of 
anhydrous THF. Cesium hydroxide (565 mg, 3.36 mmol) was added to this solution 
under ice cooling followed by 34 μL water. The reaction mixture was stirred for 24 h at 
room temperature. A milky white emulsion was obtained towards the end of reaction. 
The emulsion was acidified by dilute HCl to pH 6. The solvent was then removed under 
low pressure and the product was purified by RP-HPLC. The product was obtained as a 
while crystalline solid [76]. 
Yield: 159 mg, 86% 
RP-HPLC: Rt = 11 min (Method D/ii) 
ESI MS (m/z): [M+H]+ 566.8 
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1H NMR: 
(D2O) 
δ 8.93 (d, J = 5.1 Hz, 1H), 8.65 (d, J = 5.9 Hz, 1H), 8.19 – 8.10 (m, 
1H), 8.02 (t, J = 7.9 Hz, 1H), 7.95 (d, J = 4.9 Hz, 1H), 7.72 (ddd, J = 
25.7, 17.4, 7.1 Hz, 4H), 7.38 (d, J = 7.8 Hz, 1H), 7.16 (t, J = 6.4 Hz, 
1H), 7.05 (d, J = 8.0 Hz, 1H), 4.93 (s, 1H), 4.87 (s, 1H), 4.60 (s, 2H), 
3.75 (s, 1H), 3.70 (d, J = 12.8 Hz, 1H), 3.50 (d, J = 12.9 Hz, 1H) 
13C NMR 
(D2O) 
δ 171.52, 162.87, 162.52, 149.23, 148.62, 146.35, 140.53, 127.57, 
126.45, 125.89, 125.18 (d, J = 14.8 Hz), 117.64, 114.74, 71.12, 
69.87, 60.58, 56.05, 52.70, 48.98 
 
Diethyl-4-oxo-2,6-di(pyridin-2-yl)-1-(pyridin-2-ylmethyl)piperidine-3,5-
dicarboxylate (B11’) 
 
B11’ was obtained by drop-wise addition of pyridine-2-aldehyde (9.56 mL, 100 mmol) 
and picolylamine (5.10 mL, 50 mmol) to an ice-cold solution of diethyl 
acetonedicarbocylate (9.08 mL, 50 mmol) in methanol (30 mL). After 30 min, the brown 
solution was extracted with chloroform/water. The organic layer was removed under low 
pressure and purified by ethanol crystallization [282]. 
Yield: 16.7 mg, 79% 
ESI MS (m/z): [M+H]+ 489.1 
 
Diethyl-9-oxo-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7 diazabicyclo 
[3.3.1]-nonane-1,5-dicarboxylate (B11) 
 
To a solution of B11’ (16 g, 32.6 mmol) in 25 mL THF, 2(aminomethyl) pyridine (4.23 g, 
39.1 mmol) and formaldehyde (37%, 6.4 mL, 78.3 mmol) were added. This solution run 
under reflux for 4 h till a deep brown solution was formed. The solvent was removed 
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under low pressure and the remaining dark brown solid was recrystallized from ethanol 
[282]. 
Yield:  
ESI MS (m/z): [M+H]+ 621.2 
 
5.4.2 Synthesis of bispidines-based bioconjugates B4-EG-TATE and B5-sdAb-
7C12 
 
B4-EG-TATE-Boc 
 
TATE Peptide (1.70 mg, 1 μmol) and B4 (0.98 mg, 1.1 μmol) were dissolved in 2 mL 
anhydrous ACN. 200 µ DIPEA was added dropwise to this solution. The reaction mixture 
was stirred overnight at room temperature. The product was then lyophilized and further 
purified by RP-HPLC. The identification of the Boc-protected B4-EG-TATE product was 
done by MALDI-TOF spectrometry [289]. 
Yield: 0.9 mg, 37% 
RP-HPLC: 27 min (Method B)  
MALDI-TOF (m/z): [M+H]+ 2407.1 
 
B4-EG-TATE 
 
Boc-protected B4-EG-TATE (0.9 mg, 0.37 µmol) was dissolved in 85 μL TFA and 55 μL 
H2O. 5 μL TIPS and 0.1 mg was added as scavengers to the reaction mixture. The 
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reaction was stirred overnight at room temperature. The product B4-EG-TATE was 
lyophilized and purified by RP-HPLC. The identification was performed by MALDI-TOF 
[185, 289, 290]. 
Yield: 0.25 mg, 33% 
RP-HPLC: 12.5 min (Method B)  
MALDI-TOF (m/z): [M+H]+ 2038.5 
 
B5-sdAb-7C12 
 
Strain-promoted azide-alkyne cycloaddition 
Small-scale reactions were set up in 50 µL with variable molar rations of azide-
functionalized sdAb and B5. The optimal conditions were upscaled and the reaction 
mixture was composed of 275 nmol azide-functionalized sdAb and 1375 nmol B5. 
Reactions were incubated at 25°C for up to 4 h with gentle shaking. The unconjugated 
B5 was removed by SEC using Zeba Spin Desalting Columns (7K MWCO, Thermo 
Scientific) with elution in MES/NaOH buffer (100 mM, 150 mM NaCl, pH 6.0). The 
purified conjugate was sterile filtered using Whatman Puradisc FP 30 cellulose acetate 
syringe filter units with a pore size of 0.2 µm (GE Healthcare Life Sciences) and stored 
at 4°C. 
 
 
5.4.3 Synthesis and modification of Si NPs by hydrothermal method 
 
Synthesis of Si NPs by hydrothermal method 
 
Amine-terminated Si NPs were prepared by slight modification of a reported protocol. 
Trisodium citrate (0.8211 g, mmol) was dissolved in Argon-saturated Millipore water (20 
mL). Argon was bubbled into the citrate solution for 15 min. 3-Aminopropyl-
trimethoxysilane (APTMS) (5 mL) was then added to the solution and stirred for another 
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15 min at room temperature. The reaction mixture was transferred to a Teflon vessel in 
an Argon environment. The Si NP precursor solution was heated up to 160 OC for 5 h in 
a conventional oven. Upon completion of the reaction, the sample solution was cooled 
down to room temperature. The Si NPs were purified by dialysis (Dialysis membrane 
MWCO: 1 kDa) against water. The characterization was performed by TEM, HR-TEM, 
FTIR, UV-Vis and TGA analysis. 
 
Amine group quantification 
TGA analysis18 
The TGA analysis shows four inflexion points at 115 OC (water loss ~5%), 215 OC 
(organic functional group loss ~17.5%), 465 OC and 630 OC. The HR-TEM diameter of 
the Si NPs ~3 nm and density of amorphous silica, 2.2 g/cm3 can be used to calculate 
the surface amine groups. 
𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑏𝑖𝑙𝑎𝑦𝑒𝑟/𝑖𝑛𝑜𝑟𝑔𝑎𝑛𝑖𝑐 𝑏𝑖𝑙𝑎𝑦𝑒𝑟 =  17.5% 
Radius = 1.5 nm 
Volume = 33.5 * 10-18 mm3 
masscore = 888 * 10-18 mg 
massorg.bilayer = 15.7 * 10-18 mg 
𝑚𝑎𝑠𝑠 𝑜𝑟𝑔. 𝑏𝑖𝑙𝑎𝑦𝑒𝑟 ∗  𝑁𝐴/𝑀. 𝑊. 𝑜𝑟𝑔. 𝑏𝑖𝑙𝑎𝑦𝑒𝑟 =  162 𝑎𝑚𝑖𝑛𝑒 𝑔𝑟𝑜𝑢𝑝𝑠 𝑝𝑒𝑟 𝑆𝑖 𝑁𝑃 
 
Kaiser Test (Ninhydrin test) 
Ninhydrin solution upon reaction with Si NP solution (free amine groups) forms a 
complex, Ruhemann’s purple in weakly acidic solution. The absorbance values at 570 
nm from the complex were registered for the accessible amine group quantification. 
𝐴 =  Ɛ𝑐𝑙 
𝑐 =  𝐴 / (Ɛ𝑙) 
𝑐 =  (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 ∗  𝑉𝑜𝑙𝑢𝑚𝑒 / (Ɛ ∗  𝑀𝑎𝑠𝑠 𝑆𝑖 𝑁𝑃𝑠 ∗  1) 
=  6.8 µ𝑚𝑜𝑙 / 𝑚𝑔 𝑆𝑖 𝑁𝑃 
 
Synthesis of monomodal Si NP-based imaging agents 
 
Si NP-NOTA 
Si NP-NOTA was prepared by dispersing 1 mg of amine-terminated Si NP in deionized 
water (150 µL) in a 1.5 mL low protein binding Eppendorf-tube. The pH of the dispersion 
was set between 7−7.5 by 0.01 M NaOH solution. NOTA-Bn-SCN (0.1 µmol) was 
                                                          
18 The experiment was performed by John Ddungu at University of Strasbourg, France. 
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dissolved in water (100 µL) and added to the Si NP dispersion. The reaction was shaken 
on a thermomixer at 750 rpm for 16 h at 25 OC. The Si NP-NOTA was purified by dialyzing 
against water (MWCO: 500-1000 Da). A defined aliquot of the sample was freeze-dried 
to obtain the concentration of particles. 
 
Si NP-IR800 
To amine-terminated Si NPs (1 mg) dispersed in water (150 µL) at pH 7−7.5 (0.01 M 
NaOH), NHS-IR 800 (0.05 µmol) dissolved in water (100 µL) was added. The reaction 
was performed in a 1.5 mL low protein binding Eppendorf-tube in dark. The reaction was 
shook under a thermomixer at 750 rpm at 35 OC. The green solution starts to turn blue 
in 15 min. Upon completion of the reaction, the product was purified by dialysis (MWCO: 
5 kDa) against Millipore water. The Si NP-IR800 was analysed by fluorescence 
measurements via TLC. The sample was further purified by SEC (Sephadex G-25) with 
0.9% (wt/v) NaCl as eluent, to obtain pure Si NP-IR800. A known volume of the 
dispersion was lyophilized to determine the concentration of the nanoconjugate. 
 
Si NP-B4 
Si NPs (1 mg) basified to pH 7−7.5 (0.01 M NaOH) was dispersed in water (150 µL). 
Bispidine-Bn-SCN (B4) was dissolved in a mixture of Water/ACN (9:1) v/v. The reaction 
was stirred at 35 OC for 12 h. The dispersion turned turbid after the addition of B4, which 
clears out in 10 min. The Si NP-B4 was purified by dialysis, followed by SEC (Sephadex 
G-25 and G-50). 
 
Synthesis of bimodal Si NP-based imaging agent (Si NP-IR800-NOTA) 
One-pot synthesis 
Si NP (1 mg) dispersed in water (500 µL) was basified to pH 7−7.5 (0.01 M NaOH). To 
this solution, NOTA-Bn-SCN (0.1 µmol) and NHS-IR 800 (0.05 µmol) separately 
dissolved in 100 µL water was added. The reaction was stirred at 35 OC for 10−12 h. The 
product Si NP-IR800-NOTA was purified by dialysis and SEC. The characterization 
studies displayed non-uniform attachment of the ligands onto the surface of Si NPs. This 
method was discarded and new stepwise synthetic strategy was applied. 
 
Stepwise synthesis 
Si NP (1 mg) dispersed in water (500 µL) was basified to pH 7−7.5 (0.01 M NaOH). To 
this solution, NHS-IR 800 (0.05 µmol) dissolved in 100 µL was added and the reaction 
was stirred in dark at 35 OC for 8 h. NOTA-Bn-SCN (0.1 µmol) dissolved in 100 µL was 
added to Si NP-IR800 solution and the reaction was performed in situ. The reaction was 
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run for another r8 h at 35 OC. Si NP-IR800-NOTA was purified by dialyzing the solution 
against water (MWCO 5 kDa). SEC was also performed to yield high purity product. The 
concentration of the purified NP conjugate was obtained by freeze-drying a known 
volume of the sample. 
 
Synthesis of targeted Si NP-based imaging agents 
 
Si NP-IR800-PEG-5B9 
To synthesize Si NP-IR800-PEG-5B9 bioconjugate, Si NP-IR800 conjugate was freshly 
synthesized and the next reaction was performed in situ. To this reaction solution, Mal-
(PEG)6-SH (0.15 µmol) was added and the solution was stirred in dark for 2 h at room 
temperature. Thiol-terminated 5B9 peptide (0.16 µmol) was dissolved in water (200 µL) 
and TCEP (0.16 µmol) was added to this solution. The reaction was stirred for 15 min 
and this mixture was then transferred to Si NP conjugate solution. The reaction was now 
run at room temperature for 5 h. The Si NP-IR800-PEG-5B9 was dialyzed against water 
and repurified by SEC (Sephadex G-25). 
 
Si NP-IR800-NOTA-PEG-5B9 
Si NP-IR800-NOTA was freshly synthesized to perform further modification of the Si 
NPs. Mal-(PEG)6-SH (0.15 µmol) was added to this reaction mixture and stirred for 2 h 
at room temperature. Thiol-terminated 5B9 peptide (0.16 µmol) was dissolved in water 
(200 µL) and TCEP (0.16 µmol) was added to this solution. The reaction was stirred for 
15 min then transferred to the Si NP conjugate solution. The reaction was run at room 
temperature for 5 h. The Si NP-IR800-NOTA-PEG-5B9 was dialyzed against water and 
repurified by SEC (Sephadex G-25). 
 
Determination of dye concentration 
  
The IR 800 dye concentration in the solution of unknown concentration after the 
multifunctionalization was determined by Beer-Lambert’s Law. A stock solution of known 
concentration of IR 800 dye was prepared in Millipore water. 5 samples with increasing 
concentrations were prepared from the stock. Each dye sample was measured for 
absorbance keeping the value between 0.01−0.1 AU. A graph was plotted with this data, 
(absorbance vs concentration) which lead to a straight line passing through the origin. A 
sample with known amount of Si NP conjugates was measured for its absorbance and 
plotted on the same graph. The Beer-Lambert’s equation was also used for the 
determination of the amount of dye present per mg of Si NP conjugate. 
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Relative Quantum Yield Determination 
 
The photoluminescent quantum yield of the fluorophore coupled to unimodal and 
bimodal Si NP conjugates was determined using free IR 800 dye as a reference. The QY 
of free NHS-IR 800 dye according to previously published data is 14.2%. The UV-Vis 
absorbance spectrum of the Si NP conjugates dispersed in water, as well as for the free 
dye was measured. To minimize the re-absorption effects, the absorbance signals were 
always kept between 0.01–0.10 AU. The maximum absorbance (~615 nm) was used as 
the excitation wavelength for the fluorescence emission due to the blue shift in the IR 
800 dye signals upon conjugation to Si NPs. A slit width of 5 mm was kept constant for 
all the measurements. The resulting fluorescence signal was integrated, and the 
quantum yield was calculated. 
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5.5 Radiolabeling experiments 
 
64Cu-radiolabeling kinetics: 
 
Radiolabeling of (B1−B5), B4-PEG-TATE and B5-sdAb was performed using a standard 
protocol. Radio-TLC is performed to access the radiolabeling with 2 M NH4OAc/MeOH 
(1:2 v/v) as solvent system. The TLC strips are air-dried and exposed to a high-resolution 
phosphorimaging plate (GE Healthcare). The exposed plates are scanned with an 
Amersham Typhoon 5 Scanner (GE Healthcare). 
The chelators (B1−B5) were dissolved in acetonitrile/water solution (1:9 v/v) in stock 
solutions of 1 mg/mL. In 1.5 mL Eppendorf vials, to a 10 μL aliquot of the stock solutions 
100 μL of 0.1 M MES/NaOH buffer was added. To this solution, 6−8 MBq of [64Cu]CuCl2 
were added, and the final volume was made up to 200 μL with the buffer solution. The 
radiolabeling was monitored using radio-TLC using Method I (Table 6) at different times. 
The 64Cu-complexes were purified by Radio-HPLC C-18 columns. 
 
For B5-sdAb19, samples of variable volumes of the [64Cu]CuCl2 solution corresponding 
to different activities (0.5 MBq – 10 MBq) was prepared with constant amount of B4-sdAb 
(1 nmol). The reaction mixtures were incubated at 37°C for different times. The 
assessment was done by radio-TLC (iTLC-SG) with. 5 µL of EDTA (500 mM, pH 7.4) 
was added to 5 µL sample solutions for challenge experiment and monitored by TLC. 
The [64Cu]Cu-EDTA migrated to the solvent front (Rf = 1), whereas the radiolabeled 
proteins remained at the origin (Rf = 0). If necessary, the radiolabeled proteins were 
purified prior to further use via spin filtration (MWCO: 3kDa). 
 
Si NP conjugates (Si NP-NOTA/Si NP-IR800-NOTA) 
 
An aqueous solution of [64Cu]CuCl2 (10 MBq) was added to ~0.1 mg (1 mg/mL stock 
solution) of Si NP-NOTA and Si NP-IR800-NOTA dispersed in water. 100 mM MES 
buffer at pH 7.4 was used to make the final volume up to 400 μL. The reaction mixtures 
were shaken at RT for 30 min, which resulted in RCY ~ 80-90%. The radiolabeling was 
monitored using radio-TLC (method II). Radio-SEC was performed to purify the traces 
of free [64Cu]CuCl2. The 64Cu-complexes were purified using short NAP-5 columns or 
PD-10 size exclusion columns with the 0.9% NaCl solution as a mobile phase. The 
radiochemical yields of 64Cu(II)-labeled complexes are displayed in Table below. 
                                                          
19 The conjugation, radiolabeling and cell binding studies were performed by Dr. K. Zarschler, Institute of 
Radiopharmaceutical Cancer Research, HZDR. 
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64Cu-Bispidine complex Radiochemical purity (RCY %) 
[64Cu]Cu-B1 > 99.9 
[64Cu]Cu-B2 > 99.9 
[64Cu]Cu-B3 > 99.9 
[64Cu]Cu-B4 > 99.1 
[64Cu]Cu-B5 ≥ 99.0 
[64Cu]Cu-B4-PEG-TATE ≥ 99.0 
[64Cu]Cu-B5-sdAb ≥ 99.0 
[64Cu]Cu-Si NP-NOTA 90−95 
[64Cu]Cu-Si NP-IR800-NOTA 80−95 
 
Radiometric titration to determine the amount of chelator on Si NPs 
 
Radiometric titrations were conducted using a mixture of radioactive 64Cu(II) and non-
radioactive Cu(II) for the determination of the amount of NOTA and bispidine chelator 
conjugated to Si NPs. To 10 μL aliquots of the Si NP-NOTA, Si NP-B4 and Si NP-IR800-
NOTA (0.2 mM stock solution in 100 mM MES buffer, pH 5.5), known amounts of a 
mixture of [64Cu]CuCl2 and CuSO4 with a final concentration of 0.4 mM (stock solution) 
were added. The solutions were stirred for 1 h at room temperature on a thermomixer at 
750 rpm. After complete complexation (confirmed using radio-TLC), an 8-fold excess of 
EDTA was added to each solution vial to remove any non-specifically bound Cu(II) ions. 
The resulting solutions were stirred at 37 °C for 40 min at 750 rpm. The RCY was 
determined via radio-TLC and also on a radio-SEC (Sephadex G-25). The amount of 
chelator per mg Si NP conjugate was calculated using the percentage of Cu(II) ions 
bound to the conjugate. 
 
Using the equation; 
𝑚𝑜𝑙𝑒𝑠 𝐶𝑢(𝐼𝐼). [
% 64𝐶𝑢(𝐼𝐼) (𝑅𝑓 <  0.2)
% 64𝐶𝑢 (𝑡𝑜𝑡𝑎𝑙)
] = 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑐ℎ𝑒𝑙𝑎𝑡𝑜𝑟 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒𝑑 
The amount of chelator conjugated to Si NPs was calculated. 
 
5.6 In vitro cell experiments20 
 
Cell culture 
 
                                                          
20 Cell experiments of Si NPs were performed by Mrs. Utta Herzog assisted by Ms. Neena Patel, Institute 
of Radiopharmaceutical Cancer Research, HZDR. 
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All biocompatibility assays were conducted as per the protocol specified in the Iso Norm 
10993–5:2009.  
All cell culture reagents were purchased from Biochrom AG and Sigma-Aldrich unless 
otherwise stated. The human embryonic kidney cell lines HEK293 (DMSZ number ACC 
305) were cultured in DMEM + 10% fetal calf serum (FCS) and incubated in humidified 
atmosphere of 95% air/ 5% CO2 at 37°C. The cell number and the viability of the cells 
was determined using CASY cell counter (Roche Diagnostics) following the 
manufacturer’s protocol. The cell lines were regularly tested and were confirmed to be 
mycoplasma negative using the LookOut mycoplasma PCR detection kit (Sigma-
Aldrich). For the cell viability and LDH assays, the cells were treated with 
penicillin/streptomycin to avoid any bacterial growth during the experiments.  
 
Assessment of biocompatibility (CyQuant, MTS and LDH assay) 
 
The in vitro assessment was performed using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) calorimetric assay and the 
CyQUANT® Direct Cell Proliferation Assay. 
This MTS assay is based on the conversion of the tetrazolium salt to a formazan dye, 
presumably by NADPH and NADH produced by dehydrogenase enzymes in 
metabolically-active cells. The formation of the dye in the presence of the NP is 
monitored by optical absorbance measurement at 490 nm, and the viability is finally 
compared with the untreated cellular control. In addition to that, the membrane integrity 
was measured by an LDH assay which quantifies lactate dehydrogenase (LDH), an 
enzyme that is released upon cell lysis. The CyQUANT assay on the contrary is a 
fluorescence based proliferation and cytotoxicity assay and therefore can be used to 
assess cell growth, cell viability, or compound toxicity in a range of applications, from 
high-throughput screening to bioproduction.  
For the evaluation of biocompatibility, non-cancerous cell line, HEK 293 Human epithelial 
kidney; was seeded in sterile 96-well microtiter plates (Greiner Bio-One) at a density of 
1.8 X 104 cells per well were seeded in DMEM media and allowed to grow for 24 h prior 
to addition of the selected samples. 
CyQUANT® is a direct fluorescence-based proliferation and cytotoxicity assay consisting 
of a fluorescent nucleic acid stain that permeates live cells and concentrates in its 
nucleus. The second component is a suppresser dye that is impermeable for live cells 
and suppresses the green fluorescence. 100 μL of CyQuant dye was added to the wells 
after 24 h of incubation. The fluorescence was measured after 60 min of incubation. 
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After 24 h incubation, increasing concentrations of Si NP-NOTA, Si NP-IR800 and Si NP-
IR800-NOTA conjugates were added to the cells in triplicate. After exposure for 72 h, 20 
μL of MTS (Promega) was added to the wells and incubated for 40 min. Optical densities 
at 492 nm were measured with a microplate reader (TECAN sunrice). The viability of 
cells is expressed as a percentage of viable cells grown in the absence of the NPs. 
Additionally, to measure the membrane integration, an LDH assay was used in the same 
cell lines. For this, 2.1 X 104 cells per well were seeded in a 96 microtiter plate. After 24 
h incubation, the stock solutions of the conjugates were added and incubated for 72 h. 
10 μL of LDH lysis buffer (cytoscan LDH from G-biosciences) was added to the cells. 
Optical density was measured at 492 nm. The percentage of LDH release was expressed 
as the percentage of LDH release of cells grown in the absence of NPs. The data were 
analyzed by normalizing the absorbance from each well containing the samples to the 
absorbance value of the cells without any samples. As a positive control, a set of a 
triplicate of cells were treated with the supplied lysis buffer and the percentage of LDH 
release was expressed relative to this control. As a negative control, bovine serum 
albumin in triplicate of cells was used. 
 
5.7 Cell binding studies 
 
A total of 60,000 A431 cells were seeded in 48-well plates in 250 µL DMEM 
supplemented with 10% fetal calf serum (FCS), and incubated in a humidified 
atmosphere of 95% air/5% CO2 at 37°C. After 24 h of incubation, media was replaced 
by serum-free DMEM and cultivation was continued. After 4 h of incubation, media was 
removed and 100 µl of ice-cold PBS (total binding) or 100 µL of 1 µM sdAb in ice-cold 
PBS (unspecific binding), respectively, was added prior to incubation of the cells at 4°C. 
After 30 min, different concentrations of 64Cu-labeled sdAb-B4 in ice-cold PBS were 
added. The cell culture microplates were further incubated for 1 h at 4°C. Following 
treatment with radiolabeled sdAbs, cells were washed three times with ice-cold PBS in 
order to ensure removal of loosely attached proteins from the cell membrane. Finally, 
cell lysis was achieved by the addition of 1% SDS/0.1 M NaOH and incubation for 30 
min at room temperature with vigorous shaking. The cell associated radioactivity was 
quantified using an automated gamma counter (PerkinElmer Life and Analytical 
Sciences). Total protein concentration in cell extracts was determined as described 
above. 
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5.8 Animal experiments21 
 
In vivo small animal PET 
 
All animal experiments were carried out according to the guidelines of the German 
Regulations for Animal Welfare and the protocols approved by the local Ethical 
Committee for Animal Experiments (AZ 24-9168.21-4/2004-1, AZ 24-9168.11-4/2012-1). 
Animals received standard food and tap water ad libitum and were anesthetized prior to 
animal experiments using 10% desflurane in 30% oxygen/air. Male Wistar-Unilever rats 
(HsdCpb:WU) and male and female NMRI nu/nu mice (RjOrl:NMRI-Foxn1nu/Foxn1nu) 
were received from Harlan Winkelmann GmbH (Borchen, Germany) and Janvier Labs 
(Saint-Berthevin Cedex, France), respectively. Small animal PET imaging was 
performed using microPET® P4 scanner (Siemens Medical Solutions, Knoxville) or 
NanoScanPET/CT (Mediso, Budapest). Animals were positioned on a heated bed to 
maintain body temperature at 37°C.  
For the generation of A431 tumor xenograft model 2 × 106 human A431 epidermoid 
(squamous) carcinoma cells (ATCC: CRL 1555) were subcutaneously injected into the 
right leg of six weeks old female NMRI nu/nu mice as described elsewhere 
Rats and mice received 10-30 MBq (50−100 μg) of Si NP conjugates in 0.5 mL and 0.2 
mL E-153, respectively, intravenously over 0.5 min into a lateral tail vein. The activity of 
the injection solution was measured in a dose calibrator (Isomed 2000, Dresden, 
Germany) cross-calibrated to the PET scanners.  
Attenuation correction of PET data was performed by means of a 10 min transmission 
scan using a rotating point source of 57Co (microPET®) or by whole body CT 
(NanoScan®PET/CT). Data acquisition and reconstruction were performed as described 
elsewhere. Three-dimensional regions of interest (ROI) were determined within masks 
around the tumors or different organs by thresholding PET data within these masks. ROI 
time activity curves (TAC) were derived from subsequent data analysis. Data were 
calculated as standard uptake value (SUV, SUV = activity concentration in tissue [Bq/g] 
× body weight [g] / injected dose [Bq]) at a certain time point p.i. The ROI data and TAC 
were further analyzed using R (R is available as Free Software under the terms of the 
Free Software Foundation’s GNU General Public License in source code form) and 
specially developed program packages (Jörg van den Hoff, Helmholtz-Zentrum Dresden 
                                                          
21 All animal experiments were performed under the supervision of Prof. Pietzsch. PET experiments were 
performed by Dr. Ralf Bergmann and Ms. Regina Herrlich at the Institute of Radiopharmaceutical Cancer 
Research, HZDR. 
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- Rossendorf, Dresden, Germany). The data were calculated in standard uptake value 
(SUV, in units of grams per milliliter), defined as the tracer concentration at a certain time 
point normalized to injected dose per unit body weight. The SUV was used for better 
comparison within animals of different size and weight and with other species. The 
graphs were calculated with GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego California USA, www.graphpad.com). 
 
Ex-vivo whole-body autoradiography 
 
Following PET imaging, 100 μm thick whole body coronal cryosections were prepared 
from representative animals using a Leica Jung Cryopolycut (Leica Microsystems, 
Wetzlar, Germany) as described elsewhere. 
 
Biodistribution studies 
 
For biodistribution experiments, rats and A431 tumor-bearing NMRI nu/nu mice were 
intravenously injected with ~0.5 mL 0.5-10 MBq (10-100 μg) of 64Cu-labeled [64Cu]Cu-Si 
NP-NOTA and [64Cu]Cu-Si NP-IR800-NOTA or 68Ga labeled [68Ga]Ga-Si NP-IR800-
NOTA conjugates. Animals were sacrificed at 5 min, 60 min and 24 h p.i. Organs and 
tissues of interest were excised, weighed, and radioactivity was determined using 
Wizard™3’’ gamma counter. Activity in selected organs and tissues was expressed as 
% injected dose (%ID), %ID/g tissue, or SUV. The obtained blood volume amounted to 
400-500 μL. Afterwards, urine samples (200 - 400 μL) were obtained by puncture of 
bladder. 
 
Optical imaging  
 
For optical imaging experiments, anesthetized A431 tumor-bearing and healthy NMRI 
nu/nu mice were intravenously injected with 20 μl IR 800-labeled Si NP-IR800 and Si 
NP-IR800-NOTA (~80 μg each). Fluorescence was measured using the small animal In-
vivo-Imaging System FX Pro (Carestream Health, USA) in fluorescence mode (Ex 600 
nm, Em 753 nm; reference image for autofluorescence: Ex 430 nm, Em 535 nm). 
Fluorescence pictures were merged with the X-ray acquisitions. Afterwards, animals 
were sacrificed, organs and tissues of interest were excised, and fluorescence was 
measured again. 
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Chapter 7 Annex 
 
 
7.1 Acronyms 
 
Ab Antibody  
A431 Epithelial cell line from epidermoid carcinoma  
ADME Absorption Distribution Metabolism Excretion  
ACN Acetonitrile  
BAT Brown adipose tissue 
BFCA Bifunctional Chelating Agent  
Cyclam 1,4,8,11-Tetraazacyclotetradecane  
d Day 
DCM Dichloromethane  
DIPEA N,N-Diisopropylethylamine  
DLS Dynamic Light Scattering  
DMEM Dulbecco’s modified Eagle’s medium  
DMF N,N-Dimethylformamide  
DMPTACN 1, 4,-Bis-(2-Pyridylmethyl)-1,4,7-triazacyclononane  
DMPA 2,2.dimethoxy-2-phenylacetophenone  
DMSO Dimethyl Sulfoxide  
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid  
EDC 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide  
EDTA Ethylenediaminetetraacetic acid  
EGF Epidermal Growth Factor  
EGFR Epidermal Growth Factor Receptor  
EMEA European medicines evaluation agency  
EPR Enhanced Permeability and Retention  
ESI-MS Electrospray Ionization-Mass Spectrometry  
FDA Food and Drug Administration, USA  
Fmoc Fluorenylmethyloxycarbonyl 
FTIR Fourier transformation infrared spectroscopy  
h Hour  
HCAb Heavy chain antibodies  
HD Hydrodynamic diameter  
HEK293 Human embryonic Kidney cell line  
HPLC High-Performance Liquid Chromatography  
ICG Indocyanine green  
kDa Kilo Dalton  
Kd Dissociation constant  
LDH Lactate dehydrogenase  
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MALDI-TOF-MS Matrix-assisted laser desorption/ionization-Time of flight- mass 
spectrometry  
MES 2-(N-Morpholino) ethanesulfonic acid  
min Minute (s)  
MIP Maximum Intensity Projection  
MPS Mononuclear Phagocytic System  
MRI Magnetic Resonance Imaging  
MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay 
Mw Weight average molecular weight  
MW Molecular Weight  
MWCO Molecular weight cut-off  
NHS N-hydroxysuccinimide  
NIR Near-infrared  
NIRF Near-infrared Fluorophores 
NMR Nuclear Magnetic Resonance  
NOTA 1,4,7-Triazacyclononane-1,4,7-triacetic acid 
NP Nanoparticle  
OI Optical Imaging  
PAGE Polyacrylamide Gel electrophoresis  
PAMAM Poly(amido)amine  
PBS Phosphate buffer Saline  
PET Positron Emission Tomography  
pI Isoelectric point  
p.i. Post injection  
PL Photoluminescence 
PLQY Photoluminescence Quantum Yield 
Py Pyridine  
QDs Quantum Dots  
QY Quantum Yield  
RCY Radiochemical Yield  
Rf Retention Factor  
RT Room temperature  
sdAb Single domain antibody  
SDS Sodium dodecyl Sulfate  
SEC Size exclusion chromatography  
SPAAC Strain promoted alkyne-azide cycloaddition  
SPECT Single Photon Emission Computed Tomography  
SST Somatostatin 
SSTR Somatostatin Receptor 
SUV Standard Uptake Value  
t1/2 Half life  
TATE Tyr3-Octreotate peptide 
TCEP Tris(2-carboxyethyl)phosphine  
TEA Triethylamine 
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TEM Transmission Electron Microscopic  
TETA 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid 
TFA Trifluoroacetic Acid  
TGA Thermogravimetric Analysis  
TIPS Triisopropylsilane 
TLC Thin Layer Chromatography  
Rt Retention time  
UV-Vis Ultraviolet-Visible  
WAT White adipose tissue 
λ Wavelength  
ζ Zeta Potential  
ZW Zwitterionic  
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7.2 Supplementary Data 
 
 
Figure 7.1: ESI-MS of B1‘ [M+H]+ m/z 461.3 in MeOH:H2O (1:1) v/v (left); ESI-MS of B1 [M+py+TFA]+ 
m/z 611.6 in ACN:H2O (1:1) v/v (right) 
 
Figure 7.2: 1H NMR of B1‘ in CDCl3 
 
Figure 7.3: 1H NMR of B1 in CDCl3 
 
Annex 
 
196 
 
 
Figure 7.4: 1H NMR of B2 in CDCl3 
 
Figure 7.5: 13C NMR of L1 in CDCl3 
 
Figure 7.6: ESI-MS of B3‘ [M+H]+ m/z 751.8 in ACN:H2O (1:1) v/v 
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Figure 7.7: ESI-MS of B3 [M+H]+ m/z 651.4 in ACN:H2O (1:1) v/v (left); ESI-MS of B4 [M+H]+ m/z 843.3 
in ACN:H2O (1:1) v/v (right) 
 
Figure 7.8: 1H NMR of B4 in CDCl3 
 
Figure 7.9: 1H NMR of B5 in CDCl3 
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Figure 7.10: 1H NMR of B6 in CDCl3 
 
Figure 7.11: 13C NMR of B6 in CDCl3 
 
Figure 7.12: 13C NMR of L2 in CDCl3 
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Figure 7.13: ESI-MS of B8’ [M+H]+ m/z 899.1 in ACN:H2O (1:1) v/v (left); ESI-MS of B8 [M+H]+ m/z 799.5 
in ACN:H2O (1:1) v/v (right) 
 
Figure 7.14: ESI-MS of B9’ [M+H]+ m/z 1045.4 in ACN:H2O (1:1) v/v 
 
Figure 7.15: 1H NMR of B9’ in CDCl3 
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Figure 7.16: 1H NMR of B9 in CDCl3 
 
Figure 7.17: 1H NMR of B10 in CDCl3 
 
Figure 7.18: 13C NMR of B10 in CDCl3 
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E  
Figure 7.19: ESI-MS of B11’ [M+H]+ m/z 489.1 in ACN:H2O (1:1) v/v 
 
Figure 7.20: MALDI-TOF spectra of Boc-B4-PEG-TATE with [M+H]+ at m/z 2407.1. 
 
Figure 7.21: 1H NMR of Si NPs and trisodium citrate in D2O. 
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Figure 7.22: Radiochemical purity of purified 64Cu-labeled Si NP-B4 conjugate. 
Radio-TLC system: iTLC SG in 2M NH4OAc:MeOH 1:1(v/v); [64Cu]Cu-Si NP-B4 Rf = 0, [64Cu]CuCl2 Rf = 
1. 
 
 
Figure 7.23: TGA analysis of amine-terminated Si NPs. 
Temperature program: Heat from 20 OC to 1200 OC @ 20 OC per minute in air) 
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